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Leukemia is a heterogeneous group of disorder resulting from an uncoupling of 
the proliferation and differentiation of hematopoietic cells at various stages of 
development. Conventional anti-leukemia drugs have their limitations due to their 
relatively high cost, and often accompanied with significant toxicity and adverse side 
effects. Therefore, there is a pressing need to look for new therapeutic compounds with 
minimal toxicity and side effects, especially those derived from natural sources. 
The traditional Chinese medicine licorice (or Gancao) is the rhizome and dried 
root of Glycyrrhiza spp. It has widely been used in China and Asia for decades in the 
treatment of hepatitis, hepatocellular carcinoma, melanoma, inflammatory diseases, 
gastric ulcer and several viral diseases. The major active constituent of licorice is 
glycyrrhizin (GL), a water-soluble triterpenoid saponin glycoside that accounts for much 
of the sweetness of licorice. It is metabolised into the aglycone 18-p glycyrrhetinic acid 
(GA) after oral administration. Both glycyrrhizin and 18-p glycyrrhetinic acid have been 
found to exhibit hepatoprotective, immunomodulatory, anti-allergic, anti-carcinogenic 
and anti-tumor activities. 
In this study, the growth inhibitory and cytotoxic effects of glycyrrhizin and 18-p 
glycyrrhetinic acid on various leukemic cell lines were investigated by the tritiated 
thymidine incorporation assay and trypan blue exclusion assay respectively. It was 
found that glycyrrhizin and 18-P glycyrrhetinic acid exhibited differential anti-
proliferative activities on various leukemic cell lines in a dose-dependent manner. The 
results indicated that 18-(3 glycyrrhetinic acid was more potent than glycyrrhizin as it 
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exerted significant anti-proliferative activities on leukemia cells at micro-molar 
concentrations. It is clear that the growth-inhibitory effect of glycyrrhizin and 18-P 
glycyrrhetinic acid on myeloid leukemia cells could not be attributed directly or solely to 
their cytotoxic effect on leukemia cells, since they exerted little, if any, cytotoxicity on 
various leukemia cells. Similarly, a lack of cytotoxicity of glycyrrhizin and 18-P 
glycyrrhetinic acid on normal hematopoietic cells such as mouse bone marrow cells was 
also observed. On the other hand, it was found that glycyrrhizin and 18-P glycyrrhetinic 
acid could trigger apoptosis in myeloid leukemia cells in vitro with internucleosomal 
DNA fragmentation. Generally speaking, our results showed that the glycyrrhizin and 
18-p glycyrrhetinic acid-treated leukemia cells had a significant decrease in cell cycling 
in S phase accompanied with a cell cycle arrest at the GQ/GI phase. Apart from the anti-
proliferative activities, the effect of glycyrrhizin and 18-P glycyrrhetinic acid on the 
tumorigenicity of a transplantable murine myelomonocytic leukemia WEHI-3B JCS 
cells in syngeneic mice was also investigated. The results indicated that the in vivo 
tumorigenicity of the leukemia JCS cells was reduced significantly by pre-treating the 
cells with glycyrrhizin or 18-P glycyrrhetinic acid in vitro. 
Moreover, the differentiation-inducing ability of glycyrrhizin and 18-p 
glycyrrhetinic acid on the leukemia WEHI-3B JCS cells was assessed by a number of 
criteria, including morphological, phenotypic and functional assays. Morphological 
studies showed that glycyrrhizin and 18-p glycyrrhetinic acid could trigger the 
monocytic differentiation of the leukemia JCS cells. In additional, they could enhance 
the expression of macrophage differentiation antigens, including Mac-1 and F4/80, and 
adhesion molecules, such as VCAM-1 and LFA-1, on the surface of JCS cells. 
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Furthermore, glycyrrhizin also showed stimulation of endocytic activity in the leukemia 
JCS cells. 
Mechanistic sUidies on the anti-leukemic activities of glycyrrhizin and 18-p 
glycyrrhetinic acid showed that combinations of IFN-y or TNF-a with glycyrrhizin or 
18-p glycyrrhetinic acid could enhance their anti-proliferative effect in a synergistic 
manner. On the other hand, it was found that glycyrrhizin or 18-P glycyrrhetinic acid 
could markedly up-regulate the expression of IL-la and IL-ip genes in myeloid 
leukemia JCS cells in vitro whereas the expression levels of both TNF-a and TGF-p 
remained fairly constant. Studies on the expression of PKC isoforms indicated that the 
expression levels of six out of the nine PKC isoforms examined were found to be 
significantly enhanced (>2 fold increase) after treatment of the JCS cells with 
glycyrrhizin and 18-p glycyrrhetinic acid. The most prominent changes were the 
conventional PKC-a (-36 fold increase) for glycyrrhizin-treated JCS cells and the novel 
PKC-6 (-14 fold increase) for the 18-(3 glycyrrhetinic acid-treated JCS cells. 
Interestingly, there was little, if any, increase in the expression of the PKC-p in both 
cases. Moreover, the expressions of other growth-regulatory and apoptosis-related genes 
were also studied. It was found that NF-kB and Fas genes were significantly up-
regulated after treatment with glycyrrhizin or 18-p glycyrrhetinic acid. In addition, the 
expression level for the apoptosis-promoting gene (such as Bak) was increased while the 
expression level for the apoptosis-suppressing gene (such as ^cl-XC) was decreased in 
the 18-p glycyrrhetinic acid-treated JCS cells. 
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By unravelling the cellular and molecular mechanisms by which glycyrrhizin and 
18-p glycyrrhetinic acid might modulate the proliferation and differentiation of myeloid 
leukemia cells, it is hoped that novel treatments for some forms of leukemia, based on 
inhibition of leukemic cell proliferation, and restoration of the normal cell differentiation 













( G L )，此乃水溶性的三祐類糖昔，屬於角苷類別，味道相當甘甜。甘草 




















制。我們首先聯合甘草甜酸或甘草次酸以及細胞因子去處理 J C S血癌細 
胞，結果發現，無論甘草甜酸或甘草次酸聯合 IFN-Y或TNF-a的組合，均 
能對 JCS細胞的抗增生效應有合作的現象。此外，透過利用反向轉錄多連 
鎖反應分析法，我們發現甘草甜酸或甘草次酸均能增加JCS血癌細胞 IL- la 
和 IL- ip基因的表達。但對於TNF-a和TGF-P基因的表達，則保持不變。再 




現象。最有趣者就是甘草甜酸對P K C - a基因及甘草次酸對P K C - S基因之表 
達產生最強烈的上調作用，而兩者對 P K C - P基因之表達則沒有顯著的改 
變。我們亦發現經過甘草甜酸或甘草次酸處理的 J C S血癌細胞，其N F - k B 
及 F a s 基因之表達，皆有明顯的上鋼。最後，我們更嘗試去了解甘草 
次酸如何誘導 J C S血癌細胞中抗洞亡鋼控蛋白或摧调亡調控蛋白的表達及 
其有關的分子機制。結果發現，其中一種抗调亡調控蛋白BC1-XL及其基因 
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Chapter 1 General Introduction 
1.1 Hematopoiesis 
1.1.1 An Overview on Hematopoiesis 
Hematopoiesis is the process of formation and development of blood cells 
(including red blood cells, white blood cells and platelets) from pluripotent 
hematopoietic stem cells. Through sequential cell division and differentiation, stem cells 
develop into functional mature cells (Morrison et al., 1995). Firstly, hematopoiesis takes 
place in the yolk sac during early embryogenesis. This process is then taken over by the 
fetal liver and spleen. Finally, hematopoiesis occurs in the bone marrow and lymphatic 
tissues in adults (Hoffband & Pettit, 1993; Pallister, 1994). 
Hematopoiesis is tightly regulated to maintain a crucial balance in the number of 
blood cells and blood cell types. There are about one hematopoietic stem cell per 10^  
marrow cells and most of them are neither dividing nor differentiating (Metcalf, 1995). 
The hematopoietic stem cells are multi-potential and self-renewable, they proliferate and 
give rise to common progenitor cells, and then differentiate into immature progenitor 
cells of various blood cell lineages. They further differentiate into mature functional 
blood cells. Eight major lineages will be formed finally. The whole process of 
hematopoiesis is shown in Figure 1.1. 
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Pluripotent Stem Cells 
(Lymphoid Stem Cells j ( Myeloid Stem Cells ) 
+ I I + I I + I + 
\ Progenitor ) \ Progenitor J 
CFU-GM_ BFU-E CFU-Meg' CFU-Eo CFU-Bas 
• • ^ � II 础 
C^C^ r ^ ^ h i l l 
CFU-N^ CFU-^^ CFU-E ， � ， � ” + + + + + 
+ + + i i U 
Monocyte Granulocyte^ Erythro^^ J ^ e g ^ ^ j E o s i i ^ 姻 
Figure 1.1 Hematopoiesis 
Bas: Basophil; BFU: Burst-forming unit; CFU: Colony-forming unit; E: Erythroid; 
Eo: Eosinophil; G: Granulocyte; GM: Granulocyte-macrophage; M: Macrophage; 
Meg: Megakaryocyte 
(Modified from Albert et al, 1994) 
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All the mature blood cells may display specific antigenic, morphological and 
biochemical characteristics of the committed lineage and lose their self-renewal capacity. 
In hematopoietic differentiation, stem cells either committed to one of the two pathways, 
myeloid or lymphoid. After that, cells are obligated to specific lineages of development. 
Three major branches of myeloid lineage are found: erythroid, megakaryocytic, 
and phagocytic. In the erythroid lineage, cells give rise to red blood cells while in the 
megakaryocytic lineage, cells give rise to blood platelets. For the phagocytic lineage, it 
can be further subdivided into the monocytic and granulocytic lineages. In the 
monocytic lineage, cells give rise to monocytes in the circulation and macrophages in 
the tissues while in the granulocytic lineage, cells may give rise to neutrophilic, 
eosinophilic and basophilic lineages (Goldstein, 1995). For the lymphoid lineage, cells 




Chapter 1 General Introduction 
1.1.2 Role of Cytokines in the Control of Hematopoiesis 
Hematopoiesis is tightly regulated by a variety of hematopoietic cytokines and 
together with a complex stromal microenvironment, these lead to well control over the 
cell proliferation, differentiation and maturation process. 
Four different colony-stimulating factors (CSFs) have been discovered, these 
include macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating 
factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF) and 
interleukin-3 (IL-3) (Crosier & Clark, 1992). Among these four CSFs, M-CSF and G-
CSF are relatively lineage-specific. M-CSF can control the proliferation, differentiation 
and activation of cells of the monocyte-macrophage lineage while G-CSF can stimulate 
the growth and differentiation of neutrophils. In constrast, GM-CSF and IL-3 are multi-
lineage hematopoietic cytokines that exert their action on early myeloid progenitor cells. 
They play a role in the regulation of proliferation and terminal differentiation of these 
cells into erythroid, megakaryotic, granulocytic and monocytic lineages (Ikebuchi et ai, 
1987). 
Some regulatory cytokines, such as IL-1 and IL-6, can enhance the effects of 
CSFs by maintaining the viability and inducing the differentiation of myeloid precursor 
cells. For example, CSFs and IL-3 can induce the myeloid precursors to produce IL-6 
which then stimulates the cells to differentiate into megakaryocytes, granulocytes and 
monocytes (Sach，1995). On the other hand, GM-CSF and IL-6 can induce the 
expression of genes of the transcription factor, such as c-jiin and c-fos (Shabo et ai, 
1990), which can activate other genes, such as genes for cellular functions and other 
4 
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cytokines. These cytokines include the tumor necrosis factor a (TNF-a), GM-CSF, M-
CSF, IL-1 and IL-6 (Lotem et al, 1991). This means that a cytokine network can 
amplify the signals and enhance specific cellular functions through the induction of 
other cytokines in different cell types. 
Inhibitory cytokines act as regulators to maintain homeostasis (Lotem & Sachs, 
1991; Lotem et a!., 1991). Transforming growth factor p (TGF-P), interferon a and 丫 
( I F N - a & IFN-Y), TNF-a , macrophage inflammatory protein l a (MlP-la), act in a 
network to inhibit the activity of certain CSFs and ILs, and then inhibit the proliferation 
of various precursor and progenitor cells. 
1.2 Leukemia 
1.2.1 Abnormalities in Hematopoietic Cell Development 
Leukemia is a disorder caused by the uncoupling of proliferation and 
differentiation of hematopoietic cells, that is, the blood cells proliferate in an 
uncontrolled manner but fail to differentiate into functionally mature cells. By clonal 
proliferation from a single abnormal stem cell, leukemia cells populate the bone marrow 
and then circulate in the peripheral blood and result in bone marrow failure (Hoffbrand 
& Pettit, 1993). The leukemia cells may metastasize to other organs including testicles, 
ovaries，central nervous system, skin, kidney etc. Patients may have symptoms such as 
fever, lack of appetite and fatigue (Hoffbrand & Pettit, 1993). 
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According to the American Cancer Society, there was about 30,800 new cases of 
all types of leukemia in the United States by the end of year 2000 (The American Cancer 
Society, 2000). Among them 28,200 of these were adults and 2,600 were children. It was 
reported that there were 9,700 new cases of acute myelogenous leukemia (AML) and 
about 1,400 adults would develop acute lymphocytic leukemia (ALL). The average age 
of a patient with AML is 65 years of age and AML is slightly more common among men 
than among women. ALL is more common among children under 10 years of age than 
adults. Also, ALL is less common in middle-aged adults but become more common 
again after 70 years old. 
The most common childhood cancer in Hong Kong is leukemia (36%), followed 
by cancers of the brain (16%), lymph glands (8%), nerve cells (6%), muscle (6%), liver 
(5%)，bone (5%), kidney (3%) and eye (3%). In Hong Kong, 150 children develop 
leukemia each year and the incidence is about one in every 10,000 (Children's Cancer 
Foundation: A review 1990-2000). 
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1.2.2 Classification of Leukemia 
According to the onset and duration of the disease, leukemia can be classified 
into acute or chronic, and both the acute and chronic leukemia can be further subdivided 
into myeloid and lymphocytic leukemia on the basis of morphology and cytochemistry 
(Goasguen et al, 1996). Thus, there are four main types of leukemia: acute myeloid 
leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML) 
and chronic lymphocytic leukemia (CLL). In acute leukemia, the bone marrow cells are 
unable to properly differentiate and immature lymphoblasts and myeloblasts proliferate 
and accumulate. While in chronic leukemia, cells do undergo differentiation, but they 
are not completely normal and do not function properly. This will lead to infiltration of 
too many mature lymphocytes or granulocytes in the bone marrow. In 90-95% of 
patients with CML, there is a replacement of normal bone marrow by cells with an 
abnormal chromosome-the Philadelphia (Ph) chromosome. 
Leukemia is classified as myeloid leukemia if monocytes or granulocytes are 
involved. Lymphocytic leukemia occurs if the cancer is developed from bone marrow 
lymphocytes. Malignant lymphomas occur if the cancer is developed from lymphocytes 
in lymphoid organs or lymph nodes. 
According to the French-American-British (FAB) classification scheme, based 
on immunophenotyping, chromosome and gene rearrangement and morphological 
features, AML can be subdivided into eight categories: FAB MO to M7 (Table 1.1). ALL 
is classified into three types including LI, L2 and L3. CML and CLL are also subdivided 
7 
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into six and seven categories respectively (Hayhoe & Flemants, 1992; Hoffbrand & 
Pettit, 1993). 
Table 1.1: The French-American-British (FAB) classification scheme of leukemia 
Type Subclass FAB Type 
Acute Acute Myeloid MO: minimal differentiation ‘ 
Leukemia (AML) M1: myeloblastic (>90% myeloblasts) 
M2: myeloblastic with granulocytic maturation (>10% 
promyelocytes or later granulocytes) 
M3: promyelocytic (coarsely granular or micro granular 
promyelocytes) 
M4: myelomonocytic (>20 % granulocytes and >20% 
monocytes) 
MSA: monoblastic 
M5B: promonoblastic with differentiation 
M6: erythroblastic (>50% erythroblasts) 
M7: megakaryoblastic (>50% megakaryoblasts) 
Acute Lymphocytic LI: homogeneous small blasts with little cytoplasm 
Leukemia (ALL) L2: heterogeneous larger blasts with variable amounts of 
cytoplasm 
L3: homogeneous large blasts with vacuolated basophilic 
cytoplasm 
Chronic Chronic Myeloid Philadelphia-positive chronic myeloid leukemia 
Leukemia (CML) Philadelphia-negative chronic myeloid leukemia 
Juvenile chronic myeloid leukemia 
Chronic neutrophilic leukemia 
Eosinophilic leukemia 
Chronic myelomonocytic leukemia 
Chronic Lymphocytic B-chronic lymphocytic leukemia 
Leukemia (CLL) B-prolymphocytic leukemia 
Hairy cell leukemia 
Plasma cell leukemia 
T-chronic lymphocytic leukemia 
T-prolymphocytic leukemia 
Adult T-cell leukemia / lymphoma 
(Adapted from Greaves, 1991 and Hoffbrand & Pettit, 1993 and Goasguen et al, 1996) 
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1.2.3 Etiology and Symptoms of Leukemia 
The etiology of leukemia is still unknown. However, several factors have been 
associated with an increased risk of leukemia. These factors include chronic exposure to 
the chemical carcinogens, such as phenylbutazone, benzene, cigarette smoking and 
chloramphenicol; exposure to high doses of irradiation and electromagnetic field. These 
may cause the change in specific gene family. Also, it is believed that infection with 
infectious leukemia virus, such as adult T-leukemia/lymphoma virus and inheritance of 
the oncogenes for leukemogenesis play a role in the development of leukemia (Greaves, 
1991). These may cause changes in DNA and subsequently occurrence of deletions, 
chromosomal translocations, gene mutations, fusion, rearrangement, or inherited 
disorders that may result in the activation of oncogenes and loss of tumor suppressor 
genes and products that disturb the critical balance in favor of the cell proliferation 
(Hoffbrand & Pettit，1993; Campbell, 1995; Weinberg, 1996). 
The generalized symptom of leukemia is a lack of normal hematopoietic cells 
due to crowding out of normal hematopoietic cells by the leukemia cells. For example, 
leukocytopenia and granulocytopenia can increase the susceptibility to infection and 
cause fever. Thrombocytopenia can lead to excessive bleeding and bruising. Anemia can 
lead to shortness of breath, a pale color on the skin and tiredness. On the other hand, 
lymphadenopathy, hepatomegaly and splenomegaly are common due to the infiltration 
of leukemia cells (Maggie, 2000). 
9 
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In some serious cases, enlargement in the thymus may occur. This may compress 
the nearby trachea and lead to shortness of breath, cough, or even suffocation. Also, 
superior vena cava (SVC) syndrome may occur if the leukemia cells compress the SVC. 
This may be life threatening since it can cause the swelling of head and arms. 
1.2.4 Therapeutic Strategies for Leukemia 
1.2.4.1 Conventional Therapies 
Conventional therapies used for the treatment of leukemia include chemotherapy, 
radiotherapy and bone marrow transplantation. However, every kind of conventional 
therapy has its own drawbacks. For chemotherapy, multidrug resistance is the main 
problem. Patients are treated with combinations of several drugs to increase the 
cytotoxic effects, but these drugs usually target at the actively dividing cells. Therefore, 
there are side effects of damaging rapidly growing normal cells such as cells of hair 
follicles, digestive tracts, reproductive system and blood cells. Symptoms like weight 
loss, stomatitis, esophagitis, nausea, constipation, diarrhea, vomiting, appetite loss will 
be seen after receiving the drugs (Hoffbrand & Pettit, 1993; Maggie, 2000). 
For radiotherapy, considerable side effects, which may be permanent and 
irreversible to normal cells, are seen in the patients after the use of X-rays and y-rays 
(Hoffbrand & Pettit，1993). For bone marrow transplantation, there is a limitation in the 
searching for compatible donors for the patients and the operation cost is very expensive. 
Therefore there is an urge need to establish new and effective therapeutic strategies for 
leukemia (Hoffbrand & P明it, 1993; Maggie, 2000). 
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1.2.4.2 Differentiation Therapy and Induction of Apoptosis in Leukemia 
There is a new concept of differentiation therapy for the treatment of leukemia. 
A variety of physiological compounds, phytochemicals and cytokines have been found 
to have the function of inducing the differentiation and/or apoptosis in leukemia cells. 
For example, retinoic acid has been used clinically to treat the human promyelocytic 
leukemia (Sachs, 1996). 
A number of cytokines, such as TNF, thrombopoietin (TPO), erythropoietin 
(EPO), IL-3, stem cell factor (SCF), CSFs etc. are commonly used to induce the growth 
inhibition and differentiation of differentiation-competent clones (called D+ clones) of 
leukemia (Sachs, 1993; Touw & Dong, 1996). On the other hand, cytokines such as 
IFN-Y, T N F - a , IL-4, IL-3, G M - C S F and G - C S F have a role in the regulation of 
differentiation of myeloid leukemia cells either by acting alone or in combination with 
other cytokines (Sachs, 1993). For instance, TNF-a and IL-4 have been reported to act 
synergistically to induce the monocytic differentiation of the murine myeloid leukemia 
WEHI-3B JCS cells (Leung et al., 1994). 
On the other hand, many other compounds are also known to induce the 
differentiation or apoptosis in leukemia. Examples include vitamin analogs, 
chemotherapeutic compounds, steroid hormones, tumor promoting phorbol esters, 
certain plant lectins, insulin and bacterial lipopolysaccharide etc. (Sachs, 1996). 
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1.2.5 Regulation of Apoptosis and Cell Cycle Progression 
1.2.5.1 Apoptosis 
Programmed cell death or apoptosis is a cell suicide program that regulates the 
critical balance of cell number in tissues and to eliminate cells that threaten the animal's 
survival. It is associated with typical biochemical and morphological changes, for 
instance, chromatin aggregation, shrinkage of cell, fragmentation of DNA, nuclear and 
cytoplasmic condensation into apoptotic bodies and rapid phagocytosis by neighbouring 
cells (Compton, 1992; Kerr 1993). The occurrence of many forms of cancer is due to the 
suppression of apoptosis. 
During apoptosis, cascades of signal transduction occur after a cell receives 
stimuli, such as deprivation of growth factors and genotoxic damage, that commit it to 
undergo apoptosis. A cascade of cysteine proteases are involved, there are initiator 
caspases (caspase 2, 8, 9, 10) and effector caspases (caspase 3, 6，7). Afterwards, 
irreversible proteolytic events occur, such as disruption of nuclear membrane and cell-
cell contact, cleavage of cytoskeletal proteins and activation of DNA nuclease that leads 
to DNA fragmentation (Thornberry & Lazebnik, 1998; Saraste & Pulkki, 2000). 
Bcl-2/bax gene family plays a role in the regulation of the downstream apoptotic 
pathway via the formation of homo- or heterodimers. Sixteen members of this family 
have been identified. Bcl-2 and BCI-XL are apoptosis-inhibitory proteins while some of 
them such as Bak, Bad, Bax and Bid are apoptosis-promoting proteins (Kromer et al, 
1998; Mignotte et al., 1998). On the other hand, the p53 protein is a transcription factor 
that can bind to DNA and search for DNA damage. It can induce cell cycle arrest in Gi 
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and G2/M checkpoints by activating the p21 inhibitory protein or promotes apoptosis 
(Kuwana et al, 1998; Lundberg & Weinberg, 1999). Also, the p53 protein may function 
to control the ratios of these two forms of BcI-2 family protein dimers so as to regulate 
cell survival. For instance, a high expression level of the Bcl-2 group inhibits apoptosis 
while a high expression level of the Bax group promotes apoptosis. Mitochondria, which 
act as a central executioner of apoptosis, are also involved. Bax proteins may induce the 
release of cytochrome c from mitochondria. The released cytochrome c then binds to 
apoptotic protease activating factor-1 and subsequently activates caspase-9. Afterwards, 
caspase-9 activates downstream caspases, such as caspase-3, which trigger the 
downstream process of apoptosis (Antonsson & Martinou, 2000). 
1.2.5.2 Cell Cycle 
The mammalian cell cycle consists of four phases known as Gi, S, G2 and M 
phases. Firstly, in the Gi phase, a cell increases in size and prepares to duplicate their 
DNA. During the S phase, the DNA is duplicated and a complete copy of the 
chromosome complement is formed. Afterwards, the cell enters the G2 phase and 
prepares to divide into two cells. In the M phase, mitosis occurs and the cell is divided 
into two. There is a Go phase, which is the resting stage of a cell. 
Cydins and cyclin-dependent kinases (cdks) genes encode products that play a 
role in the regulation of the cell cycle. There is restriction point (R point), located at the 
end of Gi, which decides whether a cell should enter the rest of the cell cycle or divide 
further. The retinoblastoma protein (pRB) acts to control the R point. In the 
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unphosphorylated or hypophosphorylated form, pRB blocks the R point transition. 
When a cell receives mitotic signals, a D-type cyclin (cyclin D) combines with CDK 4 
or CDK 6 when it is activated. This leads to the phosphorylation of pRB and this 
partially phosphorylated pRB will further undergo phosphorylation via a number of 
cyclins/cdks. This permits the cell from entering and progressing in the cell cycle 
(Lundberg & Weinberg, 1999). 
A cell cycle inhibitor, the tumor suppressor gene p53, causes the expression of a 
cdk inhibitor p21. The p21 can act on a variety of cyclin/cdk complexes. On the other 
hand, the p53 protein can activate apoptosis by inducing pro-apoptotic Bax protein. 
Therefore, loss of function of p53 function may cause the cells to replicate continuously. 
This may contribute to a number of cancers when cell cycling is increased (Meikrantz & 
Schlegel, 1995). 
1.2.5.3 Disregulation of Apoptosis and Cell Cycle Contribute to the Development 
of Leukemia 
Disruption of the balance between cell loss and cell gain causes the occurrence of 
leukemia. The expression of Bcl-2 protein is increased in both B-lineage ALL and AML 
cells. This enhances the clonogenicity and resistance of leukemia cells to 
chemotherapeutic drugs. In AML, B-cell CLL and B-cell ALL, mutation of p53 gene is 
also found. This leads to the failure of Gi or G2/M cell cycle arrest and apoptosis 
(Lunderg & Weinberg, 1999). 
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The growth regulatory protein c-myc promotes apoptosis. It plays important roles 
in cell differentiation and apoptosis (Hoffman & Liebermann, 1998). It is believed that 
c-mj/c has dual roles on cell proliferation and apoptosis. It has been reported that 
disregulated c-myc expression can induce apoptosis in fibroblasts (Evan et al., 1992). On 
the other hand, activation of a c-myc gene by IL-3 induced apoptosis in a myeloid cell 
line (Askew et al, 1991). However, the downstream targets of c-myc remain poorly 
understood. It is proposed that c-myc plays a secondary role in leukemogenesis if 
apoptosis has already been suppressed by other factors. 
The tumor suppressor gene pRB blocks R point transition in the cell cycle. 
Hypophosphorylation of pRB results in differentiation of the cells, inactivation of pRB 
results in leukemogenesis. On the other hand, altered or absence of pRB expression 
leads to the suppression of differentiation of myeloid leukemia cells and results in 
uncontrolled cell cycle progression (Karp, 1997). 
Cytokines can enhance the survival of leukemia cells, for instance, IL-3 can 
protect cells from y-irradiation and IL-6, GM-CSF, G-CSF can suppress apoptosis 
induced by some chemotheraptic drugs in myeloid leukemia cells (Lotem & Sachs， 
1990). On the other hand, tumor cells can activate cell cycling by increasing the 
expression of growth factor receptors, increase the expression of cytokines and 
amplified signaling pathways (Karp, 1997). 
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1.3 Licorice 
1.3.1 Chemistry of Licorice 
Herbs have been used as food and for medical purposes for centuries. Many 
people believe that herbal medicine contains natural substances that can promote health 
and alleviate illness. Actually, many Western drugs had their origins in plant extracts. 
Therefore natural herbs such as licorice that possess anti-tumor or immune-stimulating 
properties are of great interest. 
Licorice，or Gancao (甘草）in Chinese (Figure 1.2), is the rhizome and dried 
root of Glycyrrhiza glabra L. (Leguminosae), G. inflata Bat, or G. uralensis Fisch 
(Figure 1.3). This herb mainly grows in the northern part of China. It has been used for 
many centuries in traditional Chinese medicine as an anti-allergic, anti-ulcerogenic agent, 
anti-hepatitis and anti-toxin. In Western countries, it is currently used as a sweetening 
and flavoring agent in chewing gums, cigarettes, beer and candy (Wnston, 1999). 
One of the main active components of licorice extract is glycyrrhizin (GL), also 
known as glycyrrhizic acid, which is a saponin glycoside that occurs in the root in 
concentration ranged from 5-9%, and it is a kind of pentacyclic triterpenoid 50 times 
sweeter than sugar. Glycyrrhizin is a conjugate of one molecule of glycyrrhetinic acid 
with two molecules of glucuronic acid. It has been reported that naturally occurring 
triterpenoids may be a novel and valuable class of compounds which can be used as 
chemopreventive agents against tumors. Other components from licorice include 
polysaccharide fractions, various flavonoids, an anti-ulcerative fraction called FM 100 
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and an immunosuppressant substance called LX, glycosides such as liquiritin, 
isoliquiritin and neoliquiritin (David & Morris, 1991). 
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Figure 1.2 Licorice (Gancao) 
(Adapted from Huang, 1999) 
c . 
Figure 1.3 Rhizome of licorice 
(Adapted from Huang, 1999) 
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After oral administration, glycyrrhizin is hydrolysed to glycyrrhetinic acid (GA) 
by intestinal bacteria Streptococcus spp. which can produce P-D-glucuronidase (Figure 
1.4). After intravenous administration of glycyrrhizin, both glycyrrhizin and 
glycyrrhetinic acid appear in the plasma. Intravenously administered glycyrrhizin is 
metabolized in the liver via lysosomal P-D-glucuronidase to generate glycyrrhetinic acid 
monoglucuronide (GAMG). Then it will be excreted with bile into intestine and 
transformed to glycyrrhetinic acid by intestinal bacteria Streptococcus LJ-22 via the 
removal one more glucuronic acid (Gunnarsdottir & Johannesson., 1997; Kim et al., 
1999). Glycyrrhetinic acid exists in the 18 a and P stereoisomeric forms. These 
molecules have been reported to possess several pharmacological effects including 
mineralocorticoid activities, anti-inflammatory effect, immunosuppressive and anti-
allergic effects，enhancement of immune response, anti-hepatotoxic effect, anti-viral 
activity and anti-carcinogenic and anti-tumor activities. 
Isoliquiritigenin (Figure 1.5) is a chalcone derivative isolated from licorice and 
exhibits anti-tumor-promoting activity. It has been reported that isoliquirtigenin inhibits 
7, 12-dimethyl-benz(a)anthracene (DMBA)-initiated and TPA-promoted skin papilloma 
formation. It also inhibits epidermal ornithine decarboxylase (ODC) induction and skin 
tumor promotion caused by 7-bromomethylbenz(a) anthracene (BrMBA), a non-TPA 
type of tumor-promoting agent, in DMBA-initiated mice. It is believed that 
isoliquiritigenin exerts its anti-tumor-promoting activity via the inhibition of cellular 
lipoxygenase activity by acting on cells (Yamamoto et al., 1991). Therefore, this 
chalcone derivative or flavonoid shows promise as a drug to prevent tumor promotion. 
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Figure 1.4 Sequential degradation of glycyrrhizin acid (GL) by the action of 
P-glucuronidase to 18-a/ (3 glycyrrhetinic acid (GA). 
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Figure 1.5 The chemical structure of isoliquiritigenin 
(4, 2', 4‘-trihydroxychalcone) 
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1.3.2 Pharmacological Activities of Giycyrrhizin and 18-B Glycyrrhetinic Acid 
1.3.2.1 Mineralocorticoid Activity 
It is observed that chronic administration of licorice produces symptoms of 
hypertension, weight gain, edema, retention of sodium and excretion of potassium. 
These mineralocorticoid effects of licorice are due to giycyrrhizin or its active 
metabolite, the glycyrrhetinic acid which inhibits the 11-P-hydroxy steroid 
dehydrogenase (ll-p-OHSD) in man (Huang, 1999). This enzyme promotes reversible 
interconversion of biologically active 11-P-hydroxy glucocorticoid into inactive 11-oxo 
glucocorticoid, and the conversion of Cortisol to cortisone in humans. It plays a critical 
role in regulating the level of circulating glucocorticoids and mineralocorticoids under 
normal circumstances. Therefore administration of giycyrrhizin inhibits metabolism of 
Cortisol and raises the Cortisol concentration to levels that allow it to act as a 
mineralocorticoid, resulting in mineralocorticoid excess, a condition known as 
pseudohyperaldosteronism. This can cause suppression of the renin-angiotensin-
aldosterone system and enhancement of atrial natriuretic hormone in order to 
compensate the change in homeostasis. As a result of decompensation, the symptoms 
described above will occur. This mineralocorticoid effect of licorice can be utilized for 
the treatment of Addison's disease (Monder et al., 1989; Lo et al, 1997). Chronic use or 
abuse of licorice will result in hypertension. A regular daily intake of 100 mg 
giycyrrhizin (approximately corresponding to 50 g licorice root) would be enough to 
produce such a hyperaldosteronism effect. 
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1.3.2.2 Anti-inflammatory Effect 
It was reported that glycyrrhizin could reduce capillary permeability in inflamed 
sites (Kimura et aL, 1991; Inoue et al., 1993; Bao et ai, 1997). Inflammatory factors are 
involved in the activation of phosphodiesterase which degrades cAMP level in 
neutrophils, triggering them to produce prostaglandin E2 and initiating inflammatory 
response. Ammonium glycyrrhizate may act to inhibit the activation of arachidonic acid 
by elevating cAMP level within neutrophils which then suppresses the activation of 
neutrophil and the subsequent prostaglandin E2 biosynthesis (Inoue et al., 1986; Khaksa 
et al., 1996). On the other hand, 18-P glycyrrhetinic acid was found to exhibit anti-
inflammatory action in different animal models. However, its mode of action is still not 
well understood. One possible mechanism is based on the structural resemblance 
between 18-P glycyrrhetinic acid and corticosteroids. Inhibition of 11-P-hydroxysteroid 
dehydrogenase results in an accumulation of hydrocortisone, a natural steroid with anti-
inflammatory actions (Akamatsu et al., 1991; Kroes et al, 1997). 
Experiment had also shown that the cotton-pledget-induced granulation, 
formaldehyde-induced paw swelling and subcutaneous granulomatous inflammation in 
rats were inhibited by glycyrrhetinic acid (Inoue et al, 1993). In artificial arthritis 
induced by carrageenan in rats, the anti-inflammatory effects of glycyrrhizin and 18-P 
glycyrrhetinic acid were found to be 14% and 3% of hydrocortisone respectively 
(Matsumoto et al” 1996). 
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1.3.2.3 Anti-allergic Effect 
Both glycyrrhizin and 18-p glycyrrhetinic acid have been shown to have anti-
allergic activity. It was reported that intravenous (i.v.) administration of glycyrrhizin 
into mice inhibited the passive cutaneous anaphylaxis (PCA) response to trichosanthin. 
It also antagonized the contraction of isolated rabbit ileum induced by histamine or slow 
reactive substance of anaphylaxis (SRS-A) in a concentration-dependent manner (Zhang 
et al, 1986). On the other hand，18-P glycyrrhetinic acid at a high dose (200 mg/kg 
given intraperitoneally, i.p.) inhibited (-35%) the picryl chloride (PC)-induced contact 
dermatitis in mice whereas i.p. injection of sodium carbenoxolone (a derivative of GA) 
at 50 mg/kg only marginally inhibited (-22%) the PC-induced contact dermatitis in mice 
(Inoue et al., 1987). 
1.3.2.4 Enhancement of Immune Response 
Both glycyrrhizin and 18-p glycyrrhetinic acid have been found to display 
modulatory activity on a wide variety of immune functions. For example, i.p. injection 
of glycyrrhizin into mice caused a significant increase in the weight of spleen and 
thymus. The white blood cell count and the clearance rate of i.v. injected charcoal 
particles were also increased (Zhang et al., 1984). It was found that glycyrrhizin 
stimulated both T and B cells in an equal manner. Exposure of lymphocytes to 
glycyrrhizin markedly increased their responses to mitogens such as phytohemagglutinin 
(PHA)，concanavalin A (Con A), pokeweed mitogen (PWM) and lipopolysaccharide 
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(LPS) (Clavali et al., 1987). Moreover, the action of glycyrrhizin on T cells was 
demonstrated to be dependent on the cell maturation stages. For instance, glycyrrhizin 
was found to display two dissociated actions on immature thymocytes, accelerating IL-2 
production/IL-2 receptor (IL-2R) expression on one hand and inhibiting growth response 
on the other. These actions have been shown to accompany inhibition of tyrosine 
phosphorylation of p40 and c-fos expression in thymocytes activated by anti-CD3 
(Zhang et al., 1995). On the contrary, glycyrrhizin was found to promote the receptor 
mediated T-cell proliferation by affecting the late signaling transduction for IL-2 
production and IL-2R expression in matured T cells (Zhang et al., 1993; 1995). 
Moreover, the interferon (IFN)-inducing ability of glycyrrhizin and 18-p glycyrrhetinic 
acid was established in mice and the IFN induction by glycyrrhizin is dependent on the 
T-cell population (Abe et al, 1982). Furthermore, glycyrrhizin was reported to enhance 
the nitric oxide (NO) production in mouse peritoneal macrophages (Kondo et al., 1994; 
Nose et al” 1998). The glycyrrhizin-induced macrophages showed cytostasis against 
tumor cells such as LI210 and P388 lymphoma cell lines. It was proposed that 
glycyrrhizin could enhance IFN-y production in T-lymphocytes, which subsequently 
induced the production of NO in murine macrophages. 
The effect of 18-P glycyrrhetinic acid on the activation of human complement 
was also investigated. It was demonstrated that 18-p glycyrrhetinic acid but not 18-a 
glycyrrhetinic acid is a potent inhibitor of the classical complement pathway, however, it 
has no inhibitory activity towards the alternative pathway (Kroes et al., 1997). 
Mechanistic studies have shown that 18-p glycyrrhetinic acid exerts its effect at the level 
of the classical complement component C2. Recently, it was found that both 
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glycyrrhizin and 18-(3 glycyrrhetinic acid could enhance the leukocyte counts and 
cellular immunocompetence in y-ray-irradiated mice (Lin et al., 1996)，as in vivo 
administration of glycyrrhizin or 18-p glycyrrhetinic acid into y-irradiated mice 
significantly enhanced the recovery of spleen, thymus and testes from the injury of y-
irradiation. It is important to enhance the restoration from the injury to the hematopoietic 
system，if radiation must be used, such as in the case of radiotherapy. Thus glycyrrhizin 
and 18-p glycyrrhetinic acid could enhance animal immunity and help the irradiated 
animals to recover more quickly (Lin et al, 1999). 
1.3.2.5 Anti-hepatotoxic Effects 
Both 18-a glycyrrhetinic acid and 18-P glycyrrhetinic acid showed 
hepatoprotective effects against the carbon tetrachloride (CC^-induced cytotoxicity in 
rats (Nose et a!； 1994). They can abate necrosis, cirrhosis and hepatic degeneration by 
promoting the recovery of hepatocellular glycogen, ribonucleic acid and lowering serum 
glutamic pyruvic transaminase and increasing the leukocyte count and clearance rate of 
charcoal particles. The anti-hepatotoxic effect of 18-a/18-p glycyrrhetinic acid is more 
potent than glycyrrhizin due to their adsorbability into hepatocytes (Nose et al., 1996; 
Shim et al, 2000). 
Glycyrrhizin has already been used for its therapeutic and prophylactic effects on 
chronic viral hepatitis for more than twenty years in Japan (Ito et al, 1997). It was found 
that glycyrrhizin could exhibit anti-viral effects on hepatitis A, B and C viruses. It is 
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believed that glycyrrhizin and 18-p glycyrrhetinic acid can prevent the penetration of 
hepatitis virus into the cell by decreasing the cell membrane fluidity (Abe et ai, 1978). 
On the other hand, glycyrrhizin and 18-P glycyrrhetinic acid can suppress the secretion 
of hepatitis B surface antigen (HbsAg) in vitro and modify the interaction between the 
cell surface and hepatitis B virus (HBV) (Sato et al., 1996; Van Rossum et ai, 1999). 
A commercial drug currently available, called Stronger Neo Minophagen 
(SNMC), is a solution for intravenous use and consisting of 2 mg glycyrrhizin, 1 mg 
cysteine and 20 mg glycine per mL in physiological saline solution. Glycine is added so 
as to prevent pseudoaldosteronism. After treatment with SNMC, there is a significant 
improvement in serum transaminases level and histological findings in patients (Crance 
et al., 1994; Arase et ai, 1997; Van Rossum et al, 1999). Also, it has been shown that 
long term usage of SNMC is effective in preventing hepatocellular carcinoma 
development in patients with chronic hepatitis C (Ito et al, 1997; Van Rossum et al, 
1998). Nevertheless, the mechanisms by which SNMC exhibits its hepatoprotective 
effects remain undefined (Van Rossum et al, 1998). 
1.3.2.6 Anti-viral Activity 
It has been reported that glycyrrhizin at 8 mM can completely inhibit the growth 
and cytopathic effects of herps simplex type I virus, vesicular stomatitis virus, 
Newcastle disease virus, cytomegalovirus and vaccinia virus (Pompei et al, 1979; 
Numazaki et a!., 1994; Cermelli et al., 1996). This anti-viral effect may be due to the 
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interaction of glycyrrhizin with vims proteins at the virionic stage and during a later 
phase when these proteins are synthesized in host cells. For instance, glycyrrhizin was 
found to inhibit the expression of human cytomegalvirus antigen in a human monocytic 
cell line U937 and in a human embryonic lung cell line MRC-5 (Numazaki et al., 1994). 
On the other hand, glycyrrhizin can inhibit the penetration, uncoating and release of 
vims particle as it shows anti-viral effect on varicella zoster virus in human embryonic 
fibroblast cells in vitro (Pompei et al., 1979). Also, glycyrrhizin sulfate is a potent 
chemical against the human immunodeficiency virus (HIV) in vitro and in vivo (Hatano 
et al., 1988). Glycyrrhizin can completely inhibit the HIV-induced plaque formation in 
MT-4 cells at 0.5 mg/ml, and can also inhibit the virus-specific antigen expression in 
MT-4 cells and the HIV-induced cytoplasmic effect. Moreover, glycyrrhizin can protect 
mice exposed to a lethal amount of influenza virus via the stimulation of IFN-y 
production by T cells (Utsunomiya et al., 1997). These anti-viral activities may be 
ascribed to the activation of macrophages and stimulation of NO production in vivo. 
1-3.2.7 Anti-carcinogenic and Anti-tumor Effects 
There have been many studies on the cancer chemopreventive activities of 
glycyrrhizin and 18-p glycyrrhetinic acid. It was shown that chronic oral feeding of 
glycyrrhizin in drinking water exhibited protection against DMBA-initiated and 12-0-
tetradecanoylphorbol-13-acetate (TPA)-promoted skin tumorigenesis in Senear mice 
(Agarwal et al., 1991). Moreover, long term treatment of mice with glycyrrhizin 
significantly decreased the occurrence of hepatocellular carcinoma (HCC) in mice 
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treated with diethylnitrosamine (Shiota et al, 1999). It had been postulated that the anti-
carcinogenic activity of glycyrrhizin might be attributed to its ability to induce a variety 
of phase II enzymes involved in the detoxification and excretion of carcinogenic and 
toxic substances (Mirsalis et cd., 1993). Similarly, it was reported that 18-p 
glycyrrhetinic acid inhibited the tumor-promoting activity of teleocidin and TPA in ICR 
and Senear mice in a two-stage skin carcinogenesis model using DMBA as the tumor 
initiator (Nishino et al, 1986; Wang, 1994). On the other hand, Ngo et al. (1992) 
demonstrated that 18-P glycyrrhetinic acid significantly inhibited the binding of 
aflatoxin B1 to DNA and decreased its activation to carcinogenic metabolites. Others 
had shown that 18-P glycyrrhetinic acid exhibited cancer chemopreventing activity by 
protecting DNA damage induced by benzo(a) pyrene and also inhibited the stimulation 
of unscheduled DNA synthesis caused by benzo(a)pyrene (Chen & Han, 1995). 
Moreover, the effects of glycyrrhizin and 18-P glycyrrhetinic acid on various 
tumors have been examined. It was found that glycyrrhizin and 18-p glycyrrhetinic acid 
could inhibit the growth of cultured B16 melanoma cells and stimulated melanogenesis, 
suggesting that these two compounds can have effects on the differentiation of cancer 
cells in vitro (Abe et al., 1987). Sasaki et al (1989) showed that glycyrrhizin could 
suppress the proliferation of the human hepatocellular carcinoma HuH-7 cell line in 
vitro, possibly by interfering with DNA synthesis and arresting the cells at the GQ/GI 
phase of the cell cycle. On the other hand, a prolonged treatment of Ehrlich ascites 
tumor (EAT)-bearing mice with glycyrrhizin was found to be effective in modifying the 
survival pattern of the tumor-bearing mice (Rosssi et al., 1995). 
^ 
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More recently, preliminary findings indicated that giycyrrhizin and 18-P 
glycyrrhetinic acid have growth inhibitory effects on two lymphomas (Human Burkitt's 
lymphoma and non-Hodgkin's lymphoma) and two leukemias (Raji and SupTl cells) as 
measured by the trypan blue exclusion assay (Malagoli et al., 1998). These results were 
compared with those afforded by equimolecular doses of daunorubicin and they showed 
that giycyrrhizin and 18-p glycyrrhetinic acid were fairly active against leukemia cells. 
1.3.3 Other Biological Activities of Licorice 
Besides the pharmacological activities described in the previous sections, some 
other biological effects of licorice have been reported. For example, it has been found 
that licorice is an effective antitussive and expectorant. Oral administration of licorice 
can reduce inflammation of the laryngeal mucosa and exert a protective action to reduce 
irritation (Huang, 1999). Also, it was demonstrated that licorice is a potent antitoxin 
since it can lower the toxicity of snake venom, diphtheria, strychnine, histamine, tetanus 
toxin, chloral hydrate, etc (Mirsalis et al., 1993). Moreover, licorice can stimulate 
biosynthesis of cholesterol in rat liver and can lower the plasma levels of cholesterol and 
triacylglycerol in hypertensive patients by enhancing their excretion. Therefore it has a 
protective effect against arteriosclerosis formation (Huang, 1999). 
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1.3.4 A 96-kDa Glycyrrhizin-Binding Protein (gb96) 
A 96 kDa glycyrrhizin-binding protein (gb96) was selectively purified to 
apparent homogeneity from the partially purified soybean lipoxygenase 1 (LOX-1) 
fraction by means of glycyrrhizin-affinity column chromatography. The protein was 
identified as a glycyrrhizin-binding protein since it specifically binds to [^H] 18-P 
glycyrrhetinic acid. Moreover, it is a lipoxygenase (an enzyme that catalyzes the 
oxygenation of unsaturated fatty acids) because it displays LOX activity at pH 6.5. It is 
also recognized by antibodies against LOX-1 and LOX-2 in Western blot analysis. 
Moreover, the sequence of the N-terminal 21 amino acid residues 
(SNDVYLPRDEAFGHLLSSDFL) of a 42-kDa fragment (p42) proteolytically 
generated from gp96 is identical to a sequence of soybean LOX-3. It was found that 
phosphorylation of LOX by caesin kinase II (CK-II) was significantly stimulated by 3 
I^ M glycyrrhizin with the resulting enhancement of LOX activity. It is believed that CK-
II is a kinase responsible for the activation of LOX via its specific phosphorylation and 
glycyrrhizin is one of the regulator for specific phosphorylation of gbLOX (LOX-3) by 
CK-II in plant cells (Shimoyama et al., 1996; Ohtsuki et al, 1995). It is important to 
elucidate the physiological activities of these specific glycyrrhizin-binding proteins, 
because they are mediators responsible for the biological actions of glycyrrhizin in 
plants and animals. 
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1.3.5 Evaluation of Health Hazard 
It is known that glycyrrhizin binds to the human serum albumin. It is readily 
absorbed from the intestine and is generally metabolized in glucuronate form in the liver. 
It is further converted to 18-P glycyrrhetinic acid by the glucuronidase activity of 
anaerobic bacteria in the large intestine (Gunnarsdottir & Johannesson, 1997). Human 
studies showed that the half-life of glycyrrhizin after i.v. administration is 3.5 hours, and 
is independent of the dose administered (Yamamura et al., 1992). The elimination half-
life of 18-P glycyrrhetinic acid in humans is dose-dependent and was found to be 11.5 
hours after a dose of 100 mg, and 38.7 hours after a dose of 1500 mg (Krahenbuhl et al., 
1994). 
The main health hazards of licorice administration are due to the aldosterone-like 
effects of glycyrrhizin and 18-P glycyrrhetinic acid. Regular intake of licorice root 
(greater that 3 g/day for more than 6 weeks) or glycyrrhizin (>100 mg/day) may cause 
sodium and water retention, hypokalemia, hypertension, increase in body weight and 
suppression of the renin-aldosterone system (Farese et al, 1991; Stormer et al., 1993). 
Therefore, licorice should not used in patients with a history of hypertension or renal 
failure. There is a great variation in the individual's susceptibility to glycyrrhizin. 
Adverse effects are seldom observed at levels below 100 mg/day whereas side effects 
are commonly seen at levels that are above 400 mg/day (Stormer et al., 1993). 
Although consumption of large doses of licorice over extended periods of time 
has been known to be associated with a number of side effects through the 
3 2 
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mineralocorticoid action of glycyrrhizin, nevertheless, long-term (up to 110 weeks) oral 
administration of glycyrrhizin (0.5%) to mice did not yield any evidence of chronic 
toxicity or tumorigenicity (Kobuke et al, 1985) and an intake of glycyrrhizin at a dose 
of 3 mg/day for 50 days was found to be well tolerated by mice with no apparent signs 
of toxicity (Agarwal et al, 1991). 
Licorice was approved by the German Commission E to treat peptide ulcer, in 
doses of 200-600 mg glycyrrhizin daily and for treatment period not exceeding 6 weeks. 
In USA, licorice is used as a dietary supplement and is designated as "Generally 
Recognized as Safe" (GRAS) (Newton & Cupp, 2000). In Japan, daily administration of 
glycyrrhizin is a standard practice. It was reported that glycyrrhizin administered i.v. up 
to 240 mg, thrice weekly, for 4 weeks, appeared to be safe and well tolerated by humans 
(Van Rossum et al., 1999). 
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1.4 Aims and Scopes of This Research 
It is well documented that glycyrrhizin and 18-p glycyrrhetinic acid exert a wide 
range of pharmacological activities as discussed in the previous section (Section 1.3). To 
our knowledge, however, there has been no report that demonstrates the effects of 
glycyrrhizin or 18-p glycyrrhetinic acid on the differentiation or apoptosis of leukemia 
cells. The potential therapeutic effects of these two natural products on leukemia and 
their action mechanisms have not been fully elucidated. Therefore, the aim of my project 
is to investigate the effects of glycyrrhizin and 18-P glycyrrhetinic acid on the 
proliferation, differentiation and apoptosis of leukemia cells and to elucidate their action 
mechanisms at the cellular and molecular levels. 
In my research project, a murine myelomonocytic leukemic cell line, designated 
as WEHI-3B JCS, will be used in my studies. It is an excellent and well characterized 
model to study the processes of leukemic cell proliferation, differentiation and apoptosis 
and the mechanisms by which they can be regulated. The growth of JCS cells is factor-
independent but serum dependent (Mak et a!., 1993). It has been demonstrated that the 
proliferation and differentiation of JCS can be modulated by a variety of cytokines (Mak 
et al., 1993; Leung et al., 1994; Chan et al, 1995)，some natural products and 
pharmacological agents (Fung et al., 1997). Moreover, JCS cells can be expanded in 
俞o to produce a large homogeneous population of undifferentiated myeloid leukemia 
cells. They also respond to various inducers and undergo differentiation to become 
granulocyte-like or macrophage-like cells. Thus these properties make JCS cells to be an 
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ideal model for the studies of myeloid leukemic cell proliferation, differentiation and 
apoptosis. 
Previous studies in our laboratory had shown that TNF-a, IFN-y and IL-1 could 
induce the differentiation of leukemia JCS cells into mature cells with the characteristics 
of macrophages (Mak et al., 1993; Chan et al” 1997). It was found that TNP-a alone 
can act as a differentiation signal for JCS cells and that monocytic differentiation of the 
leukemia JCS cells was synergistically enhanced by interleukin-4 (IL-4) (Leung et al., 
1994) or pertussin toxin (Mak et al., 1994). 
First of all, in this thesis project, the anti-proliferative and cytotoxic effect of 
glycyrrhizin and 18-P glycyrrhetinic acid on a number of well-characterized murine and 
human leukemic cell lines will be assessed by the tritiated thymidine incorporation assay 
and the trypan blue exclusion assay respectively. The ability of glycyrrhizin and 18-p 
glycyrrhetinic acid to induce apoptosis in leukemia cells will be measured by the DNA 
fragmentation assay. Furthermore, the cell cycle kinetics of glycyrrhizin or 18-P 
glycyrrhetinic acid-treated JCS cells will be analyzed by flow cytometry. On the other 
hand，the effect of glycyrrhizin and 18-p glycyrrhetinic acid on the in vivo 
tumorigenicity of WEHI-3B JCS will also be studied using syngeneic BALB/c mice. 
Moreover, the differentiation-inducing ability of glycyrrhizin and 18-P 
glycyrrhetinic acid will be assessed by a number of criteria, including morphologic, 
phenotypic and functional assays. Morphological changes of drug-treated cells will be 
examined by staining of cytocentrifuge preparations. Also, the surface expression of 
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lineage-specific differentiation antigens and adhesion molecules will be examined by 
flow cytometry. 
Finally, the combining effects of glycyrrhizin and 18-p glycyrrhetinic acid with 
other cytokines in modulating the growth of leukemia cells will be studied. Reverse 
transcription polymerase chain reaction (RT-PCR) and Western blot will be used to 
analyze the expression of certain growth-regulatory and apoptosis-related genes and 
proteins so as to elucidate the molecular mechanisms by which glycyrrhizin and 18-p 
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2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (H-2'') mice aged 6-8 weeks old were bred at the University 
Laboratory Animal Services Center of the Chinese University of Hong Kong. They were 
bred under a specific pathogen-free condition, fed with animal diet (Chow 5001, Rodent 
Laboratory) and tap water ad libitum. 
2.1.2 Cell Lines 
1) Myeloid Leukemias: 
a) HL-60 is a human promyelocytic leukemic cell line originated from a 36-
years-old Caucasian female with acute promyelocytic leukemia (Collins et al, 
1978). It was purchased from the American Type Culture Collection (ATCC), 
U.S.A. 
b) K562 is a human chronic myelogenous leukemic cell line established from the 
pleural effusion of a 35-years-old female with chronic myelogenous leukemia in 
terminal blast crises (Lozzio & Lozzio, 1975). It was purchased from ATCC. 
c) EoL-1 is a human eosinophilic leukemic cell line originated from the peripheral 
blood of a patient with Philadelphia chromosome-negative eosinophilic leukemia 
(EL) (Saito et al. 1985). This cell line was kindly provided by Prof. C. K. Wong, 
Department of Chemical Pathology, the Chinese University of Hong Kong. 
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d) Ml is a murine myeloblastic leukemic cell line derived from a spontaneous 
myeloid leukemia of SL strain mice in vitro (Ichikawa, 1969). It was purchased 
from ATCC. 
e) WEHI-3B D' is a mineral oil-induced murine myelomonocytic leukemic cell line 
derived from BALB/c mice and was originally obtained from Dr. D. Metcalf 
(Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia). It 
was subsequently subcloned and maintained at the John Curtin School of 
Medical Research, Australian National University, Canberra, Australia. One of 
the subclones designated as WEHI-3B JCS was used thoughout this study 
(Leung et al, 1994). 
2) Lymphoid Leukemias: 
a) MBL-2 is a Moloney leukemia virus-induced T cell lymphoma originated from 
C57BL/6J mice (Ng et al, 1978). It was obtained from the Department of 
Pathology, University of Cambridge, U.K. 
b) YAC-1 is a Moloney leukemia virus-induced T cell lymphoma originated from 
A/Sn mice (Asjo et al, 1977). It was purchased from ATCC. 
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2.1.3 Cell Culture Medium, Buffers and Other Reagents 
1) Cell Culture Medium 
a) RPMI 1640 Medium (Powder Form) 
The powder form of RPMI 1640 medium (GIBCO BRL Life Technologies Inc.), 
supplemented with 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid 
(HEPES) and 2 mM L-glutamine was used for the preparation of culture medium 
which was used for sub-culturing of cells. One-liter culture medium was prepared 
by dissolving 16.2 g of powder in double distilled water and buffered with 2 g 
sodium bicarbonate (NaHCOs) (Sigma Chemicals Co.). The solution was then 
adjusted to pH 7.2 by 1 M HCl and 1 M NaOH (Sigma Chemicals Co.). Afterwards, 
it was sterilized by membrane filtration through a 0.22 |um millipore filter and 
stored at 4°C until use. 
b) RPMI 1640 Medium (Liquid Form) 
The sterilized liquid form of RPMI 1640 medium, supplemented with 25 mM 
HEPES and 2 mM L-glutamine at pH 7.2, was purchased from GIBCO BRL Life 
Technologies Inc. It was used for the preparation of stock solution of cytokines and 
other chemicals for cell cultures. 
2) Serum Supplements 
Fetal Calf Serum (FCS) (GIBCO BRL Life Technologies Inc.) was stored as 20 
ml and 10 ml aliquots. Heat-Inactivated Fetal Calf Serum (HI-FCS) was prepared as 
20 ml and 10 ml aliquots in sterile universal bottles by heating the FCS at 56°C for 
30 minutes. They were stored at -20°C until use. 
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3) Antibiotic Solutions 
The Antibiotic-Antimycotic (PSF) [10,000 units/ml penicillin G (sodium salt), 
10,000 |ag/ml streptomycin sulfate and 25 f^g/ml amphotericin B as Fungizone in 
0.85% saline] and Antibiotic (PSN) [5,000 |ag/ml penicillin G sodium, 5,000 fag/ml 
streptomycin sulfate and 10,000 jug/ml neomycin sulfate in 0.85% saline] lOOx 
stock solutions were purchased from GIBCO BRL Life Technologies Inc. They 
were stored as 5 ml aliquots at -20°C until use. 
4) Complete RPMI Medium 
RPMI medium supplemented with only 1% antibiotics, which was catergoried as 
"Plain Medium", was usually used in washing cells. Complete RPMI Medium (CM) 
was prepared by supplementing plain medium with 10% or 20% HI-FCS or FCS. 
CM supplemented with 10% FCS was used for sub-culturing most of the human and 
murine cell lines while 20% FCS supplemented CM was used for sub-culturing HL-
60 cells. 
5) Dulbecco's Phosphate-Buffered Saline (PBS) 
PBS (Sigma Chemicals Co.) was prepared by dissolving 0.2 g monobasic 
potassium phosphate, 0.2 g potassium chloride, 8 g sodium chloride and 1.15 g 
dibasic sodium phosphate in one liter double distilled water. The pH was then 
adjusted to 7.4 by 1 M HCl and 1 M NaOH. It was then sterilized by autoclaving at 
121°C for 15 minutes. 
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6) Ficoll-Paque Solution 
Ficoll-Paque was used for the isolation of lymphocytes in vitro. It contained 5.7 
g Ficoll，9 g sodium diatrizoate and calcium EDTA in 100 ml water (density = 1.077 
g/ml). It was purchased from Pharmacia Biotech., Asia Pacific Ltd., Hong Kong. 
7) 2-Mercaptoethanol (2-ME) Solution 
Stock solution of 0.1 M of 2-ME (Sigma Chemical Co.) was prepared in 
sterilized double distilled water. It was stored as 200 |al aliquots in dark at -20°C 
until use. 
8) Normal Saline (NS) 
Normal saline was prepared by dissolving 9 g sodium chloride (Sigma Chemicals 
Co.) in one liter double distilled water. It was then sterilized by autoclaving at 121°0 
for 15 minutes. 
9) Dye solutions 
a) Hemacolor Staining Solutions 
Hemacolor staining solutions (Diagnostica Merck) were used to stain cells after 
cytocentrifugation and consisted of three different solutions. Hemacolor Solution 1 
was methanol for fixing cells, Solution 2 was a buffered color reagent red and 
Solution 3 was a buffered color reagent blue. The buffer solutions were prepared by 
dissolving 1 buffer tablet in 1 liter of freshly distilled water. They were stable for at 
least 4 weeks and stored in a tightly closed glass bottle. All staining solutions were 
light-protected and stored at room temperature. 
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b) Trypan Blue Solution 
Trypan blue solution was purchased from Sigma Chemical Co. It contained 0.4% 
(w/v) trypan blue dissolved in 0.817% sodium chloride and 0.06% dibasic potassium 
phosphate. 
10) Glycyrrhizin (GL) 
Glycyrrhizin with an estimated purity of -95% was obtained from Fluka Chemical 
Company Inc. It was freshly prepared by dissolving in plain RPMI 1640 medium as a 
10 mM stock solution. 
11) 18-PGIycyrrhetinic Acid (GA) 
18p—Glycyrrhetinic acid with an estimated purity of �97o/o was purchased from 
Aldrich Chemical Company Inc. It was dissolved in cell culture tested, sterile 
dimethylsulfoxide (DMSO) as a 60 mM stock solution. The stock solution was stored 
in dark as 250 |LI1 aliquots at -20°C until use. 
2.1.4 Recombinant Cytokines 
1) Recombinant Murine Interleukin-la (rmlL-la) 
Recombinant murine IL-la (Peprotech) is a recombinant protein derived from E. 
CO". The sterile filtered solution was lyophilized from 1 mM Tris buffer solution. The 
stock solution (100 ^ig/ml) was prepared in sterilized RPMI medium supplemented 
with 2% HI-FCS and stored as 250 |al aliquits at -70°C until use. Its biological 
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activity was measured in a cell proliferation assay using a murine helper T cell line 
DIOS cells. The specific activity was around 5x10^ units/mg. 
2) Recombinant Murine Tumor Necrosis Factor-a (rmTNF-a) 
Recombinant murine TNF-a (Pepro Tech EC Ltd.) is a lyophilized recombinant 
protein derived from E. coli. It was reconstituted in autoclaved distilled water to a 
concentration of 100 |Lig/ml and the solution was further diluted to 10 jig/ml in 
sterilized RPMI medium supplemented with 2% HI-FCS. It was kept as 250 |li1 
aliquots at -20°C until use. The specific activity was about 1 x 1 u n i t s / m g . The 
biological activity was determined by the cytolysis of murine L929 cells in the 
presence of actinomycin-D. 
3) Recombinant Murine Interferon-y (rmlFN-y) 
Concentrated recombinant murine IFN-y (Roche) was diluted to the required 
concentration with PBS. It was stored at -20°C until use. The specific activity was 
about 1x10^ units/ml. The biological activity was determined by a cytopathic effect 
inhibition assay with murine L929 cells challenged with the encephalomyocarditis 
(EMC) virus. 
2.1.5 [methyl-^H] Thymidine (^H-TdR) 
The stock solution (Amersham Life Science Ltd.) was kept as 500 i^l aliquots 
at 4°C and its specific activity was 2 Ci/mmol. It was freshly diluted with complete 
RPMI medium to make up the 25 ^iCi/ml working solution. In cell labeling 
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experiment, 20 |ul working solution was added to each well of the 96-well flat-
bottomed microtiter plate. 
2.1.6 Liquid Scintillation Cocktail 
The OptiPhase 'High' safe-2 liquid scintillation cocktail (Wallac Scintillation 
Products) is based on biodegradable solvents with dioctyl sulfosuccinate, sodium 
salts and poly(ethyleneglycol)mono(4-nonylphenyl)-ether. It was ready to use and 
stored in dark at room temperature. 
2.1.7 Reagents and Buffers for Flow Cytometry 
1) Propidium Iodide (PI) DNA Staining Buffer 
The PI DNA staining buffer was freshly prepared in PBS which contained 400 
l^g/ml ribonuclease A (RNase A) (Boehringer Mannheim), 50 ^ig/ml propidium 
iodide (Boehringer Mannheim.), 10 mM EDTA (pH 7.4) (Sigma Chemical Co.), 
0.1 o/o trisodium citric acid (Sigma Chemical Co.) and 0.1% Triton X-100 (Sigma 
Chemical Co.). It was kept at 4 � C until use. 
2) FACS Medium 
It contained 2% HIFCS and 0.05% sodium azide in PBS. The azide was added 
to inhibit the process of internalization of cell-bound antibodies as well as patching 
and capping of the cells. The FACS medium was used for washing and resuspension 
of cells in FACS analysis and was kept at 4°C. 
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3) FACS Flow Shealth Fluid 
The shealth fluid is a ready-to-use product (Becton Dickinson International) 
and a balanced electrolyte solution containing sodium chloride, potassium chloride, 
disodium EDTA, sodium fluoride and anti-microbial agent. The solution was kept at 
room temperature. 
2.1.8 Monoclonal Antibodies 
1) Rat Anti-mouse CDl la (Lymphocyte Function-Associated Antigen-1, LFA-Iccl 
chain) 
It is a rat monoclonal antibody derived from clone Ml7/4 and belongs to the 
IgG2a isotype. It was purchased from Pharmingen and the purified antibody reacts 
with the otL subunit of the LFA-1 (CDlla/CD18, ocl P2 integrin). Small volume 
aliquots of the antibody were kept at -70°C until use. 
2) Rat Anti-mouse Macrophage Differentiation Antigen CDl lb (Mac-1) 
Monoclonal Antibody (clone Ml/70, rat IgG2b isotype) 
It was prepared from the culture supernatant of the hybridoma cell line Ml/70 
that was purchased from ATCC. Small volume aliquots of the antibody were kept at 
-70^C until use. 
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3) Rat Anti-mouse Macrophage Differentiation Antigen F4/80 Monoclonal 
Antibody (done C1.A3-1, rat IgGzb isotype) 
It was prepared from the culture supernatant of the hybridoma cell line F4/80 
that was obtained from ATCC. Small volume aliquots of the antibody were kept at 
-70OC until use. 
4) Rat Anti-mouse CD54 (Intercellular Adhesion Molecule-1, ICAM-1) 
Monoclonal Antibody (clone BE29G1, rat IgG isotype) 
It was prepared from the culture supernatant of the hybridoma cell line E29G1 
that was purchased from ATCC. Small volume aliquots of the antibody were kept at 
-70°C until use. 
5) Rat Anti-mouse CD106 (Vascular Cell Adhesion Molecule-1, VCAM-1) 
Monoclonal Antibody (clone 429，rat IgG2b isotype) 
It was purchased from Pharmingen. The purified antibody specifically binds 
with VCAM-1. Small volume aliquots of the antibody were kept at -70°C until use. 
6) Rat Anti-mouse Myeloid Differentiation Antigen Gr-1 Monoclonal Antibody 
(clone RB6-8C5, rat IgGib isotype) 
It was purchased from Pharmingen. The RB6-8C5 antibody reacts with the 
myeloid differentiation antigen, Gr-1, which was also known as Ly-6G. Gr-1 is a 
21-25 kDa GPI-anchored protein (Fleming et al, 1993). The RB6-8C5 antibody 
was stored at -70°C until use. 
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7) Fluorescein Isothiocyanate (FITC)-coiijugated Goat anti-rat IgG Antibody 
It was purchased from Southern Biotechnology Associates Inc. The purified 
antibody reacts specifically with rat IgG and did not react with other heavy chain 
isotypes. 
8) Mouse IgG and Rat IgG 
They were purchased from Sigma Chemical Co. They were used to block the 
non-specific binding of immunoglobulins to the Fc receptors of the cells in 
immunophenotyping experiments. They were stored in small aliquots at -20°C. 
2.1.9 Reagents for DNA Extraction 
1) IGEPAL CA-630 Lysis Buffer 
This lysis buffer was purchased from Sigma Chemicals Co and IGEPAL is a 
registered trademark of Phone-Poulenc, Inc. The buffer was prepared in 50 mM Tris 
[hydroxylmethyl] amino methane (Tris)-HCl, pH 7.5 with 3% non-ionic detergent 
IGEPAL CA-630 ((Octylphenoxy) polyethoxyethanol) and 20 mM EDTA. It was 
kept at room temperature. 
2) Proteinase K 
It was purchased from Boehringer Mannheim. It is a highly active subtilisin 
type of protease. It was purified from the mold Tritirachium album Limber and the 
stock solution was prepared by dissolving it in autoclaved double distilled water to a 
concentration of 20 mg/ml and stored as 500 fal aliquots at -20°C until use. 
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3) RNase A 
The pancreatic RNase (Boehringer Mannheim) was dissolved at a concentration 
of 10 mg/ml in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl. The stock solution was 
heated to 100�C for 15 minutes. It was then allowed to cool slowly to room 
temperature. It was stored as 500 aliquots at -20°C until use. 
4) Sodium Acetate Solution (NaOAC) 
3 M sodium acetate solution (Sigma Chemical Co.) was prepared by dissolving 
24.61 g sodium acetate in 100 ml double distilled water. It was then sterilized by 
autoclaving at 121°C for 15 minutes. The solution was kept at room temperature. 
5) TioEo.i Buffer 
丁he TioEo.i buffer contained 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
distilled water. The solution was kept at room temperature. 
2.1.10 Reagents for Total RNA Isolation 
1) DEPC-treated Double Distilled Water 
Double distilled water was treated with 0.1% diethyl pyrocarbonate (DEPC) 
(Sigma Chemical Co.) and shaken thoroughly to disperse the DEPC. The solution 
was then autoclaved at 121�C for 15 minutes so as to destroy the remaining DEPC 
after standing overnight. 
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2) Trizol Reagent 
It is a ready-to-use reagent (GIBCO BRL Life Technologies Inc.) for the 
isolation of total RNA from cells and tissue. It is a mono-phasic solution of phenol 
and guanidine isothiocyanate. It was stored in dark at 4°C until use. 
2.1.11 Reagents and Buffers for RT-PCR 
1) Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) 
The M-MLV reverse transcriptase (GIBCO BRL Life Technologies Inc.) was 
isolated from E. coli and it uses single-stranded RNA or DNA in the presence of a 
primer to synthesize a complementary DNA strand. This enzyme was stored in a 
buffer of 20 mM Tris-HCl pH 7.5, 1 mM dithiothreitol (DTT), 0.01% (v/v) NP-40, 
0.1 mM disodium EDTA, 0.1 M sodium chloride and 50% (v/v) glycerol at -20°C. 
One unit of its activity was defined as the amount of enzyme that would incorporate 
1 mole ofdeoxythymidine triphosphate (dTTP) into acid-precipitable material in 10 
minutes at 37"C, using poly(A) and oligo-dTn-ig as template and primer 
respectively. 
2) First Strand Buffer (5X) 
The first strand buffer (GIBCO BRL Life Technologies Inc.) was supplied as a 
5X solution of 250 mM Tris-HCl (pH 8.3), 375 mM potassium chloride and 15 mM 
magnesium chloride (MgCb). 
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3) 01igo-dTi2-i8，Sodium Salt (pd(T)i2-i8，sodium salt) 
01igo-dTi2-i8 (Promega Corporation) was prepared as a stock solution of 1 
^ig/jul in TioEo.i buffer and stored at -20°C. 
4) Primer Pairs 
The reverse-transcription polymerase chain reaction (RT-PCR) was used to study 
the apoptosis-regulatory and growth-related gene expression. The specific pairs of 
oligonucleotide primers were designed according to the published sequences of their 
cloned cDNA. They were designed to prime on the sense and antisense sequences of 
the corresponding cDNA respectively (Table 2.1). The PGR primers were synthesized 
by GIBCO BRL Life Technologies Inc. The lyophilized primer pairs were 
reconstituted in DEPC-treated double distilled water to a working concentration of 
2.5 |aM. The primers were stored as 500 i^l aliquots at -20°C. They have the 
annealing temperature of 59°C. 
For the study of cytokine gene expression, the PGR primers were also 
synthesized by GIBCO BRL Life Technologies Inc. The lyophilized primer pairs 
were reconstituted in DEPC-treated double distilled water to a working concentration 
of 2.5 pmole/ul. The primers were stored as 500 aliquots at —20�C. They have the 
annealing temperature of 59°C. The oligonucleotides used in cytokine gene study 
were kindly provided by Prof. M.C. Fung, Department of Biology, the Chinese 
University of Hong Kong, Hong Kong. They were designed to prime on the sense and 
antisense sequences of the corresponding cDNA respectively (Table 2.2). 
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Table 2.1: Primers used in RT-PCR and the predicted sizes of the PGR products. 
^ ^ S e q u e n c e (5，to 3，) Predicted size 
腿P l i ^ d of the amplified 
PGR product 
(bp) 
GAPDH Sense strand: ^ 
TGA AGG TCG GAG TCA ACG GAT T T G G T 
Antisense strand: 
CAT GTG GGC CAT GAG GTC CAC CAC 
PKC-a Sense strand: ^ 
TGA ATC CTC AGT GGA ATG AGT 
Antisense strand: 
GGT TGC TTT CTG TCT TCT GAA 
PKC-P Sense strand: ^ 
TTC AGA TTT CAG CTG AAG GAA 
Antisense strand: 
GTC AAA TTT GGA GAT AGT GTT 
PKC-y Sense strand: ^ ^ 
CGG GCT CCT ACG TCG GAT GAG 
Antisense strand: 
GCA GGC GTC CTG GGC TGG CAC C 
PKC-6 Sense strand: 
CAC CAT CTT CCA GAA AGA ACG 
Antisense strand: 
CTT GCC ATA GGT CCC GTT GTT G 
PKC-s Sense strand: 
CAT CGA TCT CTC GGG ATC ATC G 
Antisense strand: 
CGG TTG TCA AAT GAC AAG GCC 
PKC-r| Sense strand: ^ 
GGA TAA TGC GAC AAG GAC TTC 
Antisense strand: 
GAA GAG TTA ACA CCG ATC CCA 
PKC-6 Sense strand: ‘ 
TTG ATC TTT CCA GAG CCA CG 
Antisense strand: 
CTT CGC ATC TCC TAG CAT G 
PKC-(!； Sense strand: “ ^ 
CGA TGG GGT GGA TGG GAT CAA AA 
Antisense strand: 
GTG TTC ATG TCA GGG TTG TCC G 
PKC-A, Sense strand: ^ 
CGT TGG GAG CTC TGA CAA TC 
Antisense strand: 
ACC TGC TTT TGC TCC ATC ATG [_ 
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NF-kB p50 Sense strand: “ ‘ “ ~ ^ 
AAA GGT TAT CGT TCA GTT 
Antisense strand: 
TTG TAT ATA GGC AAG GTC 
Fas Sense strand: p ^ 
ACA GCA ACC AGC AAT ACA 
Antisense strand: 
GTA TGG TTT CAC GAC TGG 
P53 Sense strand: ^ 
TCT GGG ACA GCC AAG TCT GT 
Antisense strand: 
GGA GGC TTC CAG TGT GAG GA 
Bad Sense strand: ^ 
ATC CCA GAG TTT GAG TCG AGG GA 
Antisense strand: 
TTC GAG CCC ACC AGG ACT GGA 
Bak Sense strand: ^ 
GCC CAG GAC ACA GAG GAG GTT TTC 
Antisense strand: 
AAA CTG GCC CAA CAG AAC CAC ACC 
BC1-XL Sense strand: ^ 
TGG CAA CCC ATC CTG GCA CCT 
Antisense strand: 
ACT GAA GAG TGA GCC CAG CAG AAC 
Table 2.1(Cont.) 
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Table 2.2: Primers used in RT-PCR and the predicted sizes of the PCR products. 
cDNA Sequence (5，to 3，) 
amplified Size of amplified 
PCR product (bp) 
IL-1 a Sense strand: 
ACA GTA TCA GCA ACG TCA AGC AA 
Antisense strand: 
CCG ACT TTG TTC TTT GGT GGC A 
IL-lp Sense strand: 
GAG CTT CAG GCA GGC AGT ATC 
Antisense strand: 
GTA TAG ATT CTT TCCTTT GAG GC 
IL-6 Sense strand: 
TGA GAA AAG AGT TGT GCA ATG GC 
Antisense strand: 
GTT AGG AGA GCA TTG GAA ATT GC 
TNF-a Sense strand: ^ 
TCC CCA AAG GGA TGA GAA GTT C 
Antisense strand: 
TCA TAG CAG GGT TTG AGC TCA G 
TGF-P Sense strand: 
CAT GGA GCT GGT GAA ACG GAA GCG 
CATC 
Antisense strand: 
CTC CAG TGA CGT CAA AAG ACA GCC 
ACTC 
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5) rRNasin Ribonuclease Inhibitor 
The rRNasin ribonuclease inhibitor (Promega Corporation) is a recombinant 
protein originated from E. coli. It was supplied at a concentration of 40 units/fil and 
this inhibitor was active over a broad pH range, but required a minimium of 1 mM 
DTT to maintain activity. It was stored at -20^C in a buffer which contained 20 mM 
HEPES-potassium hydroxide (HEPES-KOH, pH 7.6)，50 mM potassium chloride 
(KCl)，8 mM dithiothreitol (DTT) and 50% (v/v) glycerol. One unit was defined as 
the amount of rRNasin ribonuclease inhibitor required to inhibit 50% activity of 5 ng 
RNase A as measured by the inhibition of hydrolysis of cytidine 2', 3'-cyclic 
monophosphate. 
6) ThermoprimePius dNA Polymerase 
ThermoprimePius DNA Polymerase (Advanced Biotechnologies Ltd.) is a 
thermostable DNA polymerase isolated from Thermophilic bacteria. The enzyme was 
supplied with a lOX reaction buffer (Buffer IV) and a separated vial of magnesium 
chloride (MgCb). They were stored at 一20°C. ThermoprimeP'"^ DNA Polymerase is a 
single polypeptide of approximately 94 kd which has 5’ to 3’ polymerisation-
dependent exonuclease replacement activity, but lacks the 3' to 5' exonuclease 
activity. One unit of enzyme was defined as the amount that would incorporate 10 
nmoles ofdNTPs into acid insoluble material in 30 minutes at ATC, 
7) Ultrapure dNTP set, 2'-Deoxynucleoside 5，-Triphosphate，Sodium Salt 
The deoxynucleoside triphosphate (dNTP) set (Pharmacia Biotech.) was a stock 
solution containing 10 mM of each dNTP. It was prepared in 1 mM Tris-HCl (pH 7.5) 
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and stored at -20°C. Each nucleotide was originally supplied as 100 mM solution in 
double distilled water (pH 7.5). 
2.1.12 Reagents and Buffers for Gel Electrophoresis 
1) Ethidium Bromide (EtBr) 
A stock solution (10 mg/ml) of ethidium bromide (Sigma Chemical Co.) was 
prepared by dissolving the EtBr in double distilled water and the working solution 
was prepared by diluting the stock solution by 1,000 fold. Both the stock and 
working solutions were kept in dark at room temperature, 
2) Gel Loading Solution (5x) 
The gel loading solution (Sigma Chemical Co.) was a 5X solution containing 
0.05% (w/v) bromophenol blue, 40% (w/v) sucrose，0.1 M EDTA (pH 8.0) and 
0.5% sodium dodecyl sulfate (SDS). This was used for non-denaturing agarose gel 
electrophoresis of nucleic acids. 
3) Tris-HCl Buffer (pH 7.5) 
Tris[hydroxylmethyl] amino methane (Tris) (Sigma Chemicals Co.) was 
prepared as 1 M stock solution in DEPC-treated double distilled water. The buffer 
was adjusted to pH 7.5 with hydrochloric acid (HCl) and then autoclaved at 121°C 
for 15 minutes and was then stored at 4°C. 
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4) Tris-Borate-EDTA (TBE) Electrophoresis Buffer (5x) 
The 5X TBE electrophoresis buffer stock was prepared by dissolving 54 g Tris, 
27.5 g boric acid and 20 ml 0.5 M EDTA in 1 litre double distilled water. The pH of 
the buffer was adjusted to 8.0. 0.5X working TBE buffer was prepared by diluting 
one part of the 5X stock TBE buffer with nine parts of double distilled water and 
both of the working and stock solutions were both kept at 4°C. 
5) Agarose Gel 
Agarose gels (1% and 2%) were prepared by dissolving 10 g and 20 g agarose 
(Sigma Chemicals Co.) respectively in 1 liter 0.5X TBE buffer by heating at 70°C 
on a hot plate. The 1% agarose gel was used for RNA gel electrophoresis while the 
2% agarose gel was used for DNA and PGR products gel electrophoresis. 
2.1.13 Reagents and Buffers for Western Blot Analysis 
1) 30% (w/v) Acrylamide Solution 
The acrylamide (30%) stock solution was prepared by dissolving 30 g 
acrylamide and 0.8 g N,N'-methylene-bis-acryIamide (Sigma Chemicals Co.) in 100 
ml double distilled water. The arcylamide solution was light-protected and stored at 
4�C. 
2) 10% (w/v) Ammonium Persulfate (APS) 
Ammonium persulfate (Bio-Rad Lab.) was prepared by dissolving 0.5 g APS in 
5 ml double distilled water and the solution was kept in 500 |LI1 aliquots at - 2 0 � C 
until use. , 
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3) Cell Lysis Buffer 
The cell lysis buffer contained 20 mM Tris-HCl (pH 8.0), 120 mM sodium 
chloride, 1% (v/v) Triton X-100 (Sigam Chemicals Co.), 1 mM EGTA, 50 |aM 2-
mercaptoethanol and one tablet of complete protease inhibitor cocktail (Boehringer 
Mannheim) in 50 ml double distilled water. Each complete protease inhibitor 
cocktail when dissolved in 50 ml lysis buffer yielded 1 mM EDTA. A mixture of 
several protease inhibitors with a broad spectrum of activity on serine, cysteine and 
metalloproteases and calpains inhibitors would be obtained. The cell lysis buffer 
was kept as 5 ml aliquots at -70°C until use. 
4) Coomassie Blue Staining and Destaining Solution 
The staining solution was prepared by mixing one part of 0.05% Coomassie 
blue (Bio-Rad Lab.) in acetic acid, three parts of methanol and ten parts of double 
distilled water. For the destaining solution, it was prepared by mixing one part of 
acetic acid, three parts of methanol and ten parts of double distilled water. The 
Coomassie blue staining and destaining solutions were used to stain and destain the 
SDS-polyacrylamide gel and PVDF Western blotting membrane. 
5) ECL Films (Hyperfilm ^^ ECL 
The Hyperfilm ™ ECL 丁m (Amersham Life Science) was a high performance 
chemiluminescence film used for Western blot analysis. It was designed for 
processing in automatic processors at temperatures up to 38�C and the film was 
stored in a dry place at 4�C and protected from light and noxious fumes. 
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6) RPN 2108ECL Western Blotting Analysis System 
It was a Western blotting detection kit (Amersham Pharmacia Biotech.) that 
contained a detection reagent 1 (62.5 ml), detection reagent 2 (62.5 ml), anti-mouse 
Ig secondary antibody (horseradish peroxidase-linked whole antibody from sheep, 
100 |Lil), anti-rabbit Ig secondary antibody (horseradish peroxidase-linked whole 
antibody from donkey, 100 |al), and 5 g blocking reagent. It was used for the 
detection of either mouse or rabbit membrane bound primary antibodies and stored 
at 4�C. 
7) Lower Buffer for Separating Gel 
It was a 1.5 M Tris-HCl buffer adjusted to pH 8.8 (Sigma Chemicals Co.) and 
kept at 4�C. 
8) 2X SDS Sample Buffer 
SDS (2X) sample buffer containing P-mercaptoethanol and bromophenol blue 
(100 ml) was prepared by dissolving 1.51 g Tris base, 20 g glycerol, 10 ml 2-
mercaptoethanol and 4.6 g SDS in 80 ml double distilled water. The pH was 
adjusted to 6.8 with HCl, and the volume was then added up to 100 ml. 
Bromophenol blue was added to a final concentration of 0.006%. The sample buffer 
was stored at 4°C. All the reagents were purchased from Sigma Chemicals Co. 
9) N,N,N',N'-Tetra-methylethylenediamine (TEMED) 
TEMED (Bio-Rad Lab) was stored at 4°C and used to initialize the 
polymerization of SDS-polyacrylamide gel. 
5S 
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10)Prestained SDS-PAGE Standards 
The prestained SDS-PAGE standards (Bio-Rad Lab.) contained a blue dye 
attached to standard proteins including myosin (212,000), P-galactosidase 
(122,000), bovine serum albumin (83,000), ovalbumin (51,800), carbonic anhydrase 
(35,000)，soybean trypsin inhibitor (28,400), lysozyme (20,000) and aprotinin 
(7,200). The standard proteins (total 625 |ig) were prepared in 33% (v/v) glycerol, 
3% SDS, 10 mM Tris (pH 7.0)，10 mM DTT, 2 mM EDTA, 0.01% NaNs and stored 
at -20"C. 
11) PVDF Western Blotting Membranes 
The microporous polyvinylidene difluoride (PVDF) membrane (Boehringer 
Mannheim) has a pore size of 0.45 |im. It was stored at room temperature. 
12) Primary Antibodies 
a) Rabbit Anti-Bak Polyclonal Antibody 
It is a rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.) that was 
raised against a recombinant protein corresponding to amino acids 1-211. Each vial 
contained 200 [ig IgG in 1.0 ml of PBS with 0.1% sodium azide and 0.2% gelatin. 
The amino acid sequence represented the Ml length of Bak of human origin and the 
antibody reacted with Bak of mouse, rat and human origin. It was stored at 4X. 
b) Rabbit Anti-FAS Polyclonal Antibody 
It is a rabbit polyclonal antibody (Santa Cruz Biotechnology Inc.) that raised 
against a recombinant protein corresponding to amino acids 1-335 representing the 
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full length of FAS (also designated APO-1 or CD95) of human origin. Each vial 
contained 200 |Lig IgG in 1.0 ml of PBS with 0.1% sodium azide and 0.2% gelatin. 
The antibody reacted with FAS of human, mouse and rat origin and was stored at 
4°C. 
c) Mouse Aiiti-PKC5 Polyclonal Antibody 
It is a mouse polyclonal antibody (Transduction Laboratories) that was raised 
against a sequence of amino acids 114-289 of human PKC5 protein. Each vial 
contained 0.25 mg/ml mouse IgG2b in 50% glycerol, 20 mM sodium phosphate pH 
7.5, 150 mM sodium chloride, 1.5 mM sodium azide and 1 mg/ml BSA. The antibody 
reacted with PKC5 of human, mouse and rat origin and was stored as small aliquots 
at -20°C. 
13) Secondary Antibodies 
Donkey anti-rabbit IgG, peroxidase-linked species-specific whole antibody was 
purchased from Amersham Pharmacia Biotech. The enzyme horseradish peroxidase 
was attached to the immunoglobulin molecules using an adaptation of the periodiate 
oxidation technique. It was stored at 4°C. 
14) 5% Skimmed Milk Solution (Blocking Solution) 
It was used as a blocking solution in Western blot analysis by dissolving 5 g 
Nestle skimmed milk powder in 100 ml washing buffer. The solution was kept at 4 T . 
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15) 10% Sodium Dodecyl Sulfate (SDS) Solution 
SDS was purchased from Sigma Chemical Co. A 10 % SDS solution was 
prepared by dissolving 10 g SDS in 100 ml double distilled water and kept at room 
temperature. 
16)Tris-Glydne-SDS Electrophoresis Buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concentrate (Sigma Chemicals 
Co.) contained 0.25 M Tris-HCl, pH 7.5，1.92 M glycine and 1% SDS in double 
distilled water. It was then filtered through a 0.2 |am millipore filter and stored at 
4°C. The lOX concentrate was freshly diluted to IX working buffer solution for 
SDS-PAGE. 
17)Tris-Glycine Buffer (lOX) 
Tris-glycine buffer lOX concentrate (Sigma Chemicals Co.) contained 0.25 M 
Tris-HCl, pH 7.5 and 1.92 M glycine in double distilled water. It was then filtered 
through a 0.2 millipore filter and stored at 4®C. 
18) Tris-GIycine-Methanol Transfer Buffer (lOX) 
The transfer buffer was prepared by mixing 20% methanol in IX Tris-glycine 
buffer and the buffer solution was kept at 4°C. 
19) Upper Buffer for Stacking Gel 
It was a 0.5 M Tris-HCl buffer adjusted to pH 6.8 (Sigma Chemicals Co.) and 
stored at 4°C. . 
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20) Washing Buffer 
The washing buffer contained 10 mM Tris-HCl (pH 7.5), 100 mM sodium 
chloride and 0.1% (w/v) Tween 20 (Sigma Chemicals Co.). The solution was stored 
at 4"C. 
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2.2 Methods 
2.2.1 Culture of the Tumor Cell Lines 
All the cell lines were cultured in 25 or 75 cm^ tissue culture flasks and 
incubated at 37°C in a humidified incubator supplied with 5% carbon dioxide 
(CO2). The human and murine leukemic cell lines were kept in complete medium 
supplemented with 10% FCS and antibiotics as continuous suspension cultures. 
For the human leukemia HL-60 cells, they were maintained in complete medium 
supplemented with 20% FCS. The cell lines were subcultured at 2-3 day intervals 
depending on their doubling times. Leukemia cells in their exponential growth 
phase were used for experiments. Cryo-preservation in liquid nitrogen was used 
for long term storage of cell lines. Cells were normally not used beyond 30 in vitro 
passages. 
2.2.2 Isolation, Preparation and Culture of Primary Mouse Cells 
1) Mouse Splenocytes 
BALB/c mice were sacrificed by cervical dislocation and the spleens were 
removed aseptically. The spleens were washed twice with plain RPMI medium. 
Splenocytes were isolated from the spleens by cutting the spleens into small 
piecies and gently pressing the tissue through a 200-gauge stainless steel sieve 
with the plunger of a plastic 2.5 ml syringe. Viable lymphocytes were obtained by 
Ficoll-Paque gradient centrifugation (1300xg, 20 min., 18°C) after removing the 
debris and washing of the spleen cell suspension. The purified lymphocytes were 
then washed twice with plain RPMI medium and resuspended in complete medium. 
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Splenocytes (5x10^ cells/well) were cultured with or without glycyrrhizin or 18-P 
glycyrrhetinic acid at 37°C, 5% CO2 for various periods of time as indicated in the 
text. 
2) Mouse Bone Marrow Cells 
BALB/c mice were sacrificed by cervical dislocation and their femurs were 
excised and washed twice with plain RPMI medium. They were then put into a 60 
mm culture dish (Corning) containing cold complete RPMI medium. The marrow 
plugs were flushed into complete RPMI medium by using a 1 ml syringe fitted with 
a 25-gauge needle. Cells were then washed once with plain RPMI medium. By 
Ficoll-Paque gradient centrifugation (1300xg, 20 min., 18°C), bone marrow cells 
were separated from the red blood cells and dead cells. The bone marrow cells were 
then washed twice with plain RPMI medium and resuspended in complete RPMI 
medium. Bone marrow cells (2x1 O^  cells /well) were cultured with or without 
glycyrrhizin or 18-p glycyrrhetinic acid at 37�C, 5% CO2 for various periods of time 
as indicated in the text. 
2.2.3 Determination of Cell Proliferation by [^H]-TdR Incorporation Assay 
The proliferation of the glycyrrhizin- or 18-p glycyrrhetinic acid-treated tumor 
cells was measured by the [^H]-TdR incorporation assay. Various leukemia cells 
with the indicated cell number were incubated in the absence or presence of 
different concentrations of glycyrrhizin or 18-P glycyrrhetinic acid in the wells of 
96-well flat-bottomed microtiter plates at 3TC for 48 hours inside a humidified 5% 
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CO2 incubator. Cultures were then pulsed with 0.5 )j,Ci [^H]-TdR in 20 complete 
medium from 6 to 18 hours. The cells were harvested onto a glass microfiber filter 
after one cycle of freezing and thawing. The radioactivity, in counts per minute 
(cpm), was measured by the Beckman LS6000 liquid scintillation counter. 
Quadruplicates results were expressed as the percentage inhibition of [^H]-TdR 
incorporation, using the untreated cells as a control (Leung et al, 1994). The 
percentage inhibition of [^H]-TdR incorporation was calculated as follows: 
0/0 inhibition = {(cpm of control - cpm of test sample)/ cpm of control} x 100% 
2.2.4 Determination of Cell Viability 
The viability of glycyrrhizin- or 18-p glycyrrhetinic acid-treated cells was 
determined by trypan blue exclusion test. Cells were cultured with different 
concentrations of drugs or combination of drugs being tested. The viability of the 
cells was then determined after different incubation periods. This could be done by 
mixing 10 |LI1 cell suspension with 10 \i\ 0.4% trypan blue solution. Dead cells 
would be stained blue while viable cells would exclude the dye and appeared 
"bright". By counting the number of dead cells, the results were expressed as the 
mean percentage of cytotoxicity 士 S.E. of triplicate cultures. The percentage 
cytotoxicity was calculated as follows: 
0/0 cytotoxicity = (no. of dead cells/ no. of total cells counted) x 100% 
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2.2.5 Cell Morphology Study 
Cell morphology study was used to investigate the effects of glycyrrhizin or 
18-p glycyrrhetinic acid on the differentiation of leukemia cells. WEHI-3B JCS 
cells (lxl04 cells/ml) were incubated with different concentrations of glycyrrhizin 
or 18-P glycyrrhetinic acid in 25 cm^ culture flasks at 37°C for 4 days and 3 days 
respectively. Cell morphology was then examined by the preparation of cytospin 
smears. This was done by fixing the glycyrrhizin or 18-P glycyrrhetinic acid-
treated cells (5 xl04 cells) onto a microscopic slide by cytocentrifugation at 500 
rpm for 5 minutes using the Shandon Cytospin 3 centrifuge (Shadon Scientific 
Ltd., U.K.). The cells were then air-dried and they were stained with each 
Hemacolor staining solution for 15 seconds and destained under running tap water. 
The air-dried cells were mounted with neutral mounting medium, Canada Balsam 
(Sigma Chemicals Co.), and the cell morphology was examined under the light 
microscope. 
2.2.6 Apoptosis Study by DNA Fragmentation Analysis 
Apoptotic DNA fragments were isolated from the apoptotic cells by the 
method of Herrmann et al. (1994). Leukemia cells (5x10"^  cells/ml) were treated 
with appropriate concentrations of glycyrrhizin or 18-P glycyrrhetinic acid in 75 
cm2 culture flask at 37°C for different periods of time and the untreated cells were 
acted as a control. Cells (2x10^) were harvested and washed once with cold PBS 
by centrifugation at 250xg for 5 minutes. The cell pellets were treated with 200 
IGEPAL CA-630 lysis buffer for 10 minutes at 37�C. It was then centrifuged at 
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l,000xg for 5 minutes to collect the supernatants containing the apoptotic DNA 
fragments. 50 |LI1 5% SDS was added and the supernatants were incubated with 0.4 
l^ g/^ il RNase A at 56�C for 1.5 hours to remove the cellular RNA. 1.5 |Lig/)al 
proteinase K was then added at 56°C for another 1.5 hours to remove the proteins. 
The DNA was then precipitated with 0.1 volume of 3 M sodium acetate and 2.5 
volumes of absolute ethanoL After centrifugation for 30 min at 12000xg, the DNA 
pellets were washed successively with 70% ethanol and 100% ethanol followed by 
vacuum drying with a speed vacuum concentrator (Savant 110 Speed-Vac®). The 
dried pellets were resuspended in 20 |il TioEo.i buffer and incubated at 65°C for 5 
minutes. The resuspended DNA was subjected to 2 % agarose gel electrophoresis. 
2.2.7 Flow Cytometric Analysis 
1) Surface Antigen Immunophenotyping 
WEHI-3B JCS cells (2 x 10^  cells/ml) were incubated with glycyrrhizin or 
18-P glycyrrhetinic acid for 4 or 3 days respectively. Cells were collected and 
washed with PBS and then resuspensed in FACS medium so as to prevent the 
internalization of membrane components. 3 x 10^  cells were incubated with 10 
|ug/ml mouse IgG and 10 |ag/ml rat IgG for 30 min at 4 � C in order to block the Fc 
receptors so as to inhibit non-specific binding. The cells were washed with FACS 
medium and then resuspensed in 50 i^l FACS medium. Afterwards, 50 |ul 
monoclonal antibody (20 |ig/ml) or hybridoma-derived antibody was then 
incubated with the cells for 30 min at 4°C. The cells were washed twice and then 
incubated with 1 i^g FITC-conjugated anti-rat IgG antibody for 30 min at 4 � C in 
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dark. The cells were washed four times and then fixed with 800 \i\ 1% 
paraformaldehyde (Sigma Chemical Co.) in normal saline. Data acquisition was 
done by the FACSort flow cytometer (Becton Dickinson Immunocytometry 
Systems) with an argon laser set at an excitation wavelength of 488 nm. 
2) Assay of Endocytic Activity 
The endocytic activity of the differentiating cells could be indicated by the 
uptake of the fluorescent FITC-conjugated bovine serum albumin (FITC-BSA). 
Untreated, giycyrrhizin or 18-P glycyrrhetinic acid-treated WEHI-3B JCS cells (5 
X 10^  cells/ml) in 0.9 ml complete medium containing 10% HI-FCS were 
incubated with 0.1 ml FITC-BSA (1 mg/ml) in complete medium containing 10% 
HI-FCS for 6 hours at 37�C in dark. The cells were washed three times with plain 
RPMI medium and then fixed with 800 |li1 1% paraformaldehyde (Sigma Chemical 
Co.) in normal saline. Data acquisition was done by the FACSort flow cytometer 
(Becton Dickinson Immunocytometry Systems) with an argon laser set at an 
excitation wavelength of 488 nm. 
2.2.8 Cell Cycle/DNA Content Evaluation 
WEHI-3B JCS cells (1 x 10^ cells) were collected and washed with PBS. The 
cells were then fixed with 70% ethanol for 30 min at 4°C. The cells were then 
centrifuged and washed by PBS to remove ethanol. Freshly prepared pre-cooled 
propidium iodide DNA staining solution was used to stain the cells for 1.5 hours at 
room temperature in dark. Data acquisition was done by the FACSort flow 
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cytometer (Becton Dickinson Immunocytometry Systems) using Lysys II sofeware. 
The Modfit software was used to calculate the cell cycle distribution. 
2.2.9 Gene Expression Study 
1) Isolation of Total Cellular RNA 
Leukemia cells (1x10?) were first incubated with appropriate concentrations of 
glycyrrhizin or 18-P glycyrrhetinic acid for different periods of time at 37°C. The 
cells were harvested by centrifugation at 250xg for 5 minutes at 4�C. In order to 
eliminate the chance of mRNA degradation, washing of the cells was avoided. The 
cells were lysed by adding 1 ml TRIZOL reagent (1 ml TRIZOL for 5-10x10^ cells) 
and shaked vigorously. After incubated for 5 minutes at room temperature to allow 
the complete dissociation of nucleoprotein complex, 200 chloroform per ml of 
TRIZOL reagent was added to the samples and then shaked vigorously for 15 
seconds. The samples were allowed to stand at room temperature for about 3 
minutes and were centrifuged at 12,000xg for 15 minutes at 4°C. The upper aqueous 
phase containing RNA (-400 |al) was being transferred to another new micro-
centrifuge tube. 500 i^l isopropanol was then added to precipitate the RNA. The 
samples were first incubated at - 2 0 � C overnight and, then centrifuged at 12,000xg 
at 4 � C for 10 minutes. The supernatants were removed and the RNA pellets were 
washed with 1 ml 75% ethanol per ml of TRIZOL. The samples were centrifuged at 
7，500xg at 4 � C for 5 minutes. The supernatants were removed by aspiration and the 
RNA pellets were air-dried for about 5 minutes. The RNA pellets were dissolved in 
30 DEPC-treated water and stored at —70�C until use. 100 fold dilution of RNA 
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was prepared. The concentration of the diluted RNA was determined by 
spectrophotometry at 260 nm. Small aliquots of RNA with a working concentration 
of 0.5 |Lig尔 1 were prepared with DEPC-treated water and stored at - 7 0 � C until use. 
The purity was determined by measuring the ratio of A260/A280 (a value should be 
ranged from 1.0 to 2.0). The integrity of RNA was checked by gel electrophoresis in 
1% agarose. 
2) Reverse Transcription (RT) 
The total cellular RNA was incubated at 65�C for 5 minutes before being used 
in the synthesis of cDNA. A reaction mixture consising 40 units of rRNasin 
ribonuclease inhibitor, IX first strand buffer, 0.5 mM of each dNTP, 10 mM DTT, 
0.1 |ig oligo-dTi2-i8 and 200 units of M-ML reverse transcriptase was mixed with 1 
of the total RNA. The mixture was incubated at 37°C for 1 hour and 99°C for 5 
minutes. The reaction was stopped by chilling the samples on ice. The resulting 
cDNA was stored at —20�C for later use. 
3) Polymerase Chain Reaction (PGR) 
The cDNA samples were first boiled for 5 minutes followed by chilling on ice 
immediately. RT sample equivalent to 0.1 ^g of total RNA in 2 f^ l was mixed with a 
23 fil reaction mixture containing IX PGR buffer, 1.5 mM MgCb, 0.2 mM dNTPs, 
1 unit of ThermoprimePius DNA polymerase, and 0.2 |iM of each sense and anti-
sense oligonucleotide primer in a PGR tube for each sample. A negative control 
with no cDNA sample was prepared to check for any contaminations. The reaction 
mixtures were put into a thermocycler, GeneAmp PGR System 9700 (Perkin-Elmer 
10 
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Co.), which was set with certain rounds of temperature cycling. The samples were 
subjected to an initial denaturation at 94�C for 5 minutes in the first cycle. 
Afterwards 25-30 thermal cycles with denaturation at 94�C for 30 seconds, 
annealing at 59°C for 1 minute and elongation at l l X for 1 minute. In the final 
cycle, one more step in elongation for 5 minutes was required in order to complete 
the reaction. The amplified PGR products were then stored at -20°C until use. The 
annealing temperature and the number of PCR cycles were varied. It should be 
optimized empirically for each primer set. The amount of RNA used in PCR 
amplification was normalized by comparing with the amplification of GAPDH 
mRNA. 
4) Agarose Gel Electrophoresis 
The PCR products were analyzed by 2% agarose gel electrophoresis. Firstly, 5 
lal PCR sample was mixed with 1 |li1 5X gel loading buffer. And this mixture was 
subjected to electrophoresis in 0.5X TBE electrophoresis buffer on 2% agarose gel 
at a constant voltage of 100 volts for 2-3 hours. A size marker of 0.5 ^g of 100 bp 
DNA ladder (GIBCO BRL Life Technologies Inc.) was loaded. After 
electrophoresis, the gel was stained with 1 ^g/ml ethidium bromide solution for 5 
minutes and was destained with distilled water for 15 minutes. The stained gel was 
visualized and analyzed by the Bio-Rad Gel Doc 2000 under UV illumination. The 
band intensity was analyzed using the Image Quant (Molecular Dynamics) software. 
The relative intensity of each band of the RT-PCR product was normalized with 
respect to the corresponding GAPDH group. Differences of relative intensity larger 
than 100% were generally considered as significant changes and those less than 
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50 % were regarded as non-significant variations. Differences of relative intensity 
between 50-100% were defined as slight changes in our study. 
2.2.10 Protein Expression Study 
1) Extraction of Proteins 
JCS cells (5x104 cells/ml) were treated with 18-P glycyrrhetinic acid (0-70 |iM) 
for 48 hours at 37�C. The cells were collected and washed twice with cold PBS by 
centrifbging at 250xg for 5 minutes at 4�C. Cell viability was determined by trypan 
blue exclusion assay. Viable cells ( 5 x 1 w e r e mixed and vortexed with 0.25 ml 
cell lysis buffer (i.e. 2x10^ cells/ml) for 10 seconds. The cell lysate was sonicated in 
a water bath sonicator for 15 minutes after one cycle of freezing and thawing. It was 
then spun at 14,000 rpm for 5 minutes at 4°C in an Eppendorf centrifuge. The 
supernatant was collected in small aliquots and stored at —70�C until use. 
2) Quantification of Proteins 
Bradford protein assay was used to determine the protein concentration of the 
cell lysates. Standard bovine serum albumin (BSA) solutions at 2 |Lig/ml, 4 i^g/ml，6 
昭/ml，8 ^ig/ml, and 10 ng/ml were prepared with double distilled water in triplicate 
with 1 mg/ml BSA stock. Also, 2 protein samples were diluted with double 
distilled water. Afterwards, 800 |al BSA standards or protein samples were mixed 
with 200 i^l Bradford reagent (Bio-Rad Lab.) by vortexing. They were allowed to 
stand at room temperature for 5 minutes. The absorbance at 595 nm was measured 
using Bradford reagent as a blank. A standard curve was constructed by plotting the 
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using Bradford reagent as a blank. A standard curve was constructed by plotting the 
absorbance versus the concentration of BSA standards. The concentrations of the 
protein samples were determined from the standard curve. Finally, 20 ^g of the 
protein was subjected to SDS-PAGE. 
3) Western Blotting Analysis 
Proteins were separated by SDS-PAGE according to the molecular weights. 
The proteins were first normalized and 20 |ag of the protein was mixed with 2X 
protein loading buffer. The protein samples were boiled for 5 minutes and loaded 
onto the SDS-polyacrylamide gel with 5% stacking gel. The gel was run under 
constant voltage of 100 volts for 2-3 hours and 4 \i\ of pre-stained protein markers 
were also loaded. According to the molecular weight of the target protein being 
separated, the percentage of acrylamide added in the running gel was adjusted. A 
lower percentage of acrylamide gel was used for a higher molecular weight protein. 
The composition of the chemical reagents needed for various percentages of SDS-
polyacrylamide gel is shown in Table 2.3. 
Table 2.3 Composition of the SDS-polyacrylamide gel 
5 % Stacking Gel (3 ml) Separating Gel (5ml) 
7.5% I l3o/o 120/0 一 
Distilled water 1.677 ml 2.4 ml 2 ml 1.65 ml 
Lower Buffer - 1.25 ml 1.25 ml 1.25 ml 
Upper Buffer 0.75 ml -
30% Acryl S t ^ 0.5 ml 1.25 ml 1.65 ml 2 ml 
10% SDS — 0.03 ml 0.025 ml 0.025 ml 0.025 ml 
10% APS 0.04 ml 0.075 ml 0.075 ml 0.075 ml 
TEMED ~ ~ 1.25 1.25 \i\ 1.25 ml 
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After electrophoresis, the stacking gel was cut and removed. The gel was 
washed with distilled water and soaked in transfer buffer for 5 minutes. Three 
pieces of filter paper (3 MM Whatman chromatography papers) soaked with transfer 
buffer were placed on the semi-dry electroblotter (Bio-Rad Lab.). Also, one piece of 
PVDF membrane was activated by soaking with 100% methanol and covered with 
filter papers. The gel was carefully placed on the membrane and then three more 
pieces of filter papers soaked with transfer buffer were covered on the gel. Air 
bubbles were excluded by rolling a glass tube on the surface of filter paper. The 
proteins were transferred for 45-60 minutes at 16 V. The membrane was removed 
after the protein transfer. The membrane was placed in a 5% skimmed milk solution 
at room temperature for at least 1 hour so as to block the non-specific sites for 
probing. Primary antibody probing the target protein was added (1:5,000 dilution, 
could be adjusted if necessary) together with the membrane were soaked in 5% 
skimmed milk at 4°C overnight. Washing buffer was used to wash the membrane 
for 30 minutes. Horseradish peroxidase-linked secondary antibody (1:5,000 dilution) 
in 5% skimmed milk was incubated with the membrane for one hour at room 
temperature. Washing buffer was used to wash the membrane for 30 minutes. 
Finally, the specific protein bands can be visualized by ECL assay. 
4) ECL Assay 
An ECL assay that utilizes another secondary antibody could be used to visualize 
the protein bands. One ml of detection reagent 1 and detection reagent 2 (ECL 
Western blotting detection reagents from Amersham Pharmacia biotech.) were mixed 
and poured onto a piece of parafilm. The membrane was then immersed in the 
reagent mixture and allowed to react for 1 minute. The membrane was covered with 
lA 
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Glad Wrap and was placed on an ECL film in dark room for different periods of 
exposure time (30 s, 1 min, 2 min, 5 min, 10 min and 30 min) after excess solution 
was removed. Specific protein bands could be visualized after the film was 
developed. The relative intensity of each protein band was determined by 
densitometry. 
2.2.11 Statistical Analysis 
Each experiment was performed at least twice in most cases. The results of only one 
representative experiment were presented. The data were expressed as arithmetic 
mean 士 standard error. For statistical analysis, Student's t-test was used, normally, 
p< 0.05 was regarded as significantly different. 
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3.1 Introduction 
There has been an increasing interest in the studies of herbs that have medicinal 
values，especially those which possess anti-tumor or immune-stimulating properties. 
These herbs exhibit their anti-tumor effects either directly on the tumor cells by 
inhibiting their proliferation, and inducing cell apoptosis or differentiation (Mak et al., 
1996; Fung et al., 1997)，or indirectly through the enhancement of immune response 
(Choy et al.’ 1994; Wong et al, 1994). The traditional Chinese medicine Gancao (甘革） 
or licorice has widely been used in China and Asia for decades in the treatment of 
hepatitis, hepatocarcinoma, melanoma, inflammatoiy diseases, gastric ulcer and several 
viral diseases (Mills & Bone，2000). The major active component of licorice is 
glycyrrhizin (GL), a saponin glycoside that account for much of the sweetness of 
licorice. It is metabolized into 18-p glycyrrhetinic acid (GA) after oral administration 
(Kim et aL, 2000). Research in the last two decades showed that licorice exhibits diverse 
biological and pharmacological activities, including hepatoprotective, anti-ulcer, anti-
allergic, immunoregulatory, anti-inflammatory, anti-viral, anti-carcinogenic, anti-
estrogenic, and mineralocorticosteroid activities. Many of these pharmacological 
activities have been attributed mainly, if not all, to the major saponin, glycyrrhizin, and 
its aglycone, 18-p glycyrrhetinic acid (Mills & Bones, 2000). 
It had been reported that glycyrrhizin exhibited protection against DMBA-
initiated and TPA-promoted skin tumorigenesis in Senear mice (Agarwal et al., 1991). 
Moreover，prolonged treatment with glycyrrhizin had shown to decrease the occurrence 
of hepatocellular carcinoma in diethylnitrosamine-treated mice (Shiota et al.’ 1999). It 
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was also found that glycyrrhizin and 18-p glycyrrhetinic acid could inhibit the growth of 
B16 melanoma cells and stimulated melanogenesis, suggesting that these two drugs can 
trigger the differentiation of cancer cells (Abe et al., 1987). More recently, the growth 
inhibitory effects of glycyrrhizin and 18-P glycyrrhetinic acid on two lymphomas 
(Human Burkitt's lymphoma and non-Hodgkin's lymphoma) and two leukemias (Raji 
and SupTl cells) had been demonstrated by the trypan blue exclusion assay (Malagoli et 
al； 1998)，however, whether they can induce differentiation and/or apoptosis in 
leukemia cells has not been investigated. Furthermore, their precise anti-tumor 
mechanisms and the relationship between their chemical structures and anti-tumor 
effects are still poorly understood. 
Therefore, in this chapter the differential anti-proliferative and cytotoxic effects 
of glycyrrhizin and 18-p glycyrrhetinic acid on various murine and human leukemic cell 
lines will be studied by the ^H-thymidine incorporation assay and trypan blue exclusion 
assay respectively. Moreover, the ability of glycyrrhizin and 18-p glycyrrhetinic acid to 
induce apoptosis in different myeloid leukemic cell lines will be examined by the DNA 
fragmentation assay. Furthermore, the effects of glycyrrhizin and 18-p glycyrrhetinic 
acid on cell cycle kinetic in different myeloid leukemic cell lines will be analysed by 
flow cytometry. Finally, the activities of glycyrrhizin and 18-p glycyrrhetinic acid on the 
tumorigenicity of a murine myeloid leukemia in syngeneic mice will be examined. 
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3.2 Results 
3.2.1 The Growth-Inhibitory Effects of Glvcvrrhizin on Various Leukemic Cell 
Lines 
3.2.1.1 Differential Anti-proliferative Effect of Glycyrrhizin on Various Leukemic 
Cell Lines In Vitro 
Various murine and human leukemic cell lines were used to evaluate the 
differential anti-proliferative effect of glycyrrhizin. The tritiated thymidine incorporation 
assay was used to measure the anti-proliferative effect of glycyrrhizin after 48 hours 
incubation with leukemia cells. The incorporation of labeled DNA precursor, tritiated 
thymidine (^H-TdR), into the DNA of the cells is directly proportional to the degree of 
cell proliferation. It was found that glycyrrhizin could inhibit the proliferation of JCS 
(Figure 3.1), Ml (Figure 3.2)，HL-60 (Figure 3.3), K562 (Figure 3.4)，Eol-l (Figure 3.5)， 
MBL-2 (Figure 3.6) and YAC-1 (Figure 3.7) leukemia cells in a dose-dependent manner. 
These leukemic cell lines showed differential sensitivity to glycyrrhizin. The estimated 
values of 50 % inhibitory concentration (IC50) of glycyrrhizin for different leukemic cell 
lines are summarized in Table 3.1. It can be seen that the murine T cell lymphoma YAC-
1 cells and the human eosinophilic leukemia Eol-l cells were the most sensitive cells in 
response to glycyrrhizin, with an IC50 value of about 1.4 mM. On the other hand, the 
murine myeloblastic leukemia Ml cells were found to be relatively resistant to the 
cytostatic effect of glycyrrhizin, with an IC50 value of about 2.7 mM. 
7 8 
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Kinetics studies using the well-characterized and subcloned murine 
myelomonocytic leukemia WEHI-3B JCS cells showed that giycyrrhizin inhibited the 
proliferation of the leukemia cells in a time-dependent manner (Figure 3.8). It is clear 
that marked inhibition of JCS cell proliferation was seen at 48 hours but not at 12 or 24 
hour. 
- 7 9 
) 
Chapter 3 Anti-Tumor Effects 
120% 
I 
I 100% i • ^ 
I I 
8 80% / 
I / 
h- 60% / 
^ I � 
•5 I / 
§ 40% 丨 Z i I / 
- 2 0 % i 乂广 丄 
0% , ,__ 
n I , 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 
Concentration of Giycyrrhizin (mM) 
Figure 3.1: Anti-proliferative effect of giycyrrhizin on the murine myelomonocytic 
leukemia WEHI-3B JCS cells. JCS cells (1x10^ cells/ml) were incubated with 
different concentrations (0-4 mM) of giycyrrhizin at 37�C for 48 hours. Cultures were 
then pulsed with 0.5 ^Ci of^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of 3H-TdR incorporation, using the untreated cells as a control. 
Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.2: Anti-proliferative effect of glycyrrhizin on the murine myeloblastic 
leukemia Ml cells. Ml cells (5x10^ cells/ml) were incubated with different 
concentrations (0-4 mM) of glycyrrhizin at 37�C for 48 hours. Cultures were then pulsed 
with 0.5 i^Ci of^H-TdR for 6 hours before harvest. Radioactivity in counts per minute 
(cpm) was measured using a liquid scintillation counter. Results were expressed a s � / � 
inhibition of 'H-TdR incorporation, using the untreated cells as a control. Each point 
represents the mean 士 S.E. of quadruplicate cultures. 
^ 
> 





a： 60% - /I 
I / 
•5 40% / 
I / 
I 20% / 
0/) I ^ ^ 1 —^ 
0 0.5 1 1.5 2 2.5 3 T s 4 ^ 4 : 5 
Concentration of Glycyrrhizin (mM) 
Figure 3.3: Anti-proliferative effect of glycyrrhizin on the human myeloid leukemia 
HL-60 cells. HL-60 cells (5x10^ cells/ml) were incubated with different concentrations 
(0-4 mM) of glycyrrhizin at 37�C for 48 hours. Cultures were then pulsed with 0.5 ^iCi 
of 'H-TdR for 8 hours before harvest. Radioactivity in counts per minute (cpm) was 
measured using a liquid scintillation counter. Results were expressed as % inhibition of 
3H-TdR incorporation, using the untreated cells as a control. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Figure 3.4: Anti-proliferative effect of glycyrrhizin on the human chronic 
myelogenous leukemia K562 cells. K562 cells (5x10^ cells/ml) were incubated with 
different concentrations (0-4 mM) of glycyrrhizin at 37�C for 48 hours. Cultures were 
then pulsed with 0.5 i^Ci of^H-TdR for 8 hours before harvest. Radioactivity in counts 
per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of^H-TdR incorporation, using the untreated cells as a control. 
Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.5: Anti-proliferative effect of glycyrrhizin on the human eosinophilic 
leukemia Eol-l cells. EoM cells (5x10^ cells/ml) were incubated with different 
concentrations (0-3 mM) of glycyrrhizin at 37�C for 48 hours. Cultures were then 
pulsed with 0.5 nCi of^H-TdR for 8 hours before harvest. Radioactivity in counts per 
minute (cpm) was measured using a liquid scintillation counter. Results were expressed 
as % inhibition of ^H-TdR incorporation, using the untreated cells as a control. Each 
point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.6: Anti-proliferative effect of glycyrrhizin on the Moloney leukemia virus-
induced T cell lymphoma MBL-2 cells. MBL-2 cells (1x10^ cells/ml) were incubated 
with different concentrations (0-3 mM) of glycyrrhizin at 37�C for 48 hours. Cultures 
were then pulsed with 0.5 � i of ^H-TdR for 6 hours before harvest. Radioactivity in 
counts per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of^H-TdR incorporation, using the untreated cells as a control. 
Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.7: Anti-proliferative effect of giycyrrhizin on the Moloney leukemia virus-
induced T cell lymphoma YAC-1 cells. YAC-1 cells (1x10^ cells/ml) were incubated 
with different concentrations (0-3 mM) of giycyrrhizin at 37�C for 48 hours. Cultures 
were then pulsed with 0.5 ^iCi of ^H-TdR for 6 hours before harvest. Radioactivity in 
counts per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of^H-TdR incorporation, using the untreated cells as a control. 
Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Table 3.1; The estimated values of IQo of glycyrrhizin on various leukemic cell lines. 
Types of Leukemia Cell line Estimated IC.n value * 
(mM) 
(A) Myelocytic Leukemias 
Murine myelomonocytic leukemia WEHI-3B JCS 1.6 
Murine myeloblastic leukemia Ml 2 7 
Human promyelocytic leukemia HL-60 2 3 
Human chronic myelogenous K562 2 
leukemia 
Human eosinophilic leukemia Eol-l 1 4 
(B) Lymphocytic Leukemias 
Murine T-cell lymphoma MBL-2 \ 5 
Murine T-cell lymphoma YAC-1 \ 4 
* IC50 value is the estimated concentration of glycyrrhizin which can cause 50 % 
inhibition of^H-TdR incorporation under the specified experimental conditions. 
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Figure 3.8: Kinetic studies on the anti-proliferative effect of glycyrrhizin on the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (1x10^ cells/ml) were 
incubated with different concentrations (0-3 mM) of glycyrrhizin at 37°C for different 
time intervals (12, 24 and 48 hours). Cultures were then pulsed with 0.5 |_iCi of^H-TdR 
for 6 hours before harvest. Radioactivity in counts per minute (cpm) was measured using 
a liquid scintillation counter. Results were expressed as % inhibition of ^H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 士 
S.E. of quadruplicate cultures. 
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3.2.1.2 Effects of Glycyrrhizin on the Viability of Various Leukemic Cell Lines and 
Normal Hematopoietic Cells In Vitro 
The effect of glycyrrhizin on the viability of leukemia cells was determined by 
cell counting using the trypan blue exclusion assay after 24 hours and 48 hours of 
incubation. Trypan blue is a permeable dye which can stain damaged and leaky cells. 
Intact viable cells that exclude the dye were counted manually using a hemocytometer. 
It was found that glycyrrhizin exhibited little (<15% cytotoxicity), if any, 
cytotoxic effect on the murine myeloid leukemia JCS cells at a concentration equal to or 
less than 1.5 mM (Figure 3.9). However, a drastic drop in cell viability was seen at a 
concentration of 3 mM after 48 hours of incubation. Similarly, glycyrrhizin did not exert 
any detectable cytotoxicity on the human myeloid leukemia HL-60 cells at a 
concentration equal to or less than 2 mM (Figure 3.10). Unlike JCS cells, glycyrrhizin 
exhibited only a slight cytotoxic effect on HL-60 cells at a concentration of 3 mM after 
48 hours of incubation. 
The effect of glycyrrhizin on the viability of the murine normal hematopoietic 
cells such as bone marrow cells and spleen cells was also determined by cell counting 
using the trypan blue exclusion assay after 24 hours and 48 hours of incubation. It was 
found that glycyrrhizin exhibited little (<15-20 % cytotoxicity), if any, cytotoxic effect 
on both BALB/c bone marrow cells and splenocytes in vitro at all the concentrations 
tested after 24 and 48 hours of incubation (Figure 3.11 and 3.12). 
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Figure 3.9: Effect of glycyrrhizin on the viability of the murine myeloid leukemia 
WEHI-3B JCS cells in vitro, JCS cells (1x10^ cells/ml) were incubated with different 
concentrations (0-3 mM) of glycyrrhizin at 37�C for 24 and 48 hours. Cell viability was 
determined by the trypan blue exclusion test, and the results were expressed as mean % 
of viable cells 士 S.E. of triplicate cultures. 
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Figure 3.10: Effect of glycyrrhizin on the viability of the human myeloid leukemia 
HL-60 cells in vitro. HL-60 cells (5x10"^  cells/ml) were incubated with different 
concentrations (0-3 mM) of glycyrrhizin at 37°C for 24 and 48 hours. Cell viability was 
determined by the trypan blue exclusion test, and the results were expressed as mean % 
of viable cells 士 S.E. of triplicate cultures 
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Figure 3.11: Effect of glycyrrhizin on the viability of bone marrow cells in vitro, 
BALB/c bone marrow cells (1x10^ cells/well) were incubated with different 
concentrations (0-3 mM) of glycyrrhizin at 37°C for 72 hours. Cell viability was 
determined by the trypan blue exclusion test, and the results were expressed as mean % 
of viable cells 士 S.E. of triplicate cultures. 
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Figure 3.12: Effect of glycyrrhizin on the viability of murine splenic lymphocytes in 
BALB/c splenocytes (5x10"^  cells/well) were incubated with different 
concentrations (0-1.5 mM) of glycyrrhizin at 2>TC for 24 and 48 hours. Cell viability 
was determined by the trypan blue exclusion test, and the results were expressed as 
mean % of viable cells 士 S.E. of triplicate cultures. 
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3.2.1.3 Induction of DNA Fragmentation in Leukemia Cells by Glycyrrhizin 
Recently, many researches have shown that the anti-tumor mechanism of natural 
products may be related to their ability to induce apoptosis (Okabe et al., 1997; Ahmad 
e/ al., 2000). Apoptosis is characterized by the occurrence of DNA ladder, due to the 
internucleosomal fragmentation of DNA by endonucleases (Herrmann et al., 1994). A 
characteristic series of DNA fragments in 180-200 base pairs multiples will be obtained. 
This can be seen through qualitative analysis of the extracted DNA by agarose gel 
electrophoresis (Saraste & Pulkki, 2000). 
It was shown that DNA ladder appeared in the human myeloid leukemia HL-60 
cells after 24 hours and 48 hours treatment with 2.5 mM glycyrrhizin in a dose-
dependent manner (Figure 3.13). However, DNA fragmentation could not be detected at 
12 hours in glycyrrhizin-treated HL-60 cells. On the contrary, no DNA ladder formation 
could be detected in the murine myeloid leukemia JCS cells after 24 hours and 48 hours 
treatment with 2.5 mM glycyrrhizin (Figure 3.14). 
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Figure 3.13: Induction of DNA fragmentation in glycyrrhizin-treated human 
myeloid leukemia HL-60 cells. HL-60 cells (5x10^ cells/ml) were incubated with 
different concentrations of glycyrrhizin (0-2.5 mM) at 37�C for different periods of time 
(from 12 to 48 hours). Apoptotic DNA fragments were extracted by mild detergent 
IGEPAL CA-630 lysis buffer, and were analyzed by electrophoresis on 2% agarose gel 
stained with ethidium bromide. 
Lane 1: With 2.5 mM glycyrrhizin for 12 hours Lane 5: With 2 mM glycyrrhizin for 24 hours 
Lane 2: With 2.5 mM glycyrrhizin for 24 hours Lane 6: With 2.5 mM glycyrrhizin for 24 hours 
Lane 3: With 2.5 mM glycyrrhizin for 48 hours Lane 7: Untreated HL-60 cells 
Lane 4: With 1.5 mM glycyrrhizin for 24 hours Lane 8: 100 bp DNA markers 
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Figure 3.14: DNA fragmentation assay for glycyrrhizin-treated murine myeloid 
leukemia WEHI-3B JCS cells. JCS cells (1x10^ cells/ml) were incubated with 
different concentrations of giycyrrhizin (0-2.5 mM) at 37°C for 24 and 48 hours. 
Apoptotic DNA fragments were extracted by mild detergent IGEPAL CA-630 lysis 
buffer，and were analyzed by electrophoresis on 2% agarose gel stained with ethidium 
bromide. 
Lane 1: 100 bp DNA markers Lane 5: With 1.5 mM giycyrrhizin for 48 hours 
Lane 2: Untreated JCS cells Lane 6: With 2 mM giycyrrhizin for 48 hours 
Lane 3: With 2.5 mM giycyrrhizin for 24 hours 
Lane 4: With 2.5 mM giycyrrhizin for 48 hours 
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3.2.1.4 Effect of Glycyrrhizin on the Cell Cycle Kinetics of HL-60 Cells In Vitro 
It is possible that the induction of apoptosis is mediated through the regulation of 
cell cycle progression. Therefore, the effect of glycyrrhizin on the cell cycle kinetics of 
the HL-60 cells was examined by flow cytometry. As shown in Figure 3.15 and Table 
3.2, there was an appreciable arrest of the HL-60 cells in GQ/GI phase of the cell cycle. 
The percentage of cells in the GQ/GI phase showed a dose-dependent increase and this 
increase was accompanied with a decrease in the percentage of cells in the S phase when 
the HL-60 cells were incubated with glycyrrhizin (1.5 - 3 mM) for 24 hours. In addition, 
a slight decrease in the G2 + M phase cell population was observed. Thus, these results 
also demonstrated that glycyrrhizin could suppress the proliferation of HL-60 cells. A 
hypodiploid peak was seen in HL-60 cells undergoing apoptosis when the cells were 
treated with 1.5 to 3 mM of glycyrrhizin and this was consistent with the results of DNA 
fragmentation. 
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Figure 3.15 Effect of glycyrrhizin on the cell cycle profile in HL-60 cells. HL-60 
cells (5 X 104 cells/ml) were incubated with glycyrrhizin ( 0 - 3 mM) at 37 for 24 
hours. Glycyrrhizin-treated cells (1 x 10^  cells) were fixed with ethanol and stained with 
PI under hypotonic conditions. Pl-stained cells were analyzed for fluorescence intensity 
using the FACSort flow cytometer. Cell cycle distribution was calculated by the 
MODFIT program using RFIT analysis model. 
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Table 3.2: Effect of glycyrrhizin on cell cycle distribution of HL-60 cells 
Concentration of % of cells 
glycyrrhizin GQ/GI phase S phase G2+M phase 
(mM) 
0 3 5 ^ 42.29 
LS 41M 1 7 ^ 
2 f O ^ 
3 6177 ^ ^ 
HL-60 cells (5x10"^ cells/ml) were incubated with different concentrations 
(0-3 mM) of glycyrrhizin at 37 ^C for 24 hours. The DNA was stained with 
propidium iodide and the fluorescence intensity was analysed with a flow 
cytometer. The percentage of cells at different phases of the cell cycle was 
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3.2.1.5 Effect of Glycyrrhizin on the Cell Cycle Kinetics of JCS Cells In Vitro 
The effect of glycyrrhizin on the cell cycle kinetics of the JCS cells was also 
examined by flow cytometry. As shown in Figure 3.16 and Table 3.3，treatment of the 
JCS cells with glycyrrhizin had resulted in the arrest of the cells in the GQ/GI phase of 
the cell cycle. A slight increase in the percentage of cells in the G2 + M phase was also 
observed. On the other hand, there was a significant decrease in the percentage of cells 
in the S phase, indicating glycyrrhizin could effectively suppress the proliferation of JCS 
cells. 
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Figure 3.16: Effect of glycyrrhizin on the cell cycle profile in JCS cells. 
JCS cells (1 X 104 cells/ml) were incubated with glycyrrhizin (0 - 3.5 mM) at 37 for 
24 hours. Glycyrrhizin-treated cells (1 x cells) were fixed with ethanol and stained 
with PI under hypotonic conditions. Pl-stained cells were analyzed for fluorescence 
intensity using the FACSort flow cytometer. Cell cycle distribution was calculated by 
the MODFIT program using RFIT analysis model. 
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Table 3.3: Effect of glycyrrhizin on cell cycle distribution of JCS cells 
Concentration of % of cells 
glycyrrhizin —— 
Go/Gi phase S phase G2+ M phase 
(mM) 
0 37：^ ^ ^ 
2 ^ 3 3 4032 ^ 
I 5 43.86 40.32 f ^ 
3 
JCS cells (1 X 104 cells/ml) were incubated with different concentrations 
(0-3.5 mM) of glycyrrhizin at 37 for 24 hours. The DNA was stained with 
propidium iodide and the fluorescence intensity was analysed with a flow 
cytometer. The percentage of cells at different phases of the cell cycle was 
calculated by the MODFIT program, using the rectangle fit (RFIT) analysis 
model. 
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3.2.1.6 Effect of Glycyrrhizin on the In Vivo Tumorigenicity of the Murine Myeloid 
Leukemia JCS Cells 
The effect of glycyrrhizin on the in vivo tumorigenicity of a murine myeloid 
leukemia was investigated. JCS cells (1.2x10^ cells/ml) were incubated with two 
different concentrations of glycyrrhizin (2 and 2.5 mM) for 24 hours at 37°C. The cells 
were washed with RPMI medium and injected intraperitoneally into syngeneic BALB/c 
mice. Leukemia cells recoverable from the peritoneal cavity of mice were counted at day 
12 post-inoculation. As shown in Figure 3.17, pre-treatment of JCS cells with 
glycyrrhizin in vitro could significantly decrease the leukemic cell growth in syngeneic 
mice in a dose-dependent manner. This implies that glycyrrhizin is effective in reducing 
the tumorigenicity of the leukemia cells in vivo. 
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Figure 3.17: Effect of in vitro treatment of leukemia cells with glycyrrhizin on their 
tumorigenicity in syngeneic BALB/c mice. JCS cells (1.2x10^ cells/ml) were incubated 
with two different concentrations (2 and 2.5 mM) of glycyrrhizin for 24 hours at 37°C. 
The cells were washed three times with RPMI medium. 3x10^ cells/mouse viable JCS 
cells were injected intraperitoneally into BALB/c mice in groups of five. Leukemia cells 
recoverable from the peritoneal cavity of mice were counted at day 12 post-tumor 
inoculation. 
Significantly different from control untreated cells: * P<0.005. 
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3.2.2 The Growth-Inhibitory Effects of 18-B Glycyrrhetinic Acid on Various 
Leukemic Cell Lines 
3.2.2.1 Differential Anti-proliferative Effect of 18-p Glycyrrhetinic acid on Various 
Leukemic Cell Lines In Vitro 
In the present study, various murine and human leukemic cells lines were used to 
evaluate the differential anti-proliferative effect of 18-p glycyrrhetinic acid on leukemia 
cells, as measured by a standard tritiated thymidine incorporation assay. Similar to that 
of giycyrrhizin, the results show that 18-p glycyrrhetinic acid could inhibit the 
proliferation of JCS (Figure 3.18), Ml (Figure 3.19)，HL-60 (Figure 3.20)，K562 (Figure 
3.21), Eol-l (Figure 3.22), MBL-2 (Figure 3.23) and YAC-1 (Figure 3.24) leukemia 
cells in a dose-dependent manner. As shown in Table 3.4, different leukemia cells 
showed differential sensitivity to the growth-inhibitory effect of 18-P glycyrrhetinic acid. 
It was found that the JCS, Ml, MBL-2 and Eol-l leukemia cells were the most sensitive 
cells in response to 18-P glycyrrhetinic acid, with an IC50 value of about 60 fiM. This is 
followed by the K562 and YAC-1 leukemia cells (IC50： -84 jiM), whereas the HL-60 
leukemia cells was found to be the most resistant to the cytostatic effect of 18-P 
glycyrrhetinic acid, with an IC50 value of about 134 |aM. 
Moreover, kinetics studies on the anti-proliferative effect of 18-P glycyrrhetinic 
acid were also performed using the murine myeloid leukemia JCS cells and it can be 
seen that 18-P glycyrrhetinic acid inhibited the proliferation of the leukemia JCS cells in 
a time-dependent manner (Figure 3.25). 
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Figure 3.18: Anti-proliferative effect of 18-P glycyrrhetinic acid on the murine 
myelomonocytic leukemia WEHI-3B JCS cells. JCS cells (1x10^ cells/ml) were 
incubated with different concentrations (0-100 ^M) of 18-P glycyrrhetinic acid at 37�C 
for 48 hours. Cultures were then pulsed with 0.5 |iCi of ^H-TdR for 6 hours before 
harvest. Radioactivity in counts per minute (cpm) was measured using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR incorporation, 
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Figure 3.19: Anti-proliferative effect of 18-P glycyrrhetinic acid on the murine 
myeloblastic leukemia Ml cells. Ml cells (5x1 O^  cells/ml) were incubated with 
different concentrations (0-100 |iM) of 18-p glycyrrhetinic acid at yj°C for 48 hours. 
Cultures were then pulsed with 0.5 |iCi of ^H-TdR for 6 hours before harvest. 
Radioactivity in counts per minute (cpm) was measured using a liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation, using the 
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Figure 3.20: Anti-proliferative effect of 18-P glycyrrhetinic acid on the human 
promyelocytic leukemia HL-60 cells. HL-60 cells (5x10^ cells/ml) were incubated 
with different concentrations (0-180 ^M) of 18-P glycyrrhetinic acid at 37°C for 48 
hours. Cultures were then pulsed with 0.5 ^iCi of ^H-TdR for 8 hours before harvest. 
Radioactivity in counts per minute (cpm) was measured using a liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation, using the 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Figure 3.21: Anti-proliferative effect of 18-P glycyrrhetinic acid on the human 
chronic myelogenous leukemia K562 cells. K562 cells (5x10"^ cells/ml) were 
incubated with different concentrations (0-100 ^iM) of 18-P glycyrrhetinic acid at 37�C 
for 48 hours. Cultures were then pulsed with 0.5 |aCi of ^H-TdR for 8 hours before 
harvest. Radioactivity in counts per minute (cpm) was measured using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR incorporation, 
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Figure 3.22: Anti-proliferative effect of 18-p glycyrrhetinic acid on the human 
eosinophilic leukemia Eol-l cells. Eol-l cells (5x10^ cells/ml) were incubated with 
different concentrations (0-100 ^iM) of 18-p glycyrrhetinic acid at 37"C for 48 hours. 
Cultures were then pulsed with 0.5 |LiCi of ^H-TdR for 8 hours before harvest. 
Radioactivity in counts per minute (cpm) was measured using a liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation, using the 
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Figure 3.23: Anti-proliferative effect of 18-(3 glycyrrhetinic acid on the Moloney 
leukemia virus-induced T cell lymphoma MBL-2 cells. MBL-2 cells (IxlO^ cells/ml) 
were incubated with different concentrations (0-100 |iM) of 18-p glycyrrhetinic acid at 
37°C for 48 hours. Cultures were then pulsed with 0.5 |LiCi of ^H-TdR for 6 hours before 
harvest. Radioactivity in counts per minute (cpm) was measured using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR incorporation, 
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Figure 3.24: Anti-proliferative effect of 18-P glycyrrhetinic acid on the Moloney 
leukemia virus-induced T cell lymphoma YAC-1 cells. YAC-1 cells (1x10^ cells/ml) 
were incubated with different concentrations (0-100 |uM) of 18-p glycyrrhetinic acid at 
37�C for 48 hours. Cultures were then pulsed with 0.5 jiCi of^H-TdR for 6 hours before 
harvest. Radioactivity in counts per minute (cpm) was measured using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR incorporation, 
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Table 3.4: The estimated values of IC50 of 18-p glycyrrhetinic acid on various 
leukemic cell lines. 
Types o f L e u k ^ Cell line Estimated I C g n v a l i ^ 
(A) Myelocytic Leukemias 
Murine myelomonocytic leukemia WEHI-3B JCS 63 
Murine myeloblastic leukemia Ml 60 
Human promyelocytic leukemia HL-60 134 
Human chronic myelogenous K562 84 
leukemia 
Human eosinophilic leukemia EoM 60 
(B) Lymphocytic Leukemias 
Murine T-cell lymphoma MBL-2 60 
Murine T-cell lymphoma YAC-1 84 
* IC50 value is the estimated concentration of glycyrrhetinic acid which can cause 50 % 
inhibition of^H-TdR Incorporation under the specified experimental conditions. 
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Figure 3.25: Kinetic studies on the anti-proliferative effect of 18-p glycyrrhetinic 
acid on the murine myeloid leukemia WEHI-3B JCS cells. JCS cells (1x10^ cells/ml) 
were incubated with different concentrations (0-100 juM) of 18-p glycyrrhetinic acid at 
37°C for different time intervals (12, 24 and 48 hours). Cultures were then pulsed with 
0.5 |LiCi of ^H-TdR for 6 hours before harvest. Radioactivity in counts per minute (cpm) 
was measured using a liquid scintillation counter. Results were expressed as % 
inhibition of ^H-TdR incorporation, using the untreated cells as a control. Each point 
represents the mean 士 S.E. of quadruplicate culture 
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3.2.2.2 Effects of 18-B Glycyrrhetinic Acid on the Viability of Various Leukemic 
Cell Lines and Normal Hematopoietic Cells In Vitro 
Firstly, the effect of 18-P glycyrrhetinic acid on the viability of leukemia cells 
was determined by cell counting using the trypan blue exclusion assay after 24 hours 
and 48 hours of incubation. It was found that 18-p glycyrrhetinic acid did not exhibit 
any appreciable cytotoxicity on the murine myeloid leukemia JCS cells at concentrations 
up to 60 juM (Figure 3.26) even after 48 hours of incubation. However, a marked 
cytotoxic effect on JCS cells was seen at a concentration of 80 |aM. While for the human 
myeloid leukemia HL-60 cells, 18-P glycyrrhetinic acid did not exhibit any significant 
cytotoxic effect at concentrations up to 140 ^M (less than 10 % cytotoxicity) after 48 
hours of incubation (Figure 3.27). 
The effect of 18-p glycyrrhetinic acid on the viability of the murine normal 
hematopoietic cells such as bone marrow cells and spleen cells was also determined by 
cell counting using the trypan blue exclusion assay. Figure 3.28 shows that 18-P 
glycyrrhetinic acid did not exhibit any cytotoxic effect on the mouse bone marrow in 
偷0 at all the concentrations (10-80 |aM) tested when compared with the solvent control. 
Unlike bone marrow cells, the murine splenic lymphocytes were found to be more 
sensitive to the cytotoxic effect of 18-p glycyrrhetinic acid. Although little (<10% 
cytotoxicity), if any, cytotoxicity was seen at a concentration up to 40 ^iM, however, 
significant cytotoxicity was observed at higher concentrations (60 I^M and 80 |liM) of 
18-P glycyrrhetinic acid after 48 hours of incubation (Figure 3.29). 
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Figure 3.26: Effect of 18-P glycyrrhetinic acid on the viability of the murine 
myeloid leukemia WEHI-3B JCS cells in vitro. JCS cells (IxlO^ cells/ml) were 
incubated with different concentrations (0-60 |LIM) of 18-p glycyrrhetinic acid at 37�C 
for 24 and 48 hours. Cell viability was determined by the trypan blue exclusion test, and 
the results were expressed as mean % of viable cells 士 S.E. of triplicate cultures. 
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Figure 3.27: Effect of 18-P glycyrrhetinic acid on the viability of the myeloid 
leukemia HL-60 cells in vitro. HL-60 cells (5x10"^ cells/ml) were incubated with 
different concentrations (0-140 |iM) of 18-p glycyrrhetinic acid at 37�C for 24 and 48 
hours. Cell viability was determined by the trypan blue exclusion test, and the results 
were expressed as mean % of viable cells 士 S.E. of triplicate cultures. 
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Figure 3.28: Effect of 18-p glycyrrhetinic acid on the viability of murine bone 
marrow cells in vitro. BALB/c bone marrow cells (IxlO"^ cells/well) were incubated 
with the solvent (DMSO) control or with different concentrations (0-80 |aM) of 18-P 
glycyrrhetinic acid at 37°C for 72 hours. Cell viability was determined by the trypan 
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Figure 3.29: Effect of 18-P glycyrrhetinic acid on the viability of murine splenic 
lymphocytes in vitro. BALB/c splenocytes (5x10"^ cells/well) were incubated with 
different concentrations (0-80 _ of 18-P glycyrrhetinic acid at 37�C for 24 and 48 
hours. Cell viability was determined by the trypan blue exclusion test, and the results 
were expressed 
as mean % of viable cells 士 S.E. of triplicate cultures. 
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3.2.2.3 Induction of DNA Fragmentation in Leukemia Cells by 18-B Glycyrrhetinic 
Acid 
Previous section (Section 3.2.1.3) showed that glycyrrhizin could induce DNA 
fragmentation in the human myeloid leukemia HL-60 cells after 24 and 48 hours of 
incubation. In contrast, this study showed that DNA fragmentation was detectable in 
HL-60 cells as early as 6 hours after treatment with 150 [iM 18-P glycyrrhetinic acid 
(Figure 3.30). The apoptosis-inducing effect of 18-P glycyrrhetinic acid was also found 
to be time- and dose-dependent. The amount of fragmented DNA increased as the 
concentration of 18-P glycyrrhetinic acid was increased and marked DNA fragmentation 
was seen when HL-60 cells were treated with 200 |LIM 18-p glycyrrhetinic acid for 8 
hours (Figure 3.30). 
Interestingly enough, DNA ladder was also detected in JCS cells after 1 hour 
treatment with 60 i^M 18-P glycyrrhetinic acid (Figure 3.31). The amounts of 
fragmented DNA increased from 1 hour to 4 hours in JCS cells treated with 60 jiM 18-P 
glycyrrhetinic. Moreover, the amount of fragmented DNA increased as the concentration 
of 18-P glycyrrhetinic acid was increased from 20 fiM to 80 fiM. 
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Figure 3.30: Induction of DNA fragmentation in 18-p glycyrrhetinic acid-treated human 
myeloid leukemia HL-60 cells. HL-60 cells (5x1cells/ml) were incubated with different 
concentrations of 18-P glycyrrhetinic acid (0-200 |iM) at 37�C for different periods of time 
(from 6 to 10 hours). Apoptotic DNA fragments were extracted by mild detergent IGEPAL CA_ 
630 lysis buffer, and were analyzed by electrophoresis on 2% agarose gel stained with ethidium 
bromide. 
Lane 1: 100 bp D N A markers 
Lane 2: Untreated HL-60 cells 
Lane 3: With 150 [ iM 18-P glycyrrhetinic acid for 6 hours 
Lane 4: With 150 |LIM 18-p glycyrrhetinic acid for 8 hours 
Lane 5: With 150 |uM 18-P glycyrrhetinic acid for 10 hours 
Lane 6: With 80 |aM 18-p glycyrrhetinic acid for 8 hours 
Lane 7: With 200 ^iM 18-p glycyrrhetinic acid for 8 hours 
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Figure 3.31: Induction of DNA fragmentation in 18-P glycyrrhetinic acid-treated murine 
myeloid leukemia WEHI-3B JCS cells. JCS cells (IxlO^ cells/ml) were incubated with 
different concentrations of 18-P glycyrrhetinic acid (0-80 |aM) at 37�C for different periods of 
time (from 1 to 4 hours). Apoptotic DNA fragments were extracted by mild detergent IGEPAL 
CA-630 lysis buffer, and were analyzed by electrophoresis on 2% agarose gel stained with 
ethidium bromide. 
Lane 1; Untreated JCS cells 
Lane 2: With 60 |LIM 18-P glycyrrhetinic acid for 1 hours 
Lane 3: With 60 ^iM 18-p glycyrrhetinic acid for 2 hours 
Lane 4: With 60 ^iM 18-P glycyrrhetinic acid for 4 hours 
Lane 5: With 20 | iM 18-P glycyrrhetinic acid for 1 hour 
Lane 6: With 40 [ iM 18-p glycyrrhetinic acid for 1 hour 
Lane 7: With 80 ^iM 18-p glycyrrhetinic acid for 1 hour 
Lane 8: 100 bp D N A markers 
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3.2.2.4 Effect of 18-B Glycyrrhetinic acid on the Cell Cycle Kinetics of HL-60 Cells 
In Vitro 
The effect of 18-P glycyrrhetinic acid on the cell cycle kinetics of the HL-60 
cells was examined by flow cytometry. As shown in Figure 3.32 and Table 3.5, there 
was only a slight increase in the percentage of cells in the G2 + M phase of the cell cycle 
when the HL-60 cells were incubated with 150 i^M 18-p glycyrrhetinic acid for 8 hours, 
and this increase was accompanied with a corresponding decrease in the percentage of 
cells in S phase. Moreover, a hypodiploid peak was observed in HL-60 cells treated with 
150 [iM of 18-P glycyrrhetinic acid, indicating that 18-P glycyrrhetinic acid can induce 
apoptosis in HL-60 leukemia cells. 
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Figure 3.32: Effect of 18-p glycyrrhetinic acid on the cell cycle profile in HL-60 
cells. HL-60 cells (5 x 10^ cells/ml) were incubated with different concentrations 
( 0 - 1 5 0 |iM) of 18-p glycyrrhetinic acid at 37 for 8 hours. 18-P glycyrrhetinic acid-
treated cells (1 x 10^ cells) were fixed with ethanol and stained with PI under hypotonic 
conditions. Pl-stained cells were analyzed for fluorescence intensity using the FACSort 
flow cytometer. Cell cycle distribution was calculated by the MODFIT program using 
RFIT analysis model. 
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Table 3.5: Effect of 18-P glycyrrhetinic acid on cell cycle distribution of 
HL-60 cells 
Concentration of f" % of cells 
18-P glycyrrhetinic GO/G丨 phase S phase G2+M 
phase 
0 4]J3 VLSI 
100 4145 
n o 41：^ yjA9 
150 4Z33 34^80 22.87 
HL-60 cells (5 x cells/ml) were incubated with different concentrations 
(0-150 i^M) of 18-p glycyrrhetinic acid at 37 for 8 hours. The DNA was 
stained with propidium iodide and the fluorescence intensity was analysed with a 
flow cytometer. The percentage of cells at different phases of the cell cycle was 
calculated by the MODFIT program, using the rectangle fit (RFIT) analysis 
model. 
125 
Chapter 3 Anti-Tumor Effects 
3.2.2.5 Effect of 18-B glycyrrhetinic acid on the Cell Cycle Kinetics of JCS Cells Tm 
Vitro 
In this experiment, kinetic studies on the effect of 18-p glycyrrhetinic acid on the 
cell cycle distribution of the leukemia JCS cells was investigated by flow cytometry. As 
shown in Figure 3.33 and Table 3.6, there was a marked arrest of the JCS cells in GQ/GI 
phase of the cell cycle, and this increase was accompanied with a corresponding 
decrease in the percentage of cells in S phase when JCS cells were incubated with 60 
i^M 18-P glycyrrhetinic acid for 2 to 8 hours. The results clearly show that 18-P 
glycyrrhetinic acid could suppress the proliferation of JCS cells by arresting cells at the 
GQ/GI phase . 
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Figure 3.33: Effect of 18-P glycyrrhetinic acid on the cell cycle profile in JCS cells. 
JCS cells (1 X 104 cells/ml) were incubated with 60 ^M 18-P glycyrrhetinic acid for 2 to 
8 hrs at 37 18-P glycyrrhetinic acid-treated cells (1 x 10^ cells) were fixed with 
ethanol and stained with PI under hypotonic conditions. Pl-stained cells were analyzed 
for fluorescence intensity using the FACSort flow cytometer. Cell cycle distribution was 
calculated by the MODFIT program using RFIT analysis model. 
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Table 3.6: Effect 18-P glycyrrhetinic acid on cell cycle distribution of JCS cells 
Time after treatment with % of cells “ 
60 i^M 18-p glycyrrhetinic ^―r 
W G i S phase G2+M 
acid 
phase phase 
0 47；^ 40?78 f m 
2 hours 44.99 ^ 
4 hours 50.83 38.39 
6 hours 52M STSO 15^ 
8 hours 67.86 21.04 I L U 
JCS cells (1 X 104 cells/ml) were incubated with 60 |liM 18-p glycyrrhetinic 
acid for different time intervals at 37 The DNA was stained with propidium 
iodide and the fluorescence intensity was analysed with a flow cytometer. The 
percentage of cells at different phases of the cell cycle was calculated by the 
MODFIT program, using the rectangle fit (RFIT) analysis model. 
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3.2.2.6 Effect of 18-B Glycyrrhetinic acid on the In Vivo Tumorijgenicitv of the 
Murine Myeloid Leukemia JCS Cells 
The ability of 18-P glycyrrhetinic acid to reduce the in vivo tumorigenicity of the 
murine myeloid leukemia JCS cells was investigated. As shown in Figure 3.34，pre-
treatment of JCS cells with 70 or 90 _ 18-p glycyrrhetinic acid in vitro for 8 hours 
could significantly decrease the leukemic cell growth in syngeneic mice in a dose-
dependent manner. These results indicate that 18-P glycyrrhetinic acid is very effective 
in reducing the tumorigenicity of the myeloid leukemia cells in vivo. 
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Figure 3.34: Effect of in vitro treatment of leukemia cells with 18-P glycyrrhetinic 
acid on their tumorigenicity in syngeneic BALB/c mice. JCS cells (1.2x10^ cells/ml) 
were incubated with two different concentrations (70 and 90 _ of 18-P glycyrrhetinic 
acid for 8 hours at 37�C. The cells were washed three times with RPMI medium. 
3xl0^cells/mouse viable JCS cells were injected intraperitoneally into BALB/c mice in 
groups of five. Leukemia cells recoverable from the peritoneal cavity of mice were 
counted at day 12 post-tumor inoculation. 
Significantly different from control untreated cells: * P<0.005. 
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3.3 Discussion 
In the present study, the effects of glycyrrhizin and 18-P glycyrrhetinic acid on 
the proliferation and apoptosis of leukemia cells were investigated, using a panel of well 
characterized and cloned murine and human leukemic cells lines. It was found that both 
glycyrrhizin and 18-p glycyrrhetinic acid exhibited potent anti-proliferative effect on 
various leukemic cell lines in a dose-dependent manner. 
Differential growth-inhibitory effect of glycyrrhizin and 18-P glycyrrhetinic acid 
on different leukemia cells was measured by using the tritiated thymidine incorporation 
assay. It was found that the YAC-1 and Eol-l cells were the most sensitive cells in 
response to glycyrrhizin, whereas the Ml cells were found to be relatively resistant to 
the cytostatic effect of glycyrrhizin. On the other hand, a different pattern of sensitivity 
to growth inhibition was seen with 18-P glycyrrhetinic acid. The results showed that Ml , 
MBL-2 and Eol-l cells were the most sensitive to the anti-proliferative effect of 18-P 
glycyrrhetinic acid, whereas the HL-60 cells was found to be relatively resistant. The 
reason(s) for the differential sensitivity of a leukemic cell line (e.g. Ml cells) to the anti-
proliferative effect of glycyrrhizin and 18-P glycyrrhetinic acid remains obscure and 
awaits further investigation. It is clear that the growth-inhibitory effect of glycyrrhizin 
and 18-P glycyrrhetinic acid on myeloid leukemia cells could not be attributed directly 
or solely to their cytotoxic effect on the leukemia cells, since glycyrrhizin did not exhibit 
any cytotoxic effect on different leukemia cells at concentrations up to 2 mM after 48 
hours of incubation. Similarly, 18-p glycyrrhetinic acid did not exhibit any cytotoxic 
effect on JCS cells at concentrations up to 60 |_iM and on HL-60 cells at concentrations 
up to 140 |iM after 48 hours of incubation. Our results are similar to that of Abe et al 
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(1987) who showed that growth inhibition of the B16 melanoma cells was the result of 
cytostatic but not cytotoxic effect of 18-p glycyrrhetinic acid. A lack of cytotoxicity of 
glycyrrhizin on normal hematopoietic cells was also observed with the mouse bone 
marrow cells and splenocytes. Nevertheless, unlike bone marrow cells, the murine 
splenocytes were found to be more sensitive to the cytotoxic effect of 18-p 
glycyrrhetinic acid in vitro, especially at higher concentrations and after prolonged 
incubation. Similarly, it was shown that 18-p glycyrrhetinic acid did exhibit potent 
cytotoxic effect on the leukemia JCS cells at higher concentrations (greater or equal to 
80 
Moreover，it was found that glycyrrhizin exhibited an apoptosis-inducing effect 
on the human myeloid leukemia HL-60 cells in a dose and time-dependent manner but it 
could not induce DNA fragmentation in the murine myeloid leukemia JCS cells under 
the prescribed experimental conditions. At present it is unclear why glycyrrhizin failed 
to trigger apoptosis in the JCS leukemia cells. A recent report showed that glycyrrhizin 
alone did not induce apoptosis in the human T cell leukemic cell lines such as Jurkat and 
Molt-4F cells (Ishiwata et al., 1999). In addition, these investigators also demonstrated 
that glycyrrhizin but not 18-p glycyrrhetinic acid could enhance the Fas-mediated 
apoptosis in these two T cell lines. Although the underlying mechanism by which 
glycyrrhizin could enhance apoptosis in T leukemia cells has not yet been established, it 
was suggested that the enhancement of apoptosis by glycyrrhizin might be caused by its 
interaction with the plasma membrane of the cells and is independent of their caspase 
activities (Ishiwata et aL, 1999). Interestingly enough, Yoshikawa et al (1999) showed 
that glycyrrhizin partially inhibited the apoptosis of the human hepatoblastoma cell line 
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HepG2 induced by TNF-a and actinomycin D but had no effect on the Fas-mediated 
apoptosis of the HepG2 cells. To our knowledge, the effect of 18-(3 glycyrrhetinic acid 
on the apoptosis of tumor cells has not yet been investigated. In this study, we found that 
18-P glycyrrhetinic acid could exhibit an apoptosis-inducing effect on both HL-60 and 
JCS cells in a dose- and time-dependent manner. It is because the induction of apoptosis 
may be mediated through the regulation of cell cycle progression, therefore, the effect of 
glycyrrhizin and 18-P glycyrrhetinic acid on cell cycle perturbations was studied. Our 
results indicated that the glycyrrhizin-treated HL-60 cells and 18-(3 glycyrrhetinic acid-
treated JCS cells had a significant decrease in cell cycling in S phase accompanied with 
a cell cycle arrest in the GQ/GI phase. These data are consistent with that of Yano et al. 
(1994) who showed that the herbal medicine Sho-saiko-to (which contains glycyrrhizin 
and baicalein as two main active ingredients) inhibited the proliferation of the human 
hepatocellular carcinoma cell line (KIM-1) by inducing apoptosis and cell cycle arrest at 
the Go/Gi phase. On the other hand, our results also showed that there was a significant 
decrease in cell cycling in S phase accompanied with a cell cycle arrest in the GQ/GI 
phase in glycyrrhizin-treated JCS cells. However, the reason for absence of DNA 
fragmentation in this case was unknown. Also, for the 18-(3 glycyrrhetinic acid-treated 
HL-60 cells, it was observed that there was a slight decrease in the percentage of cells in 
S phase accompanied with cell cycle arrest in the G2 + M. The discrepancy in these 
findings remains unclear. 
Apart from their anti-proliferative and apoptosis-inducing activities, the effect of 
glycyrrhizin and 18-P glycyrrhetinic acid on the tumorigenicity of the transplantable 
leukemia JCS cells in syngeneic mice was also investigated. It was found that JCS cells 
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recoverable from the peritoneal cavity of mice were significantly reduced if the cells 
were pre-treated in vitro with glycyrrhizin for 24 hours and 18-p glycyrrhetinic acid for 
8 hours. Our results indicated that both glycyrrhizin and 18-p glycyrrhetinic acid not 
only can inhibit the proliferation of leukemia JCS cells in vitro, but also can inhibit their 
tumorigenicity in vivo. Similarly, others had demonstrated that both glycyrrhizin and 18-
p glycyrrhetinic acid could exert their anti-tumor activity in vivo. For instance, it was 
reported that the prolonged treatment with glycyrrhizin was effective in modifying the 
survival pattern of mice bearing EAT tumor (Rossi et al., 1995). Wang et al. (1991), on 
the other hand, found that in vivo administration of glycyrrhizin and 18-P glycyrrhetinic 
acid effectively inhibited the inception and growth of skin tumor. Moreover, Suzuke et 
al. (1992) showed that in vivo administration of glycyrrhizin into Meth A tumor-bearing 
mice partially inhibited the growth of the tumor cells, possibly by enhancing the host 
immune defense against the tumor. 
Although the exact mechanisms by which glycyrrhizin and 18-p glycyrrhetinic 
acid can inhibit the growth and induce apoptosis in leukemia cells are as yet unclear, 
however, a close relationship between apoptosis, cellular differentiation and cell cycle 
arrest of the myeloid leukemia cells had been suggested (Elias & Berry, 1991, Csokay et 
al., 1997). Investigation on the differentiation-inducing activity of glycyrrhizin and 18-p 
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4.1 Introduction 
Myeloid cell differentiation is characterized by the cessation of proliferation and 
expression of surface markers typical for myeloid cells, such as the I region-associated 
(la) antigen and Fc receptor (Guyre et aL, 1983). Moreover, there are other markers of 
cell differentiation, such as increase in heterogeneity in functions, as well as 
morphological and expression of phenotypic markers. The induction of monocyte-
specific enzymes such as non-specific esterase, lysozyme and type IV collagenase 
occurs along the differentiation pathway of mature monocytes (Ricciardi-Castagonli & 
Paglia, 1992; Leenen et al., 1994). Also, the increase in functional characteristics such 
as superoxide anion production, nitric oxide generation and stimulation of phagocytic 
and endocytic activities are commonly observed in myeloid cell differentiation (Leung et 
cd., 1994). It has been reported that certain flavonoids, such as isoflavone and genistein, 
can induce the differentiation of malignant cells to a mature phenotype (Constaninou et 
al., 1990). 
Myeloid leukemia is a heterogeneous group of disorder resulting from an 
uncoupling of the proliferation and differentiation of myeloid cells at various stages of 
development along the hematopoietic pathway, so that the immature precursor cells 
accumulate, retain their proliferative ability without completing the differentiation 
program (Stunnenberg et al, 1999). Conventional anti-leukemia drugs have their 
limitations due to their relatively high cost, significant toxicity and adverse side effects. 
Differentiation therapy represents a novel approach for the treatment of myeloid 
leukemia. Earlier work have shown that myeloid leukemia cells will stop to proliferate 
and are induced to differentiate in response to a wide variety of agents, including 
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cytokines, vitamin analogs and phytochemicals from Chinese medicinal herbs (Sachs, 
1993; Leung et al., 1994; Mak et al, 1996; Fung et al, 1997). Licorice is one of the 
most widely used medicinal herbs since ancient time. Its major active component is 
glycyrrhizin (GL), which has been shown to be metabolized to its aglycone form, 18-P 
glycyrrhetinic acid (GA) after oral administration (Kim et al., 1999). Although 
glycyrrhizin and 18-P glycyrrhetinic acid have shown to have hepatoprotective, anti-
inflammatory, immunomodulatory and cancer chemopreventive activities (Mills & 
Bone, 2000), yet their direct anti-tumor activity and therapeutic potentials have not been 
fully explored. Earlier work of Abe et al. (1987) demonstrated that glycyrrhizin and 18-
P glycyrrhetinic acid were effective against the growth and differentiation of mouse 
melanoma cells in vitro. More recently, a report showed that glycyrrhizin and 18-(3 
glycyrrhetinic acid are fairly active against the in vitro growth of human lymphoma and 
leukemia cells (Malagoli et al” 1998)，but whether they can induce differentiation in 
leukemia cells has not been investigated. 
The murine myelomonocytic leukemia WEHI-3B JCS cells have been shown to 
differentiate into macrophage-丨ike cells in response to inducers such as TNF-a and IFN-
y (Chan el al., 1995), lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate (PMA) 
(Mak et al., 1993), I L - l a and IL-lp (Chan et al., 1997). Thus, these cells can be used as 
a cellular model for comparative analysis of the effects of glycyrrhizin and 18-P 
glycyrrhetinic acid on the differentiation of myeloid leukemia cells in vitro and for 
elucidation of their action mechanisms. In this chapter, the differentiation-inducing 
effects of glycyrrhizin and 18-P glycyrrhetinic acid on JCS cells will be investigated by 
a number of criteria, including morphologic, phenotypic and functional assays. 
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Morphological changes in the drug-treated cells will be examined by staining of 
cytocentrifuge preparations. Also, the surface expression of lineage-specific 
differentiation antigens will be examined by flow cytometry. Finally, other 
differentiation-associated functional characteristics of matured myeloid cells such as the 
expression of endocytic activity will be investigated. 
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4.2 RESULTS 
4.2.1 Morphological Changes in Glycyrrhizin or 18-BGlvcvrrhetinic Acid-treated 
JCS Cells 
Cytocentrifuge preparations of the cells were examined under the light 
microscope for the morphological changes of the cells after glycyrrhizin or 18-p 
glycyrrhetinic acid treatment. First of all, JCS cells were incubated with 1.5 mM of 
glycyrrhizin or 40 i^M 18-p glycyrrhetinic acid at 37°C for 4 days or 3 days respectively. 
The cells were then centrifuged onto microscopic slides. As shown in Figure 4.1, 
glycyrrhizin could induce the formation of vacuoles and cause cell enlargement in JCS 
cells and a decrease in the ratio of nucleus to cytoplasm was observed. Therefore, the 
glycyrrhizin-treated JCS cells showed features of the more mature stages of myeloid 
cells. Similar morphological changes were also seen in 18-P glycyrrhetinic acid-treated 
JCS cells (Figure 4.2). Collectively, these results demonstrated that these two drugs had 
the ability to induce the differentiation of leukemia cells into more mature macrophage-
like cells. 
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Figure 4.1: Morphological changes in glycyrrhizin-treated JCS cells. 
JCS cells (1 X 104 cells/ml) were incubated with (A) culture medium; (B) 1.5 mM 
giycyrrhizin at 37 ^C for 4 days. The cells were cytocentrifuged onto microscopic slide 
and were stained with Hemacolor solutions (Magnification x 400). 
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Figure 4.2: Morphological changes in 18-P glycyrrhetinic acid-treated JCS cells. 
JCS cells (1 X 104 cells/ml) were incubated with (A) culture medium; (B) 40 )LIM 18-p 
glycyrrhetinic acid at 37 for 3 days. The cells were cytocentrifuged onto 
microscopic slide and were stained with Hemacolor solutions (Magnification x 400). 
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4.2.2 Surface Antigen Immunophenotyping of Glycyrrhizin or 18-3 Glycyrrhetinic 
Acid-treated JCS cells 
When cells undergoing differentiation, some lineage-specific differentiation 
antigens are expressed on the surface of cells. Therefore, the expression of certain 
surface markers can be used as an indicator for cell differentiation study. With the help 
of fluorescent FITC conjugated monoclonal antibodies, the expression of surface antigen 
can be analysed by flow cytometry. This enables us to identify what lineage-specific 
cells are being differentiated due to the treatment with the corresponding drugs (Leenen 
et al, 1994). 
FACS analysis (Figure 4.3 to 4.5) showed that at concentrations of 1.5 and 2 mM, 
glycyrrhizin markedly enhanced the expression of macrophage differentiation antigens, 
Mac-1 and F4/80，on the surface of glycyrrhizin-treated cells. This implied that 
glycyrrhizin-treated JCS cells underwent phenotypic changes associated with the 
acquisition of mature macrophage or monocyte features. However, the glycyrrhizin 
treated cells did not show any enhancement of the expression of granulocyte 
differentiation antigen, Gr-1. This implied that JCS cells did not acquire the 
characteristics of granulocytes. Therefore JCS cells were committed to the 
differentiation pathway towards the macrophage or monocyte lineage after glycyrrhizin 
treatment. Moreover, the glycyrrhizin-treated JCS cells were induced to express certain 
adhesion molecules, such as the vascular cell adhesion molecule-1 (VCAM-1) (Figure 
4.6) and lymphocyte function-associated antigen-1 (LFA-1) (Figure 4.7). However, there 
was very little, if any, increase in the expression of the intercellular adhesion molecule-1 
(ICAM-1) (Figure 4.8). 
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On the other hand, FACS analysis (Figure 4.9 to 4.11) showed that at 
concentrations of 20 and 40 |iM, 18-P glycyrrhetinic acid could enhance the expression 
of macrophage differentiation antigens, Mac-1 and F4/80, on the surface of 18-p 
glycyrrhetinic acid-treated cells. This implied that 18-(3 glycyrrhetinic acid-treated JCS 
cells also underwent phenotypic changes associated with the acquisition of mature 
macrophage or monocyte characteristics. However, 18-p glycyrrhetinic acid had no 
effect on the expression of granulocyte differentiation antigen, Gr-1, on JCS cells. 
Therefore JCS cells were committed to the differentiation pathway towards the 
macrophage or monocyte lineage rather than the granulocytic lineage after 18-P 
glycyrrhetinic acid treatment. Moreover, same as the glycyrrhizin-treated JCS cells, the 
18-P glycyrrhetinic acid-treated JCS cells were induced to express the lymphocyte 
function-associated antigen-1 (LFA-1) (Figure 4.12). On the other hand, there was only 
a slight increase in the expression of VCAM-1 molecules on the surface of 18-P 
glycyrrhetinic acid-treated JCS cells (Figure 4.13). Finally, there was no detectable 
increase in the expression of the intercellular adhesion molecule-1 (ICAM-1) in the 18-P 
glycyrrhetinic acid-treated JCS cells (Figure 4.14). 
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Figure 4.3 FACS analysis of Mac-1 antigen expression on glycyrrhizin-treated JCS 
cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 mM 
and (C) 2 mM glycyrrhizin at 37®C for 4 days. Cells were then stained with monoclonal 
antibody to Mac-1. The paraformaldehyde-fixed cells (1 x 10 4 cells) were analysed for 
fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.4 FACS analysis of F4/80 antigen expression on glycyrrhizin-treated JCS 
cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 mM 
and (C) 2 mM glycyrrhizin at 37�C for 4 days. Cells were then stained with monoclonal 
antibody to F4/80. The paraformaldehyde-fixed cells (1 x 10 斗 cells) were analysed for 
fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.5 FACS analysis of Gr-1 antigen expression on glycyrrhizin-treated JCS 
cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 mM 
and (C) 2 mM glycyrrhizin at 37�C for 4 days. Cells were then stained with monoclonal 
antibody to Gr-1. The paraformaldehyde-fixed cells (1 x 10 � cells) were analysed for 
fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.6 FACS analysis of VCAM-l antigen expression on glycyrrhizin-treated 
JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 
mM and (C) 2 mM glycyrrhizin at 37�C for 4 days. Cells were then stained with 
monoclonal antibody to VCAM-l. The paraformaldehyde-fixed cells (1 x 10 ^ cells) 
were analysed for fluorescence intensity (FL-1 height) using the FACSort flow 
cytometer. 146 
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Figure 4.7 FACS analysis of LFA-1 antigen expression on glycyrrhizin-treated JCS 
cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 mM 
and (C) 2 mM giycyrrhizin at 37°C for 4 days. Cells were then stained with monoclonal 
antibody to LFA-1. The paraformaldehyde-fixed cells (1 x 10 � cells) were analysed for 
fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.8 FACS analysis of ICAM-1 antigen expression on glycyrrhizin-treated 
JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; (B) 1.5 
mM and (C) 2 mM glycyrrhizin at 37°C for 4 days. Cells were then stained with 
monoclonal antibody to ICAM-1. The paraformaldehyde-fixed cells (1 x 10 4 cells) were 
analysed for fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.9 FACS analysis of Mac-1 antigen expression on 18-|3 glycyrrhetinic acid-
treated JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; 
(B) 20 i^M and (C) 40 |LIM 18-p glycyrrhetinic acid at 37"C for 3 days. Cells were then 
stained with monoclonal antibody to Mac-1. The paraformaldehyde-fixed cells 
(1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the FACSort 
flow cytometer. 
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Figure 4.10 FACS analysis of F4/80 antigen expression on 18-P glycyrrhetinic acid-
treated JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; 
(B) 20 i^M and (C) 40 i^M 18-p glycyrrhetinic acid at 37�C for 3 days. Cells were then 
stained with monoclonal antibody to F4/80. The paraformaldehyde-fixed cells 
(1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the FACSort 
flow cytometer. 
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Figure 4.11 FACS analysis of Gr-1 antigen expression on 18-P glycyrrhetinic acid-
treated JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture medium; 
(B) 20 i^M and (C) 40 |iM 18-p glycyrrhetinic acid at 37T for 3 days. Cells were then 
stained with monoclonal antibody to Gr-1. The paraformaldehyde-fixed cells 
(1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the FACSort 
flow cytometer. 
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Figure 4.12 FACS analysis of LFA-1 antigen expression on 18-P glycyrrhetinic 
acid-treated JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with (A) culture 
medium; (B) 20 |LIM and (C) 40 i^M 18-(3 glycyrrhetinic acid at 37X for 3 days. Cells 
were then stained with monoclonal antibody to LFA-1. The paraformaldehyde-fixed 
cells (1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the FACSort flow cytometer. 
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Figure 4.13 FACS analysis of VCAM-1 antigen expression on 18-P glycyrrhetinic 
acid-treated JCS cells. JCS cells (2 x cells/ml) were incubated with (A) culture 
medium; (B) 20 ^M and (C) 40 i^M 18-p glycyrrhetinic acid at 37�C for 3 days. Cells 
were then stained with monoclonal antibody to VCAM-1. The paraformaldehyde-fixed 
cells (1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the 
FACSort flow cytometer. 
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Figure 4.14 FACS analysis of ICAM-1 antigen expression on 18-P glycyrrhetinic 
acid-treated JCS cells. JCS cells (2 x cells/ml) were incubated with (A) culture 
medium; (B) 20 ^M and (C) 40 |LIM 18-(3 glycyrrhetinic acid at 37�C for 3 days. Cells 
were then stained with monoclonal antibody to ICAM-1. The paraformaldehyde-fixed 
cells (1 X 104 cells) were analysed for fluorescence intensity (FL-1 height) using the 
FACSort flow cytometer. 
154 
Chapter 4 Pfferentiation-inducing Effects 
4.2.3 Endocytic Activity of Glycyrrhizin or 18-B Glycyrrhetinic Acid-treated 
JCS Cells 
It has been reported that monocytic differentiation of the myeloid leukemia cells 
is always accomplished by an increase in the endocytic activity of the differentiating 
cells (Leung et al., 1994). In this study, the endocytic activity of the glycyrrhizin- or 18-
P glycyrrhetinic acid-treated JCS cells was determined by the uptake of FITC-
conjugated bovine serum albumin (FITC-BSA) which was analyzed by flow cytometry. 
As shown in Figure 4.15, after treatment of JCS cells with 2 mM and 2.5 mM 
glycyrrhizin for 4 days at 37°C, there was an enhancement of the endocytic activity of 
the JCS cells. However, there was no significant change in the endocytic activity of JCS 
cells after treatment with 18-p glycyrrhetinic acid (20-60 uM) for 4 days (Figure 4.16). 
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Figure 4.15 Induction of endocytic activity in glycyrrhizin-treated JCS cells. JCS 
cells (2 X 103 cells/ml) were incubated with different concentrations of glycyrrhizin 
(0-2.5 mM) at 37°C for 4 days. Endocytic activity was determined by the uptake of 
FITC-BSA, using untreated JCS cells as a control. The paraformaldehyde-fixed cells 
(1 X 104 cells) were analyzed for fluorescence intensity using the FACSort flow 
cytometer. The x-axis was plotted in a logarithmic scale. 
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Figure 4.16 Effect of 18-P glycyrrhetinic acid on the induction ofendocytic activity 
in JCS cells. JCS cells (2 x 10^  cells/ml) were incubated with different concentrations 
(0-60 ^iM) of 18-p glycyrrhetinic acid at 37"C for 4 days. Endocytic activity was 
determined by the uptake of FITC-BSA, using untreated JCS cells as a control. The 
paraformaldehyde-fixed cells (1 x cells) were analyzed for fluorescence intensity 
using the FACSort flow cytometer. The x-axis was plotted in a logarithmic scale. 
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4.3 Discussion 
It has been reported that certain flavonoids have anti-proliferative and 
differentiation-inducing activity on different myeloid leukemic cell lines, such as HL-60 
and K562 (Constaninou et al., 1990). It was found that the isoflavone, genistein, could 
induce the differentiation of human erythroid K-562-J and myeloid HL-205 leukemia 
cells. The induced cells expressed the mature phenotype, the appearance of mature 
monocytic or granulocytic markers, the acquisition of staining for non-specific esterase 
(Middleton, 1996). 
When cells undergoing differentiation, some lineage-specific differentiation 
antigens are expressed on the surface of cells. Therefore, the expression of certain 
surface markers can be used as an indicator for cell differentiation study. With the help 
of fluorescent FITC conjugated monoclonal antibodies，the expression of surface antigen 
can be analysed by flow cytometry. This enables us to identify what lineage-specific 
cells are being differentiated due to the treatment of the drugs. In this present study, 
glycyrrhizin and 18-p glycyrrhetinic acid were shown to have the capacity of inducing 
the monocytic differentiation of the myeloid leukemia WEHI-3B JCS cells in a dose-
dependent manner. They had the ability to induce the differentiation of leukemic cell 
lines into a more mature stage since they could induce the formation of vacuoles and 
cause cell enlargement in JCS cells and the ratio of nucleus to cytoplasm was decreased 
(Section 4.2.1). 
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Also, glycyrrhizin and 18-(3 glycyrrhetinic acid could enhance the expression of 
macrophage differentiation antigens, including Mac-1 and F4/80, on the surface of JCS 
leukemia cells (Section 4.2.2). The Mac-1 antigen is a differentiation antigen that is 
present in a variety of cell types, such as natural killer cells, polymorphs and 
macrophages (Springer et al., 1979). It was shown that a variety of differentiation agents, 
such as TNF-a, TNF-a together with IL-4, PMA and IL-1, could up-regulate the 
expression of Mac-1 antigen on JCS cells (Mak et al., 1993; Leung et al, 1994; Chan et 
al., l " 7 ) . On the other hand, the F4/80 antigen is a differentiation antigen that is present 
in normal and mature macrophages (Starkey et al., 1987). In addition, adhesion 
molecules such as VCAM-1 and LFA-1 were up-regulated after treatment of JCS cells 
with glycyrrhizin or 18-p glycyrrhetinic acid. The vascular cell adhesion molecule-1 
(VCAM-1) is expressed on myeloid cells and bone marrow stromal cells and its 
expression on endothelial cells can be up-regulated by inflammatory cytokines (Kinashi 
& Springer，1994). It was found that VCAM-1 could be strongly up-regulated in 
glycyrrhizin-treated JCS cells but was only weakly expressed in 18-p glycyrrhetinic 
acid-treated JCS cells. On the other hand, the leukocyte function associated molecule-1 
(LFA-1) is expressed on the surface of lymphocytes, neutrophils, monocytes and 
macrophages and it plays a role in mediating adhesion to endothelium in inflammatory 
response (Arnaout et al., 1988). LFA-1 was found to be expressed on the PMA-induced 
HL-60 cells which differentiated along the monocyte/macrophage pathway (Back et al., 
1992). Similarly, the expression of LFA-1 was greatly stimulated upon treatment of JCS 
cells with glycyrrhizin or 18-p glycyrrhetinic acid. Interesting enough, it was found that 
both glycyrrhizin and 18-p glycyrrhetinic acid failed to stimulate the expression of 
ICAM-1 in JCS cells. The intercellular adhesion molecule-1 (ICAM-1) is expressed on 
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endothelial cells and monocytes. It was reported that cytokines such as TNF-a, IL- la 
and IFN-y can induce the expression of ICAM-1 in myeloid leukemia cells (Most et al., 
1992). It is believed that these adhesion molecules are involved in the adhesion of 
peripheral blood leukocytes to endothelial cells which is a key step in the inflammatory 
process (Wawryk et al.’ 1989). Cell-cell interactions can be prevented when the 
expression levels of cell adhesion molecules in undifferentiated JCS are low. However, 
efficient interactions with other cellular mediators of the inflammatory response is 
allowed when glycyrrhizin- or 18-P glycyrrhetinic acid triggers cellular differentiation. 
Finally, it was shown that JCS cells induced by glycyrrhizin had acquired the 
functional characteristics of mature macrophages, such as stimulation of endocytic 
activity (Section 4.2.3). However, unexpectedly, there was no significant increase in the 
endocytic activity in JCS cells after treatment with 18-p glycyrrhetinic acid (20-60 uM) 
under the prescribed experimental conditions. Whether 18-p glycyrrhetinic acid can 
enhance other functional activities of JCS cells such as phagocytic activity and 
superoxide anion production still awaits further investigation. 
In conclusion, the underlying molecular and cellular mechanisms by which 
glycyrrhizin or 18-(3 glycyrrhetinic acid can inhibit myeloid leukemic cell proliferation 
and induce monocytic cell differentiation have not yet been elucidated. Further 
investigations on the mechanisms by which glycyrrhizin and 18-p glycyrrhetinic acid 
can exert their anti-leukemic effect on the murine myeloid leukemia JCS cells will be 
carried out and the results will be shown in the next chapter. 
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Chapter 5 Mechanistic Studies 
5.1 INTRODUCTION 
In the last decade or so, there has been an increasing interest in the studies of the 
anti-mutagenic, anti-carcinogenic and anti-tumor activities of licorice and its active 
constituents, glycyrrhizin and 18-P glycyrrhetinic acid. It was found that licorice extract 
could decrease the mutation frequencies induced by a number of mutagens and 
carcinogens in vitro over a wide range of concentrations well below the toxic level 
(Wang et al., 1991). Also, the anti-carcinogenic activity of licorice components has been 
well documented. On the other hand, it was reported that 18-P glycyrrhetinic acid 
inhibited the tumor promotion activity of teleocidin and 12-0-tetradecanoylphorbol-13-
acetate (TPA) in ICR mice in a two-stage skin carcinogenesis protocol (Nishino et al, 
1986). Glycyrrhizin has been shown to inhibit hepatocellular carcinoma formation in 
diethylnitrosamine-treated mice, indicating glycyrrhizin has chemopreventive activity 
for hepatocellular carcinoma (Shiota et al., 1999). Moreover, it was shown that 18-P 
glycyrrhetinic acid also inhibited the skin tumor initiating and tumor promoting 
activities of benzo(a) pyrene, 2-aminoflourene and aflatoxin B1 in SENCAR mice 
(Wang et al., 1991). The molecular mechanisms for the anti-carcinogenic activity of 
glycyrrhizin and 18-(3 glycyrrhetinic acid had been examined. It was demonstrated that 
18-p glycyrrhetinic acid could protect rapid DNA damage and inhibit the stimulation of 
unscheduled DNA synthesis caused by benzo(a)pyrene (Chen & Han, 1995). Moreover, 
it was reported that a single dose of glycyrrhizin administered to SD rats was unable to 
affect cytochrome P450 (CYP) superfamily, but 4 daily doses (240 or 480 mg/kg) of 
glycyrrhizin induced the phase I carcinogen-metabolizing enzymes, including the 
CYP3A, CYP1A2 and to varying extents CYP2B1-linked monooxygenases (Paolini et 
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a/.，1999). In addition, it was also found that licorice and giycyrrhizin possess anti-
carcinogenic activity because they can induce a variety of phase II enzymes involved in 
the detoxification and excretion of carcinogenic and toxic substances (Mirsalis et al, 
1993). Unlike the cancer chemopreventive activity, there have been relatively few 
studies on the direct anti-leukemic activities of licorice and its active components. 
Previous chapters (Chapter 3 and 4) in this thesis show that both giycyrrhizin and 18-p 
glycyrrhetinic acid can inhibit the proliferation, induce the apoptosis and monocytic 
differentiation of the murine myeloid leukemia JCS cells in a dose- and time-dependent 
manner. Moreover, the underlying cellular and molecular mechanisms by which 
giycyrrhizin and 18-p glycyrrhetinic acid can modulate the growth, differentiation and 
survival of the myeloid leukemia cells remain poorly understood. 
Cytokines are known to play an important role in the regulation of the 
proliferation, differentiation, survival and functions of hematopoietic cells in 
hematopoiesis. In the present study, the possible synergistic interactions of giycyrrhizin 
and 18-p glycyrrhetinic acid with hematopoietic cytokines, which include IL-1, IFN-y 
and TNP-a, in modulating the growth of JCS leukemia cells will be examined. On the 
other hand, since the growth and differentiation of hematopoietic cells are tightly 
regulated by a group of hematopoietic growth factors including the colony stimulating 
factors (CSFs) and certain cytokines (e.g. IL-1, IFN-y and TNP-a), therefore, in order to 
study the mechanisms by which giycyrrhizin and 18-P glycyrrhetinic acid can induce 
leukemic cell differentiation and growth arrest, the expression of various cytokine genes 
will be monitored by the reverse transcription polymerase chain reaction (RT-PCR). In 
addition, in view of the fact that proto-oncogene and transcriptional factor gene 
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expressions are often used as a tool to dissect out the processes of growth and 
differentiation in the developmental cascade, therefore, in this study the effects of 
glycyrrhizin and 18-p glycyrrhetinic acid on the expression of the growth- and 
differentiation-related genes such as proto-oncogenes and transcriptional factor genes 
during induction of myeloid leukemic cell differentiation and growth arrest will be 
investigated by RT-PCR and Western blotting techniques. 
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5.2 RESULTS 
5.2.1 Combining Effect of Glycyrrhizin or 18-3 Glycyrrhetinic Acid with 
Hematopoietic Cytokines in Modulating the Proliferation of the Murine Myeloid 
Leukemia JCS Cells 
5.2.1.1 Combining Effect of Glycyrrhizin and IL-la on the Proliferation of JCS 
Cells 
It has been reported that IL-la can induce the differentiation of various myeloid 
leukemia cells into macrophage-like cells (Onozaki et al, 1987; Chan et al, 1997). In 
this part of study, the modulatory effect of a number of cytokines on the anti-
proliferative effect of glycyrrhizin on the myeloid leukemia JCS cells was investigated. 
The JCS cells were incubated with two different concentrations of glycyrrhizin (1 mM 
and 1.5 mM) and IL-la (25-200 ng/ml) at 37°C for 48 hours. The cell proliferation was 
determined by tritiated thymidine incorporation. As shown in Figure 5.1, IL-la alone 
exhibited a slight inhibitory effect on the proliferation of JCS cells, only -15% of 
inhibition was observed at 50 ng/ml of IL-la. It did not show any synergistic activity 
when combined with glycyrrhizin at the indicated concentrations. However, an additive 
inhibitory effect of IL-la on JCS cell proliferation was observed when it was combined 
with glycyrrhizin. 
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Figure 5.1: Effect of glycyrrhizin and IL-la on the proliferation of JCS cells. JCS 
cells (lxl04 cells/ml) were incubated at 37 with glycyrrhizin (1 mM and 1.5 mM) in 
the presence of IL-la (0-200 ng/ml) for 48 hours. Cultures were then pulsed with 0.5 
fiCi of^H-TdR for 6 hours before harvest. Radioactivity in counts per minute (cpm) was 
measured using a liquid scintillation counter. Results were expressed as % inhibition of 
H-TdR incorporation, using the untreated JCS cells as a control. Each point represents 
the mean 士 S.E. of quadruplicate cultures. 
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5.2.1.2 Combining Effects of Glycyrrhizin with IFN-y or TNF-a on the 
Proliferation of JCS Cells 
As shown in Figure 5.2 and 5.3，IFN-y or TNF-a alone inhibited the proliferation 
of JCS cells in a dose-dependent manner, and the inhibition was about 34% at a 
concentration of 3000 units/ml of IFN-y and about 27% at a concentration of 2000 
units/ml of TNF-a. It was found that glycyrrhizin significantly enhanced the anti-
proliferative effect of IFN-y and TNF-a on JCS cells in a synergistic manner at a 
concentration of 1 mM and 1.5 mM respectively. 
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Figure 5.2: Effect of glycyrrhizin and IFN-y on the proliferation of JCS cells. JCS 
cells (lxl04 cells/ml) were incubated at 37 with glycyrrhizin (1 mM and 1.5 mM) in 
the presence of IFN-y (0-3000 units/ml) for 48 hours. Cultures were then pulsed with 0.5 
i^Ci of^H-TdR for 6 hours before harvest. Radioactivity in counts per minute (cpm) was 
measured using a liquid scintillation counter. Results were expressed as % inhibition of 
^H-TdR incorporation, using the untreated JCS cells as a control Each point represents 
the mean 士 S.E. of quadruplicate cultures. 
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Figure 5.3: Effect of glycyrrhizin and TNF-a on the proliferation of JCS cells. JCS 
cells (lxl04 cells/ml) were incubated at 37 with glycyrrhizin (1 mM and 1.5 mM) in 
the presence of TNF-a (0-2000 units/ml) for 48 hours. Cultures were then pulsed with 
0.5 i^Ci of ^H-TdR for 6 hours before harvest. Radioactivity in counts per minute (cpm) 
was measured using a liquid scintillation counter. Results were expressed as % 
inhibition of ^H-TdR incorporation, using the untreated JCS cells as a control. Each 
point represents the mean 土 S.E. of quadruplicate cultures. 
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5-2.1.3 Combining Effect of 18-p Glycyrrhetinic Acid and IL-la on the 
Proliferation of JCS Cells 
In the present study, the modulatory effect of IL-la on the anti-proliferative 
activity of 18-p glycyrrhetinic acid on the murine myeloid leukemia JCS cells was 
investigated. The JCS cells were incubated with two different concentrations of 18-(3 
glycyrrhetinic acid (20 |LIM and 40 ^iM) and IL-la (25-200 ng/ml) at 37°C for 48 hours. 
Cell proliferation was determined by the tritiated thymidine incorporation assay. As 
shown in Figure 5.4, IL-la alone exhibited a slight inhibitory effect on the proliferation 
of JCS cells. Similar to that of glycyrrhizin, no synergistic activity was observed when 
IL-la was combined with 18-p glycyrrhetinic acid. 
5.2.1.4 Combining Effects of 18-(3 Glycyrrhetinic Acid with IFN-y or TNF-a on the 
Proliferation of JCS Cells 
As shown in Figure 5.5 and 5.6, IFN-y or TNF-a alone slightly inhibited the 
proliferation of JCS cells in a dose-dependent manner. Again, similar to the results of 
glycyrrhizin, it was found that 18-p glycyrrhetinic acid acted in synergy with IFN-y or 
TNF-a in inhibiting the proliferation of the JCS cells, especially at lower concentrations 
of the cytokines. 
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Figure 5.4: Effect of 18-p glycyrrhetinic acid and IL-la on the proliferation of JCS 
cells. JCS cells (IxlO* cells/ml) were incubated at 37 ^C with 18-p glycyrrhetinic acid 
(20 fiM and 40 i^M) in the presence o f lL- l -a (0-200 ng/ml) for 48 hours. Cultures were 
then pulsed with 0.5 jtiCi of^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of^H-TdR incorporation, using the untreated JCS cells as a 
control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 5.6: Effect of 18-p glycyrrhetinic acid and TNF-a on the proliferation of 
JCS cells. JCS cells (IxlO'^ cells/ml) were incubated at 37 with 18-p glycyrrhetinic 
acid (20 fiM and 40 \iM) in the presence of TNF-a (0-2000 units/ml) for 48 hours. 
Cultures were then pulsed with 0.5 i^Ci of ^H-TdR for 6 hours before harvest. 
Radioactivity in counts per minute (cpm) was measured using a liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation, using the 
untreated JCS cells as control. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Figure 5.5: Effect of 18-p glycyrrhetinic acid and IFN-y on the proliferation of JCS 
cells. JCS cells (IxlO"^ cells/ml) were incubated at 37 with 18-p glycyrrhetinic acid 
(20 |LIM and 40 |IIM) in the presence of IFN-y (0-2000 units/ml) for 48 hours. Cultures 
were then pulsed with 0.5 gCi of ^H-TdR for 6 hours before harvest. Radioactivity in 
counts per minute (cpm) was measured using a liquid scintillation counter. Results were 
expressed as % inhibition of ^H-TdR incorporation, using the untreated JCS cells as a 
control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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5.2.2 Elucidation of the Molecular Mechanisms of Giycyrrhizin or 18-p 
Glycyrrhetinic Acid on Leukemic Cell Differentiation and Growth Arrest 
5.2.2.1 Modulatory Effects of Giycyrrhizin and 18-p Glycyrrhetinic Acid on the 
Expression of Cytokine Genes in the Leukemia JCS Cells 
The technique of reverse transcription-polymerase chain reaction (RT-PCR) was 
used to analyze the expression of cytokine genes, such as IL-1 a , IL-lp, IL-6, TNP-a 
and TGF-P, in the leukemia JCS cells after treatment with 2 mM giycyrrhizin or 60 i^M 
18-(3 glycyrrhetinic acid. The time profile for the expression of cytokine genes after 
treatment with giycyrrhizin or 18-P glycyrrhetinic acid was shown in Figure 5.7 and Fig 
5.8. It was found that the expression of IL-1 a gene was markedly increased at 1 hour 
after treatment with giycyrrhizin or 18-P glycyrrhetinic acid, which peaked at 2 hours 
and then declined rapidly thereafter. Similarly, the expression of IL-1 (3 gene was greatly 
enhanced at 1-2 hours after treatment with giycyrrhizin or 18-P glycyrrhetinic acid, but 
the expression level dropped below the control value at 4 hours and thereafter. 
Moreover, a slight increase in the IL-6 gene expression was seen at 1 hour after 
treatment of JCS cells with giycyrrhizin (Figure 5.7). On the other hand, the expression 
level of IL-6 was found to be significantly elevated at all time points tested after 
treatment of JCS cells with 18-p glycyrrhetinic acid, but like giycyrrhizin, maximum 
stimulation of IL-6 gene expression was seen at 1 hour after treatment (Figure 5.8). 
Finally，the expression levels of TNF-a and TGF-p in JCS cells remained relatively 
constant throughout 6 hours after treatment of the leukemia cells with giycyrrhizin or 
18-P glycyrrhetinic acid. 
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I L - l a I B E a B B 
1.00 2.58 56.4 24.8 1.29 
TT iR P H W H H V M V H I i l ^ ^ 
IL-IP I C S X m X m m M S m K M 35 cycles; 382 bp 
1.00 2.09 2.74 0.233 0.078 
u u m m m n i m m 479 bp 
1.00 1.72 0.756 0.844 0.838 
TNF-a 
1.00 1.07 0.892 1.14 1.22 
T G F - P B ^ B S l ^ ^ ^ ^ H 3 8 4 9 7 bp 
1 00 1.08 1.12 1_15 1.22 
GAPDH I . 1 1 38 cycles; 226 bp 
Figure 5.7: Time expression profile of cytokine genes in glycyrrhizin-treated 
WEHI-3B JCS cells. 
JCS cells (5 X 10^ cells) were either untreated or treated with 2 mM glycyrrhizin for 
different periods of time (60-360 min). Total RNA was extracted from JCS cells 
using the TRIZOL reagent according to the method described in Chapter 2. The 
RNAs were reverse transcribed and amplified by PGR using specific primer pairs. 
RT-PCR products were separated in a 2% agarose gel. The band intensity was 
analysed using the ImageQuant (Molecular Dynamics) software. The value at the 
bottom of each band represents the relative intensity after normalization with 
respect to GAPDH and comparison was made with the corresponding control 
respectively. 
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IL-la m m m i l ^ i m Q ^ ^ m ^^ cycles; 546 bp 
1.00 3.9 51.5 9.55 1.13 
IL-IP 35 cycles; 382 bp 
1.00 8.08 5.33 0.480 0.296 ^ 
IL_6 m m U ^ J ^ ^ ^ m ^ ^ H ^^ cycles; 479 bp 
1.00 10,9 2 .34 2.06 1.97 
TNF-a B B S l l ^ B 9 32 cycles; 411bp 
1.10 1.11 7 0 9 ^ 1 ^ 3 P 
TGF-P B i ^ B S ^ ^ B 38 cycles; 497bp 
~ 1.U6 1,11 ^ 
GAPDH 38 cycles; 266 bp 
Figure 5.8: Time expression profile of cytokine genes in 18-P glycyrrhetinic acid-
treated WEHI-3B JCS cells. 
JCS cells (5 X lO^cells) were either untreated or treated with 60 pM glycyrrhizin for 
different periods of time (60-360 min). Total RNA was extracted from JCS cells using 
the TRIZOL reagent according to the method described in Chapter 2. The RNAs were 
reverse transcribed and amplified by PGR using specific primer pairs. RT-PCR products 
were separated in a 2% agarose gel. The band intensity was analysed using the 
ImageQuant (Molecular Dynamics) software. The value at the bottom of each band 
represents the relative intensity after normalization with respect to GAPDH and 
comparison was made with the corresponding control respectively. 
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5.2.2.2 Modulatory Effects of Glycyrrhizin and 18-P Glycyrrhetinic Acid on the 
Expression ofPKC Isoforms in the Leukemia JCS Cells 
Reverse transcription-polymerase chain reaction (RT-PCR) was used to study the 
gene expression of nine PKC isoforms after treatment of JCS cells with 2 mM 
glycyrrhizin or 80 i^M 18-p glycyrrhetinic acid. It was found that the control JCS cells 
express two Ca'-^-dependent PKC isoforms (PKC-a and P) and five Ca'^-independent 
PKC isoforms (PKC-5, s, r), (； and X). There was no expression of PKC-y and PKC-B 
isoforms throughout the 8 hours study period (data not shown). The time profile for the 
expression of PKC isoforms after treatment with glycyrrhizin was shown in Figure 5.9. 
For the expression of the Ca^'-dependent PKC isoforms, maximum increase (36 fold) in 
the expression of PKC-a was seen at 30 min after treatment with glycyrrhizin and 
declined thereafter. In contrast, there was no significant change in the expression of 
PKC-P throughout the 8 hours study period. On the other hand, for the expression of 
Ca^^-independent novel PKC isoforms, it was found that maximum up-regulation of 
PKC-S expression with a 4.7 fold increase was seen at 8 hours. Similarly, maximum up-
regulation of PKC-s expression with a 6.3 fold increase occurred at 6 hours. Moreover, 
it was found that there was a 4.1 fold increase in the expression level of PKC-TI at 30 
min and the expression level was decreased thereafter. Finally, the expression level of 
the atypical PKC-*； was maximally up-regulated with a 6.7 fold increase at 6-8 hours. 
For the atypical PKC-X, its expression level was also up-regulated and reached a 
maximum with a 5.2 fold increase at 6 hours. 
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The time profile for the expression of PKC isoforms after treatment with 80 
18-p glycyrrhetinic acid was shown in Figure 5.10. Firstly, the expression level of the 
2+ 
Ca -dependent PKC-a was maximally up-regulated at 1 hour with a 4.6 fold increase 
after treatment with 18-p glycyrrhetinic acid and its expression level was then decreased 
thereafter. Moreover, unlike glycyrrhizin treatment, there was a slight increase (�1.7-2 
fold) in the expression for PKC-P at 30-60 min after treatment with 18-P glycyrrhetinic 
acid. Secondly, for the expression of Ca^"'-independent novel PKC isoforms, it was 
found that there was a marked up-regulation of PKC-6 expression with a 13.6 fold 
increase at 30 min and its expression level was then declined thereafter. Moreover, the 
PKC-s expression was also up-regulated at all time points tested but was peaked at 4 
hours with a 6.8 fold increase. Similar to that of glycyrrhizin, the expression level of 
PKC-r] was maximally up-regulated with a 4.3 fold increase at 30 min and the 
expression level was decreased thereafter. Finally, the expression levels of the two 
atypical PKC isoforms, PKC-(；, and ？KC-X, were up-regulated at all time points after 
treatment with 18-p glycyrrhetinic acid, with maximum stimulation of gene expression 
occurred at 2 hours and 30 min respectively. 
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PKC-a 
25 cycles; 324 bp 
1.00 36.0 34.0 32.6 21.9 17.4 6.4 
E ^ H ^ S ^ ^ H ^ ^ ^ S S 25 cycles; 309 bp 
1 00 1.04 1.00 1.07 0.932 0.805 0,837 
PKC-a ^ B B B B 25 cye.es; 352 bp 
1 00 2.15 2.17 2.15 4.45 4 .43 4 .72 
P K c - s HHHB^BBSBBESESI 25 cycles； 732 bp 
1 0 0 1.98 0.97 1.05 0.98 6.34 5.74 
H V H m m i i H P i M 
tm^^^mmamrnammmmKiUmiUmtm 25 cycles; 238 bp 
1.00 4 .08 3.51 3.24 2.64 2.42 2 .13 
PKC_; 25 cycles; 680 bp 
1.00 5.13 4 .88 5.92 5.83 6.71 6.73 
PKC-X B — C P 1 1 1 ! 25 cycles; 240 bp 
1.00 1.33 2.43 4 .48 4 .93 5.19 3.79 
GAPDH 25 cycles; 226 bp 
Figure 5.9: Time expression profile of PKC isoforms in glycyrrhizin-treated 
WEHI-3B JCS cells. 
JCS cells (5 X lO^cells) were either untreated or treated with 2 mM glycyrrhizin for 
different periods of time (30-480 min). Total RNA was extracted from JCS cells using 
the TRIZOL reagent according to the method described in Chapter 2. The RNAs were 
reverse transcribed and amplified by PCR using specific primer pairs. RT-PCR products 
were separated in a 2% agarose gel. The band intensity was analysed using the 
ImageQuant (Molecular Dynamics) software. The value at the bottom of each band 
represents the relative intensity after normalization with respect to GAPDH and 
comparison was made with the corresponding control respectively. 
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PKC-P C S C Z i Z J C l E S C Z Z S 25 cycles; 309 bp 
1.00 1.96 1.73 1.28 1,23 1.21 1.18 
PKc-3 m^imiQBSilE^E^^Bi bp 
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PKC-n — — — • 
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Figure 5.10: Time expression profile of PKC isoforms in 18-P glycyrrhetinic 
acid treated WEHI-3B JCS cells. 
JCS cells (5 X 10Wis) were either untreated or treated with 80 ^M 18-P 
glycyrrhetinic acid for different periods of time (30-300 min). Total RNA was 
extracted from JCS cells using the TRIZOL reagent according to the method 
described in Chapter 2. The RNAs were reverse transcribed and amplified by PGR 
using specific primer pairs. RT-PCR products were separated in a 2% agarose gel. 
The band intensity was analysed using the ImageQuant (Molecular Dynamics) 
software. The value at the bottom of each band represents the relative intensity after 
normalization with respect to GAPDH and comparison was made with the 
corresponding control respectively. 
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5.2.2.3 Modulatory Effects of Glycyrrhizin and 18-P Glycyrrhetinic Acid on the 
Expression of Growth-regulatory Genes in the Leukemia JCS Cells 
The expression of several growth-regulatory genes, such as NF-kB p50, Fas and 
p53 was examined after treatment of JCS cells with 2 mM glycyrrhizin or 80 i^M 18-P 
glycyrrhetinic acid. The time profile for the expression of growth-regulatory genes after 
treatment with glycyrrhizin was shown in Figure 5.11. It was found that there was a 
time-dependent increase in the expression of NF-RB p50 and a marked increase (16.1 
fold) was seen at 8 hours after treatment with glycyrrhizin. The expression level of Fas 
was significantly enhanced as early as 30 min after treatment with glycyrrhizin and 
reached a peak (48.3 fold increase) at 4 hours and slowly declined thereafter. In contrast, 
the expression level of p53 remained fairly constant with a slight increase (28-49% 
increase) at later time points (2-8 hours) after treatment with glycyrrhizin. 
On the other hand, the time profile for the expression of growth-regulatory genes 
after treatment with 18-p glycyrrhetinic acid was shown in Figure 5.12. In contrast to 
glycyrrhizin treatment, the expression of NF-kB p50 was up-regulated as early as 30 min 
(10.4 fold increase) after treatment with 18-P glycyrrhetinic acid and its expression level 
was then decreased thereafter. Also, the expression level of Fas was up-regulated at all 
time points tested after treatment with 18-p glycyrrhetinic acid with maximal expression 
at 5 hours ( � 3 . 3 fold increase). Moreover, unlike glycyrrhizin treatment, the expression 
level of p53 was increased by 3.1 fold at 30 min and its expression level was then 
declined thereafter. 
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Figure 5.11: Time expression profile of growth-regulatory genes in 
glycyrrhizin-treated WEHI-3B JCS cells. 
JCS cells (5 X lO^cells) were either untreated or treated with 2 mM glycyrrhizin for 
different periods of time (30-480 min). Total RNA was extracted from JCS cells 
using the TRIZOL reagent according to the method described in Chapter 2. The 
RNAs were reverse transcribed and amplified by PGR using specific primer pairs. 
RT-PCR products were separated in a 2% agarose gel. The band intensity was 
analysed using the ImageQuant (Molecular Dynamics) software. The value at the 
bottom of each band represents the relative intensity after normalization with 
respect to GAPDH and comparison was made with the corresponding control 
respectively. 
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p5o 38 250 bp 
1.00 10.4 7.52 7.08 4.72 4 .26 1.86 
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1.00 2.50 2.51 2.62 2 .40 2.35 3.35 
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Figure 5.12: Time expression profile of growth-regulatory genes in 18-P 
glycyrrhetinic acid-treated WEHI-3B JCS cells. 
JCS cells (5 X lO^cells) were either untreated or treated with 80 ^iM 18-p 
glycyrrhetinic acid for different periods of time (30-300 min). Total RNA was 
extracted from JCS cells using the TRIZOL reagent according to the method 
described in Chapter 2. The RNAs were reverse transcribed and amplified by PCR 
using specific primer pairs. RT-PCR products were separated in a 2% agarose gel. 
The band intensity was analysed using the ImageQuant (Molecular Dynamics) 
software. The value at the bottom of each band represents the relative intensity after 
normalization with respect to GAPDH and comparison was made with the 
corresponding control respectively. 
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5.2.2.4 Modulatory Effects of 18-(3 Glycyrrhetinic Acid on the Expression of 
Apoptosis-related Genes in the Leukemia JCS Cells 
Since in Chapter 3, it was shown that 18-P glycyrrhetinic acid but not 
glycyrrhizin could induce apoptosis in the murine myeloid leukemia JCS cells. 
Therefore, in this chapter, the effects of 18-P glycyrrhetinic acid on the expression of 
several apoptosis-related genes were examined. The hcl-2 family genes including the 
anti-apoptotic genes (such as bcl-Xi) and pro-apoptotic genes (such as hak and had). It is 
reported that the hcl-2 family genes play important roles in regulating the mitochondria-
dependent apoptosis (Reed, 1998). Reverse transcription-polymerase chain reaction 
(RT-PCR) was used to analyse the expression of apoptosis-related genes, such as Bak, 
Bad and Bcl-Xi after treatment of JCS cells with 18-P glycyrrhetinic acid. The time 
profile for the expression of apoptosis-related genes after the treatment with 80 [xM 18-P 
glycyrrhetinic acid was shown in Figure 5.13. It was found that the expression level of 
the Bak gene was enhanced at all time points tested and maximal up-regulation was seen 
at 5 hours (7.7 fold increase) after treatment with 18-p glycyrrhetinic acid. In contrast, 
the expression level of the Bad gene remained unchange throughout the 5 hours period 
when JCS cells were treated with 80 |_iM 18-|3 glycyrrhetinic acid. Finally, the 
expression level of the BCI-XL gene was found to have a 3.7 fold decrease at 5 hours after 
treatment with 18-P glycyrrhetinic acid. 
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Figure 5.13: Time expression profile of apoptosis-related genes in 18-P 
glycyrrhetinic acid-treated WEHI-3B JCS cells. 
JCS cells (5 X lO^cells) were either untreated or treated with 80 juM 18-p glycyrrhetinic 
acid for different periods of time (30-300 min). Total RNA was extracted from JCS cells 
using the TRIZOL reagent according to the method described in Chapter 2. The RNAs 
were reverse transcribed and amplified by PGR using specific primer pairs. RT-PCR 
products were separated in a 2% agarose gel. The band intensity was analysed using the 
ImageQuant (Molecular Dynamics) software. The value at the bottom of each band 
represents the relative intensity after normalization with respect to GAPDH and 
comparison was made with the corresponding control respectively. 
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5.2.2.5 Modulatory Effects of 18-P Glycyrrhetinic Acid on the Expression of 
Growth-regulatory and Apoptosis-related Proteins in JCS Cells 
In the previous sections (Section 5.2.2.3 and 5.2.2.4) the effects of 18-p 
glycyrrhetinic acid on the expression of certain growth-regulatory and apoptosis-related 
genes had been investigated. In this section, the expression of these gene products in 18-
P glycyrrhetinic acid-treated leukemia JCS cells was examined by Western blot analysis 
to see whether these gene transcripts would be translated to their corresponding 
functional proteins to exert their effects within target cells. 
The leukemia JCS cells were incubated with two different concentrations of 18-P 
glycyrrhetinic acid (50 )liM and 70 ^iM) at 37 for 48 hours and the expression of the 
PKC-5, Bak and Fas proteins were analyzed by Western blotting technique. As shown in 
Figure 5.14，the expression of the growth-related proteins, PKC-6, was markedly up-
regulated with a 24 fold increase at 48 hours after treatment with 70 [iM of 18-p 
glycyrrhetinic acid. Moreover, the expression levels of two apoptosis-related proteins, 
Bak and Fas were significantly up-regulated with a 3 fold and 4 fold increase in protein 
expression respectively after treatment with 70 i^M of 18-p glycyrrhetinic acid. 
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c 50 70 _ 
PKC-6 — — 7 8 kDa 
2.51 50.2 60.3 
Bak 23 kDa 
1.21 3.03 3.63 
Fas 一 * ^ 48 kDa 
1.89 5.67 7.56 
Figure 5.14 The expression of growth-regulatory or apoptosis-related proteins 
in 18-p glycyrrhetinic acid-treated WEHI-3B JCS cells. 
JCS cells (5 xl04 cells/ml) were treated with two different concentrations of 18-P 
glycyrrhetinic acid (50 i^M and 70 |aM) for 48 hours at 37^C. Details for the 
extraction of proteins were described in Chapter 2. The proteins were probed with 
specific secondary antibodies and visualized by the ECL assay. The value at the 
bottom of each band represents the relative intensity as determined by densitometry. 
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5.3 Discussion 
The advantage of differentiation therapy in leukemia is that higher therapeutic 
efficacy can be achieved through the combinational use of various differentiation and 
apoptotic inducers. It is because they can work in a synergistic way to lower the 
concentration of each other (Zhang et cd,, 1992). In our study, the possible synergistic 
anti-leukemic effects of glycyrrhizin or 18-p glycyrrhetinic acid in combination with 
hematopoietic cytokines were investigated. Moreover, the molecular mechanisms by 
which glycyrrhizin or 18-P glycyrrhetinic acid could exert their effects on the myeloid 
leukemia cells were also elucidated. 
It was reported that exogenous IL- la and IL-ip could inhibit the proliferation 
and induce the monocytic differentiation of JCS cells either alone or synergistically with 
TNF-a (Chan et al., 1997). Moreover, it was found that flavone acted in synergy with 
IL- la in inhibiting the growth and in inducing the monocytic differentiation of JCS cells 
(Kong, 1998). In another study it was found that TNF-a could inhibit the growth and 
induce the differentiation of JCS cells into macrophage-like cells (Mak et al., 1993). It 
was believed that the differentiation inducing effect of TNF-a was mediated through the 
production of IL-1 (Chan et al, 1997). In addition, it was suggested that 18-p 
glycyrrhetinic acid could act in synergy with EGCG (-)-epigallocatechin-3-gallate (a 
major component of green tea) in inhibiting the proliferation of the human myeloid 
leukemia HL-60 cells (Ip, 2000). On the other hand, it was reported that patients with 
CML had good response when treated with IFN-y alone or in combination with low dose 
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of IFN-y or TNF-a (Wandl et aL, 1992). Our data showed that the combination o f l L - l a 
with glycyrrhizin or 18-p glycyrrhetinic acid could enhance their anti-proliferative effect 
on JCS cells in an additive manner only. On the contrary, the combination of 
glycyrrhizin or 18-P glycyrrhetinic acid with IFN-y and TNF-a could enhance their anti-
proliferative effect in a synergistic way. Our results imply that the combinations of 
IFN-y or TNF-a with glycyrrhizin or 18-P glycyrrhetinic acid might have potential 
therapeutic value in the treatment of some forms of myeloid leukemia, although further 
investigation is needed to elucidate the exact mechanism of synergistic interactions. 
Therefore, the combined use of glycyrrhizin or 18-p glycyrrhetinic acid with certain 
cytokines may have benefits over the use of single one and a greater therapeutic index 
can be achieved with lower non-cytotoxic doses and the possibility for the development 
of drug resistance can also be reduced. 
In the present study, the molecular mechanisms by which glycyrrhizin and 18-p 
glycyrrhetinic acid can exert their growth-inhibitory, apoptosis-inducing and 
differentiation-inducing actions on myeloid leukemia cells have been elucidated, 
including their ability to modulate the hematopoietic cytokine gene expression profiles 
as well as their influence on the expression of growth-regulatory and apoptosis-related 
genes in leukemia cells. IL- la and IL-ip are pro-inflammatory cytokines that are 
produced mainly from monocytes/macrophages. They are involved in the regulation of 
normal hematopoietic cell growth and differentiation (Bagby, 1989). IL-1 is a mediator 
for tumor cytostasis and it acts synergistically with TNF-a, IFN-a/p or IL-6 to induce 
myeloid leukemia cell differentiation (Weinberg & Manson, 1991). Moreover, IL-ip is a 
neutrophil chemoattractant and can induce neutrophil to release superoxide (Pattor et al., 
m 
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1995). Our findings showed that there was a remarkable up-regulation of IL- la and IL-
ip expression at 1-2 hours after JCS cells were treated with glycyrrhizin or 18-P 
glycyrrhetinic acid. This rapid increase in the expression of IL- la and IL-lp may be 
related with cell maturation and acquisition of macrophage functions of JCS cells upon 
treatment with glycyrrhizin or 18-P glycyrrhetinic acid. Our results are in agreement 
with our previous finding that these two cytokines may be involved in TNF-a-induced 
monocytic differentiation of the leukemia JCS cells (Chan et al., 1997). 
It has been reported that IL-6 is involved in the maintenance of the viability and 
induces the differentiation of normal myeloid precursor cells (Lotem et al., 1989). 
Moreover, it was found that IL-6 can induce the terminal differentiation of the 
myeloblastic leukemia Ml cells (Gothelf et al, 1991). Using RT-PCR, our results 
indicated that the expression level of IL-6 was significantly elevated in 18-P 
glycyrrhetinic acid-treated JCS cells, suggesting that the secondary induction of this 
hematopoietic cytokine may play a role in triggering the monocytic differentiation of 
JCS cells by 18-p glycyrrhetinic acid. 
Tumor necrosis factor-a (TNF-a) is a cytokine produced mainly from 
monocytes or macrophages. It plays a role in the regulation of immune response. 
Moreover, it can trigger the differentiation of JCS cells into mature macrophage-like 
cells (Mak et al., 1993). Transforming growth factor-(3 (TGF-P) is the most potent 
monocyte chemoattractant since its maximal chemotactic effect is achieved at 
femtomolar levels (Wahl et al., 1987). It can act in a paracrine or autocrine manner to 
attract macrophages. Our results showed that the expression levels of both TNF-a and 
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TGF-P remained fairly constant when JCS cells were treated with giycyrrhizin or 18-p 
glycyrrhetinic acid, indicating that these two cytokines may not play a significant role in 
the giycyrrhizin or 18-P glycyrrhetinic acid-induced monocytic differentiation of the 
JCS cells. 
Protein kinase C (PKC) constitutes a structurally homologous family of enzymes 
that are activated by cell membrane lipids and catalyze the rapid and reversible 
phosphorylation of serine and threonine residues in a wide variety of proteins. It is 
therefore that PKC can modulate the biological functions of these proteins. Different 
members of PKC family play distinct roles by causing differential phosphorylation of 
their substrates since they undergo differential activation, translocation and down-
regulation (Zeidman et al, 1999; Watters & Parsons，1999). Mammalian protein kinase 
C consists of at least 11 isoforms, which show slight differences in their molecular 
structure and enzymatic properties. They are involved in diverse intracellular signalling 
events including growth, differentiation and tumor promotion etc. (Way et al., 2000). 
Recent studies have shown that changes in the expression of PKC isoforms and 
their activities are correlated with the differentiation of neuroblastoma cells (Mohan et 
al., 1999; Zeidman et al., 1999; Mak et al, 2001). In this study, we found that the 
untreated JCS cells express two conventional, Ca^^-dependent PKC isoforms (PKC-a 
and PKC-P) and three novel Ca^^-independent PKC isoforms (PKC-6, s and r|) and two 
atypical PKC isoforms (PKC-(^ and \ \ whereas the expression of two other PKC 
isoforms (PKC-y and 6) was not detectable in JCS cells. Our results indicated that the 
expression levels of six out of nine PKC isoforms examined were found to be 
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significantly enhanced (>2 fold increase) after treatment of the JCS cells with 
glycyrrhizin and 18-P glycyrrhetinic acid. The most prominent changes were the 
conventional PKC-a ( � 3 6 fold increase) for glycyrrhizin-treated JCS cells and the novel 
PKC-5 (-14 fold increase) for the 18-P glycyrrhetinic acid-treated JCS cells. 
Interestingly, there was little, if any, increase in the expression of the PKC-p in both 
cases. In addition, the expression of PKC-y and PKC-G was not detected in both 
untreated and glycyrrhizin or 18-p glycyrrhetinic acid-treated JCS cells, suggesting that 
these two PKC isoforms might not be involved in modulating the growth and 
differentiation of the leukemia JCS cells. 
In Chapter 3 and 4，it was found that glycyrrhizin could inhibit cellular 
proliferation and induced monocytic differentiation of the leukemia JCS cells. In the 
present study, we showed that PKC-a may be involved in glycyrrhizin-induced 
leukemic cell differentiation. Our results are consistent with that Dieter and Schwende 
(2000) who showed that PKC-a could promote the differentiation process of the human 
myeloid leukemia THP-1 cells. More recently, Kang et al (2001) demonstrated that 
PKC-a may be involved in silibinin-induced monocytic differentiation of the human 
promyelocytic leukemia HL-60 cells. On the other hand, we showed that PKC-6 was 
markedly up-regulated in the 18-p glycyrrhetinic acid-treated JCS cells. This PKC 
isoform is expressed in most tissues. Recent studies have indicated that PKC-6 is 
involved in cell differentiation. PKC-6 has also found to play a role in regulation of 
shape change and cell adhesion during the differentiation of the myeloid leukemia HL-
60 cells (Owen et a!., 1996). In addition, over-expression of PKC-5 has also found to be 
involved in the TPA-induced differentiation of the myeloid leukemia 32D cells (Wang et 
191 
Chapter 5 Mechanistic Studies 
a l , 1997). Taken together, our results suggest that PKC-5 might play a role in 18-P 
glycyrrhetinic acid-induced differentiation of JCS cells. 
NF-kB is a heterodimer consisting of p50 and p65 subunit. It is a transcription 
factor that regulates various cellular responses such as proliferation, apoptosis and 
inflammation (May et al., 1998). It has been shown that there is an activation of NF-kB 
during apoptosis of HL-60 cells (Boland et a/., 1997; Granville et al., 2000). Moreover, it 
was found that NF-kB could activate the FasL expression in T-lymphocytes and a NF-kB 
site in the FasL promoter had been identified (Hsu et al,, 1999; Kasibhatla et al., 1999). 
It had been suggested that the enhanced expression of NF-kB might contribute to the 
enhanced expression of FasL in HL-60 cells since NF-kB activator was a regulator of 
human granulocyte apoptosis in vitro (Ward et al, 1999). Our results showed that there 
was an enhancement in the expression of NF-kB after exposure to glycyrrhizin at 8 hours 
whereas a rapid induction of NF-kB gene expression was seen as early as 30 min after 
treatment with 18-p glycyrrhetinic acid. The reason for the apparent discrepancy in the 
kinetics of induction of NF-kB gene expression in glycyrrhizin and 18-P glycyrrhetinic 
acid-treated JCS cells remain obscure and awaits further investigations. 
It is known that the tumor suppressor gene p53 can induce the expression of a 
cdk inhibitor p21. The p21 can act on a variety of cyclin/cdk complexes. Moreover, the 
p53 protein can activate apoptosis by inducing pro-apoptotic Bax protein. Loss of p53 
function may cause the cells to replicate in an uncontrolled way. This may contribute to 
a number of cancers when cell cycling is increased (Meikrantz & Schlegel，1995). 
Disruption of the balance between cell loss and cell gain causes the occurrence of 
^ 
Chapter 5 Mechanistic Studies 
leukemia. In AML, B-cell CLL and B-cell ALL, mutation of the p53 gene is commonly 
found. This leads to the failure of Gi or G2/M cell cycle arrest and apoptosis. (Lunderg 
& Weinberg, 1999). Our results showed that the expression level of p53 remained 
relatively constant after treatment with glycyrrhizin for 6 hours. On the other hand, there 
was a transient up-regulation of p53 after treatment with 18-p glycyrrhetinic acid. Since 
18-P glycyrrhetinic acid but not glycyrrhizin was found to be capable of triggering the 
apoptosis of JCS cells, thus our results suggest that p53 may play a role, at least in part, 
in the 18-P glycyrrhetinic acid-induced apoptosis of the leukemia JCS cells. 
Since the bcl-2 family plays an important role in the regulation of apoptosis, 
therefore, the effects of 18-P glycyrrhetinic acid on the expression of apoptosis-related 
genes were also studied. From our results, it was found that the expression level for the 
apoptosis-promoting gene such as Bak was increased while the expression level for the 
apoptosis-suppressing gene such as BC1-XL was decreased. It has been reported that the 
BC1-2 proteins act in heterodimers or homodimers with Bax to control apoptosis. Thus, 
the ratio of these proteins plays an important role in the execution of apoptosis. 
Nevertheless, whether the induction of apoptosis in 18-p glycyrrhetinic acid-treated JCS 
cells might be mediated via the release of cytochrome c from mitochondria and 
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Licorice, or Gancao ( 甘 草 ) i n Chinese, is the rhizome and dried root of 
Glycyrrhiza supp. It is one of the most widely used medicinal herbs since ancient time. 
The main active components of licorice extract is glycyrrhizin (GL), also known as 
glycyrrhizic acid, which is a kind of pentacyclic triterpenoid 50 times sweeter than sugar. 
Glycyrrhizin is metabolized into the aglycone 18-p glycyrrhetinic acid (GA) after oral 
administration (Kim et al, 2000). These molecules have been reported to possess several 
pharmacological effects including mineralocorticoid activity, anti-inflammatory effect, 
immunosuppressive and anti-allergic effects, enhancement of immune response, anti-
hepatotoxic effect, anti-viral activity, as well as anti-carcinogenic and anti-tumor-
activities. Although the importance of glycyrrhizin and 18-p glycyrrhetinic acid has 
become more prominent in this decade when their cancer chemopreventive effects are 
unravelled, yet their anti-tumor activity and therapeutic potentials have not been fully 
explored. A review of literature (in Chapter one) has shown that there has been relatively 
few studies on the direct anti-tumor properties of licorice and its active constituents. It 
was found that glycyrrhizin and 18-P glycyrrhetinic acid could inhibit the growth of 
cultured B16 melanoma cells and stimulate melanogenesis, suggesting that these two 
compounds can induce the differentiation of cancer cells in vitro (Abe et aL, 1987). In 
vivo study revealed that prolonged treatment with glycyrrhizin was effective in 
modifying the survival pattern of mice bearing Ehrlich ascites tumor (Rossi et al., 1995). 
Moreover, it was found that in vivo administration of glycyrrhizin and 18-p 
glycyrrhetinic acid effectively inhibited the inception and growth of skin tumour (Wang 
et al., 1991). Also, there are preliminary findings that glycyrrhizin and 18-P 
glycyrrhetinic acid have growth inhibitory effects on two lymphomas (Human Burkitt's 
lymphoma and non-Hodgkin's lymphoma) and two leukemias (Raji and SupTl cells) as 
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measured by the trypan blue exclusion assay (Malagoli et al., 1998). The results were 
compared with those afforded by equimolecular doses of daunorubicin and it was 
concluded that glycyrrhizin and 18-P glycyrrhetinic acid were fairly active against 
leukemia cells. 
As shown in Chapter 3, glycyrrhizin and 18-P glycyrrhetinic acid were found to 
exhibit differential anti-proliferative activity on various leukemic cell lines in a dose-
dependent manner. It was found that 18-P glycyrrhetinic acid was more potent than 
glycyrrhizin as it exerted its anti-proliferative effect on a wide variety of leukemic cell 
lines at micro-molar concentrations. On the other hand, they exerted little, if any, 
cytotoxic effect on various leukemic cell lines over a wide range of concentrations. 
Moreover, the in vivo tumorigenicity of the murine myeloid leukemia JCS cells was 
reduced significantly by treating the cells with glycyrrhizin or 18-p glycyrrhetinic acid 
in vitro. Whether glycyrrhizin and 18-P glycyrrhetinic acid can also inhibit the growth of 
other murine leukemia in syngeneic mice or human leukemia in nude mice still awaits 
further investigation. In Chapter 4，the differentiation-inducing ability of glycyrrhizin 
and 18-P glycyrrhetinic acid was assessed by a number of criteria, including 
morphological, phenotypic and functional assays. Our results clearly show that both 
glycyrrhizin and 18-P glycyrrhetinic acid have the ability to induce the monocytic 
differentiation of a murine myeloid leukemic cell line (JCS) into a more mature stage 
since they induced the formation of vacuoles and caused cell enlargement in JCS cells 
and the ratio of nucleus to cytoplasm was decreased. Also, glycyrrhizin and 18-P 
glycyrrhetinic acid could enhance the expression of macrophage differentiation antigens, 
including Mac-1 and F4/80, as well as adhesion molecules, such as VCAM-l and LFA-1, 
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1, on the surface of the leukemia cells. Moreover, it was shown that JCS cells induced 
by glycyrrhizin had acquired the functional characteristics of mature macrophages, such 
as stimulation of endocytic activity. Since both glycyrrhizin and 18-P glycyrrhetinic 
acid could inhibit leukemic cell proliferation and trigger leukemic cell differentiation, 
therefore, our findings suggested that these two compounds might have therapeutic 
potentials in leukemia therapy. From our results, it was found that 18-(3 glycyrrhetinic 
acid at 40 [iM could induce the differentiation of JCS cells while 18-P glycyrrhetinic 
acid at 60 |iM could trigger the apoptosis of JCS cells. The underlying molecular and 
cellular mechanisms by which 18-P glycyrrhetinic acid can promote differentiation as 
well as apoptosis on myeloid cells at different concentrations have not yet been 
elucidated. However, a close relationship between apoptosis, cellular differentiation and 
cell cycle arrest of the myeloid leukemia cells had been suggested (Elias & Berry，1991, 
Csokay et al., 1997). Also, the molecular mechanisms by which glycyrrhizin and 18-P 
glycyrrhetinic acid can modulate the proliferation and inducing differentiation of 
leukemia cells are not fully understood. It is well known that several hematopoietic 
cytokines (IFN-y, IL-1 and TNF-a) are effective in inducing lineage-restricted myeloid 
leukemic cell differentiation (Olsson et al., 1990; Warrell, 1995). In order to enhance the 
anti-leukemic potential of glycyrrhizin and 18-P glycyrrhetinic acid, it is of interest to 
examine whether they can interact with these differentiation-inducing cytokines in 
modulating the growth and differentiation of leukemic cells. Our results show that the 
combinations of IFN-y and TNF-a with glycyrrhizin or 18-P glycyrrhetinic acid acted in 
synergy in inhibiting the proliferation of the leukemia JCS cells, thus they might have 
potential therapeutic value in the treatment of some forms of myeloid leukemia. At 
present it is unclear why glycyrrhizin and 18-P glycyrrhetinic acid can interact 
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synergistically with certain cytokines (e.g. IFN-y and TNF-a) but not with others (e.g. 
IL-1), and whether combination of glycyrrhizin or 18-p glycyrrhetinic acid with IFN-y 
and TNF-a can exhibit anti-leukemic activity in vivo are interesting aspects that are 
worthy of future investigation. 
On the other hand, it was found that glycyrrhizin or 18-P glycyrrhetinic acid 
could trigger apoptosis in myeloid leukemia cells in vitro with internucleosomal DNA 
fragmentation. However, the exact mechanism of how apoptosis occurs is still unknown 
and whether there is any structure-function relationship of these drugs that could lead to 
apoptosis in tumor cells remains to be seen. Our preliminary mechanistic studies showed 
that BCI-XL expression was suppressed with an enhancement of Bak expression in 18-p 
glycyrrhetinic acid-treated JCS cells. Therefore, whether 18-p glycyrrhetinic acid could 
trigger apoptosis via the release of cytochrome c followed by the activation of caspase-9 
and caspase-3 still awaits further investigation. In addition, the induction of apoptosis 
may be mediated through the regulation of cell cycle progression. Our results indicated 
that the glycyrrhizin-treated HL-60 cells or JCS cells and 18-P glycyrrhetinic acid-
treated JCS cells had a significant decrease in cell cycling in S phase accompanied with 
a cell cycle arrest in the GQ/GI phase. However, the reason for absence of DNA 
fragmentation in glycyrrhizin-treated JCS cells remains obscure. Also, for 18-p 
glycyrrhetinic acid-treated HL-60 cells, it was observed that there was a slight decrease 
in cell cycling in S phase accompanied with a cell cycle arrest in the G2+M phase rather 
than the GQ/GI phase. The discrepancy in these findings remains unclear. 
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Using RT-PCR, the expressions of other growth-regulatory and apoptosis-related 
genes in giycyrrhizin or 18-(3 glycyrrhetinic acid-treated leukemia JCS cells were also 
studied. It was found that some PKC isoforms were up-regulated after treatment with 
giycyrrhizin or 18-p glycyrrhetinic acid. Moreover, the transcriptional factor NF-kB was 
also up-regulated. It is known that NF-kB regulates a variety of genes involved in the 
immune response and the inflammatory process. For example, it is needed for the 
expression of genes for the K light chain of immunoglobulin, IL-2, IL-6 and interferon 
(May & Ghosh, 1998). Therefore whether the up-regulation of NF-kB gene expression is 
one of the mechanisms that account for the enhancement of immunity by giycyrrhizin 
requires further elucidation. On the other hand, the expression of cytokine genes were 
studied. IL-1 a and IL-ip are pro-inflammatory cytokines that are produced mainly from 
monocytes/macrophages and they are involved in the regulation of normal 
hematopoietic cell growth and differentiation. From our results, a remarkable up-
regulation of IL-1 a and IL-ip expression occurred when JCS cells were treated with 
giycyrrhizin or 18-p glycyrrhetinic acid and this increase in the expression of IL-1 a and 
IL-lp may be related with cell maturation and acquisition of macrophage characteristics. 
Increasing evidences showed that the cell-cycle regulatory factors such as cyclin-
dependent kinases (CDKs) are also involved in myeloid cell differentiation (Stein et a!., 
1998; Burger et al., 1994; Horiguchi-Yamade et a!., 1994), therefore, whether there are 
any changes in cydins (e.g. cyclin D, E) and CDKs (e.g. cdk4, cdk2) during the 
differentiation of myeloid leukemia cells induced by giycyrrhizin and 18-P 
glycyrrhetinic acid remain to be seen. More recently, the STAT transcription factors 
have been reported to play an important role in various myeloid malignancies (Coffer et 
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a/.，2000), therefore, in the future, attempts should be made to study the expression of 
various STATs (in particular STAT 3 and STAT 5 which are often activated during 
myeloid differentiation in a cell-type and maturation-state dependent manner) in 
glycyrrhizin and 18-P glycyrrhetinic acid-treated myeloid leukemia cells. Furthermore, a 
recent report showed that the extracellular signal-regulated kinases (ERK) and mitogen-
activated protein kinase (MAPK) pathway is required for the PMA-induced growth 
arrest and differentiation of the myeloid leukemia K562 cells (Herrmann et a!., 1998). 
Whether this pathway is also involved in glycyrrhizin and 18-p glycyrrhetinic acid-
induced monocytic differentiation is an intriguing area that requires future in-depth 
investigation. 
Although our preliminary findings showed that glycyrrhizin and 18-P 
glycyrrhetinic acid have anti-proliferative effect and can induce differentiation in 
myeloid leukemia cells, their mechanisms of action have not yet been fully elucidated. 
There are still many gaps in our knowledge with regard to the anti-leukemic activities of 
these two natural products. It is hoped that more researches will be done to give us more 
insights into why and how leukemia occurs, so that more effective treatment for 
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